[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4257
1. Kimura Y, Grevich S, Beukelman T, Morgan E, Nigrovic PA, Mieszkalski K, Graham TB, Ibarra M, Ilowite N, Klein-Gitelman M, Onel K, Prahalad S, Punaro M, Ringold S, Toib D, Van Mater H, Weiss JE, Weiss PF, Schanberg LE, CARRA Registry Investigators: Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. Pediatr Rheumatol Online J; 2017 Apr 11;15(1):23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Untreated systemic JIA patients enrolled in the CARRA Registry were begun on one of 4 CTPs chosen by the treating physician and patient/family (glucocorticoid [GC] alone; methotrexate [MTX] ± GC; IL1 inhibitor [IL1i] ± GC; IL6 inhibitor [IL6i] ± GC).
  • RESULTS: Thirty patients were enrolled at 13 sites; eight patients were started on a non-biologic CTP (2 GC, 6 MTX) and 22 patients on a biologic CTP (12 IL1i, 10 IL6i) at disease onset.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2013 Oct;65(10):2499-512 [24092554.001]
  • [Cites] Lancet. 2011 Jun 18;377(9783):2138-49 [21684384.001]
  • [Cites] BMC Med Res Methodol. 2010 Jan 06;10:1 [20053272.001]
  • [Cites] Arthritis Rheumatol. 2016 Dec;68(12 ):3023-3034 [27332999.001]
  • [Cites] N Engl J Med. 2012 Dec 20;367 (25):2396-406 [23252526.001]
  • [Cites] Arthritis Care Res (Hoboken). 2013 May;65(5):745-52 [23139240.001]
  • [Cites] J Rheumatol. 2011 Apr;38(4):741-6 [21285163.001]
  • [Cites] J Rheumatol. 1992 Mar;19(3):424-30 [1578458.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):998-1006 [18358927.001]
  • [Cites] J Rheumatol. 2008 Feb;35(2):343-8 [18085728.001]
  • [Cites] J Rheumatol. 2016 Sep;43(9):1755-62 [27307527.001]
  • [Cites] J Rheumatol. 2004 Nov;31(11):2290-4 [15517647.001]
  • [Cites] Arthritis Rheum. 2000 Nov;43(11):2402-9 [11083261.001]
  • [Cites] Ann Rheum Dis. 2011 May;70(5):747-54 [21173013.001]
  • [Cites] Arthritis Rheumatol. 2014 Jun;66(6):1405-13 [24623686.001]
  • [Cites] Arthritis Rheum. 2006 May;54(5):1595-601 [16645998.001]
  • [Cites] Arthritis Rheumatol. 2014 Apr;66(4):1034-43 [24757154.001]
  • [Cites] J Rheumatol. 2004 Feb;31(2):390-2 [14760812.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Jul;64(7):1001-10 [22290637.001]
  • [Cites] Ann Intern Med. 2009 Aug 4;151(3):203-5 [19567618.001]
  • [Cites] Arthritis Care Res (Hoboken). 2014 Sep;66(9):1430-1 [24719268.001]
  • [Cites] Lifetime Data Anal. 2007 Mar;13(1):119-37 [17031496.001]
  • [Cites] N Engl J Med. 2012 Dec 20;367 (25):2385-95 [23252525.001]
  • [Cites] Arthritis Rheum. 2011 Feb;63(2):545-55 [21280009.001]
  • [Cites] Arthritis Care Res (Hoboken). 2011 Jul;63(7):929-36 [21717596.001]
  • [Cites] Arthritis Care Res (Hoboken). 2011 Apr;63(4):465-82 [21452260.001]
  • [Cites] Ann Rheum Dis. 2016 Sep;75(9):1654-60 [26644233.001]
  • (PMID = 28399931.001).
  • [ISSN] 1546-0096
  • [Journal-full-title] Pediatric rheumatology online journal
  • [ISO-abbreviation] Pediatr Rheumatol Online J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Biologic response modifiers / Comparative effectiveness / Pediatric rheumatology / Registries / Still’s disease / Systemic Juvenile Idiopathic Arthritis
  • [Investigator] Abramson L; Anderson E; Andrew M; Battle N; Becker M; Benham H; Beukelman T; Birmingham J; Blier P; Brown A; Brunner H; Cabrera A; Canter D; Carlton D; Caruso B; Ceracchio L; Chalom E; Chang J; Charpentier P; Clark K; Dean J; Dedeoglu F; Feldman B; Ferguson P; Fox M; Francis K; Gervasini M; Goldsmith D; Gorton G; Gottlieb B; Graham T; Griffin T; Grosbein H; Guppy S; Haftel H; Helfrich D; Higgins G; Hillard A; Hollister JR; Hsu J; Hudgins A; Hung C; Huttenlocher A; Ilowite N; Imlay A; Imundo L; Inman CJ; Jaqith J; Jerath R; Jung L; Kahn P; Kapedani A; Kingsbury D; Klein K; Klein-Gitelman M; Kunkel A; Lapidus S; Layburn S; Lehman T; Lindsley C; Macgregor-Hannah M; Malloy M; Mawhorter C; McCurdy D; Mims K; Moorthy N; Morus D; Muscal E; Natter M; Olson J; O'Neil K; Onel K; Orlando M; Palmquist J; Phillips M; Ponder L; Prahalad S; Punaro M; Puplava D; Quinn S; Quintero A; Rabinovich C; Reed A; Reed C; Ringold S; Riordan M; Roberson S; Robinson A; Rossette J; Rothman D; Russo D; Ruth N; Schikler K; Sestak A; Shaham B; Sherman Y; Simmons M; Singer N; Spalding S; Stapp H; Syed R; Thomas E; Torok K; Trejo D; Tress J; Upton W; Vehe R; von Scheven E; Walters L; Weiss JE; Weiss PF; Welnick N; White A; Woo J; Wootton J; Yalcindag A; Zapp C; Zemel L; Zhu A
  •  go-up   go-down


2. Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS, Shprecher DR, Davis C, Davis MD, Stamler D, Anderson KE: Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology; 2017 May 23;88(21):2003-2010
Genetic Alliance. consumer health - Tardive dyskinesia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred seventeen patients with moderate to severe TD received deutetrabenazine or placebo in this randomized, double-blind, multicenter trial.
  • Secondary endpoints included treatment success at week 12 on the Clinical Global Impression of Change (CGIC) and Patient Global Impression of Change.
  • CONCLUSIONS: In patients with TD, deutetrabenazine was well tolerated and significantly reduced abnormal movements.
  • CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in patients with TD, deutetrabenazine reduces AIMS scores.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
  • [Cites] Neurotherapeutics. 2014 Jan;11(1):166-76 [24310603.001]
  • [Cites] Handb Clin Neurol. 2011;100:601-16 [21496610.001]
  • [Cites] Am J Psychiatry. 2016 Feb 1;173(2):184-92 [26472629.001]
  • [Cites] Expert Opin Ther Pat. 2014 Oct;24(10):1067-75 [25069517.001]
  • [Cites] Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S113-7 [24262160.001]
  • [Cites] Tremor Other Hyperkinet Mov (N Y). 2014 Oct 23;4:266 [25374768.001]
  • [Cites] J Clin Psychiatry. 2010 Apr;71(4):463-74 [20156410.001]
  • [Cites] Neuropsychiatr Dis Treat. 2013;9:1371-80 [24072972.001]
  • [Cites] Postgrad Med J. 2011 Feb;87(1024):132-41 [21131613.001]
  • [Cites] Res Nurs Health. 2009 Aug;32(4):465-74 [19434651.001]
  • [Cites] Neurol Clin. 2011 Feb;29(1):127-48, viii [21172575.001]
  • [Cites] JAMA. 2016 Jul 5;316(1):40-50 [27380342.001]
  • [Cites] Neurology. 2013 Jul 30;81(5):463-9 [23897874.001]
  • [Cites] Am J Geriatr Pharmacother. 2010 Aug;8(4):331-73 [20869622.001]
  • [Cites] Tremor Other Hyperkinet Mov (N Y). 2013 Jul 12;3:null [23858394.001]
  • [Cites] Neurology. 2006 Feb 14;66(3):366-72 [16476934.001]
  • [Cites] Mov Disord. 1987;2(2):125-9 [3504264.001]
  • [Cites] Psychiatr Danub. 2008 Dec;20(4):461-5 [19011586.001]
  • [Cites] Drug Des Devel Ther. 2013 Nov 06;7:1329-40 [24235816.001]
  • [Cites] West J Med. 1990 Nov;153(5):535-41 [1979705.001]
  • [Cites] Drug News Perspect. 2010 Jul-Aug;23(6):398-404 [20697607.001]
  • (PMID = 28446646.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuromuscular Agents; 0 / deutetrabenazine; Z9O08YRN8O / Tetrabenazine
  •  go-up   go-down


3. Tan J, You Y, Guo F, Xu J, Dai H, Bie P: Association of elevated risk of pancreatic cancer in diabetic patients: A systematic review and meta-analysis. Oncol Lett; 2017 Mar;13(3):1247-1255

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of elevated risk of pancreatic cancer in diabetic patients: A systematic review and meta-analysis.
  • PubMed, EMBASE, Scholar, Web of Science and Scopus databases were searched to identify clinical and patient oriented studies that examined the incidence of diabetes in pancreatic cancer patients and vice versa, over the last 10 years.
  • Parameters analyzed included, the Incidence of diabetes in pancreatic cancer patients; duration history of T2D in pancreatic cancer patients; influence of insulin therapy in T2D patients on pancreatic cancer incidence.
  • Eleven studies with a total of 14,399 patients, of whom 4,080 were T2D-positive and 9,721 were non-diabetic were included in this meta-analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2008 Jan;134(1):95-101 [18061176.001]
  • [Cites] J Clin Endocrinol Metab. 2013 Sep;98(9):3550-4 [23861463.001]
  • [Cites] Cancer Res. 2015 Aug 15;75(16):3355-64 [26113084.001]
  • [Cites] Pancreas. 2011 Aug;40(6):931-7 [21747317.001]
  • [Cites] Pancreas. 2013 Mar;42(2):202-8 [23000889.001]
  • [Cites] Ann Surg Oncol. 2014 Apr;21(4):1082-9 [24322532.001]
  • [Cites] Eur J Cancer. 2012 Jul;48(10):1434-42 [22119354.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16009-12 [20798346.001]
  • [Cites] J Natl Cancer Inst. 2013 Jul 17;105(14):1027-35 [23847240.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2013 Mar 5;110(10 ):3919-24 [23407165.001]
  • [Cites] J Gastroenterol. 2013 Feb;48(2):238-46 [22735942.001]
  • [Cites] BMC Public Health. 2014 Oct 10;14:1058 [25300498.001]
  • [Cites] World J Surg Oncol. 2012 Aug 24;10:171 [22920886.001]
  • [Cites] Am J Cancer Res. 2015 Sep 15;5(10):3260-9 [26693076.001]
  • [Cites] Biochim Biophys Acta. 2015 Jan;1855(1):61-82 [25489989.001]
  • [Cites] JOP. 2014 Jul 28;15(4):319-21 [25076332.001]
  • [Cites] Sci Rep. 2015 Nov 24;5:17102 [26598798.001]
  • [Cites] Cancer Res Treat. 2016 Jan;48(1):171-9 [25779362.001]
  • [Cites] Cancer Med. 2012 Dec;1(3):357-62 [23342285.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1458-63 [16896032.001]
  • [Cites] Acta Oncol. 2015 Jul;54(7):986-92 [25734801.001]
  • [Cites] Cancer Causes Control. 2011 Feb;22(2):189-97 [21104117.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1986-92 [17230509.001]
  • [Cites] Br J Cancer. 2015 Dec 1;113(11):1607-14 [26575601.001]
  • [Cites] Diabetes Care. 2012 Nov;35(11):2402-11 [23093685.001]
  • [Cites] Eur J Cancer. 2011 Jan;47(2):248-54 [20709528.001]
  • [Cites] Korean J Gastroenterol. 2016 Apr 25;67(4):168-77 [27112242.001]
  • [Cites] Urol Ann. 2012 May;4(2):98-101 [22629005.001]
  • [Cites] Lancet. 2005 Apr 9-15;365(9467):1333-46 [15823385.001]
  • [Cites] HPB (Oxford). 2012 Apr;14(4):228-35 [22404260.001]
  • [Cites] Ann Oncol. 2014 Oct;25(10):2065-72 [25057164.001]
  • (PMID = 28454242.001).
  • [ISSN] 1792-1074
  • [Journal-full-title] Oncology letters
  • [ISO-abbreviation] Oncol Lett
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Keywords] NOTNLM ; HbA1c / carbohydrate antigen 19-9 / insulin therapy / overall survival / pancreatic cancer / type 2 diabetes
  •  go-up   go-down


Advertisement
4. Welch VA, Akl EA, Pottie K, Ansari MT, Briel M, Christensen R, Dans A, Dans L, Eslava-Schmalbach J, Guyatt G, Hultcrantz M, Jull J, Katikireddi SV, Lang E, Matovinovic E, Meerpohl JJ, Morton RL, Mosdol A, Murad MH, Petkovic J, Schünemann H, Sharaf R, Shea B, Singh JA, Solà I, Stanev R, Stein A, Thabaneii L, Tonia T, Tristan M, Vitols S, Watine J, Tugwell P: GRADE equity guidelines 3: health equity considerations in rating the certainty of synthesized evidence. J Clin Epidemiol; 2017 Apr 04;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (2) consider patient-important outcomes relevant to health equity;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28389397.001).
  • [ISSN] 1878-5921
  • [Journal-full-title] Journal of clinical epidemiology
  • [ISO-abbreviation] J Clin Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Applicability / GRADE / Guidelines / Health / Indirectness / Meta-analysis / Subgroup analysis / Systematic review / equity
  •  go-up   go-down


5. Cox H, Dickson-Hall L, Ndjeka N, Van't Hoog A, Grant A, Cobelens F, Stevens W, Nicol M: Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study. PLoS Med; 2017 Feb;14(2):e1002238

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,734 patients diagnosed in 2014.
  • The number of diagnosed patients has increased substantially with the introduction of the Xpert MTB/RIF test, used for tuberculosis (TB) diagnosis for all patients with presumptive TB.
  • Routine aggregate data suggest a large treatment gap (pre-treatment loss to follow-up) between the numbers of patients with laboratory-confirmed RR-TB and those reported to have started second-line treatment.
  • METHODS AND FINDINGS: A nationwide retrospective cohort study was conducted to assess second-line treatment initiation and treatment delay among laboratory-diagnosed RR-TB patients.
  • Cohorts, including approximately 300 sequentially diagnosed RR-TB patients per South African province, were drawn from the years 2011 and 2013, i.e., before and after Xpert implementation.
  • Patients with prior laboratory RR-TB diagnoses within 6 mo and currently treated patients were excluded.
  • Treatment initiation was determined through data linkage with national and local treatment registers, medical record review, interviews with health care staff, and direct contact with patients or household members.
  • National estimates of the percentage of patients who initiated treatment and time to treatment were weighted to account for the sampling design.
  • There were 2,508 and 2,528 eligible patients in the 2011 and 2013 cohorts, respectively; 92% were newly diagnosed with RR-TB (no prior RR-TB diagnoses).
  • Nationally, among the 2,340 and 2,311 new RR-TB patients in the 2011 and 2013 cohorts, 55% (95% CI 53%-57%) and 63% (95% CI 61%-65%), respectively, started treatment within 6 mo of laboratory receipt of their diagnostic specimen (p < 0.001).
  • However, in 2013, there was no difference in the percentage of patients who initiated treatment at 6 mo between the 1,368 new RR-TB patients diagnosed by Xpert (62%, 95% CI 59%-65%) and the 943 diagnosed by other methods (64%, 95% CI 61%-67%) (p = 0.39).
  • In 2013, across the nine provinces, there were substantial variations in both treatment initiation (range 51%-73% by 6 mo) and median time to treatment (range 15-36 d, n = 1,450), and only 53% of the 1,448 new RR-TB patients who received treatment were recorded in the national RR-TB register.
  • Other limitations include the use of names and dates of birth to locate patient-level data, potentially resulting in missed treatment initiation among some patients.
  • However, given improved case detection with Xpert, a larger proportion of RR-TB patients overall have received treatment, with reduced delays.
  • Nonetheless, strategies to further improve linkage to treatment for all diagnosed RR-TB patients are urgently required.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28222095.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Neyt M, Baeyens H, Pouppez C, Slegers P, Hulstaert F, Stordeur S, Vinck I: Introduction of high-risk medical devices: national measures that can be taken under the current European legislation to put the patient interest central. Expert Rev Med Devices; 2017 Mar;14(3):181-188

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Introduction of high-risk medical devices: national measures that can be taken under the current European legislation to put the patient interest central.
  • INTRODUCTION: High-risk medical devices may not always provide a therapeutic added value to patients.
  • In conclusion, within the framework of the (revised) European legislation, measures at national level can be taken to temporarily restrict and follow up the use of high-risk medical devices with a greater focus on the therapeutic added value for the patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28128008.001).
  • [ISSN] 1745-2422
  • [Journal-full-title] Expert review of medical devices
  • [ISO-abbreviation] Expert Rev Med Devices
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Device approval / European union / equipement and supplies / government regulation / treatment outcome
  •  go-up   go-down


7. Serrano R, Borade A, Mir H, Shah A, Watson D, Infante A, Frankle MA, Mighell MA, Sagi HC, Horwitz DS, Sanders RW: Anterior-Inferior Plating Results in Fewer Secondary Interventions Compared to Superior Plating for Acute Displaced Mid-Shaft Clavicle Fracture. J Orthop Trauma; 2017 Apr 05;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Retrospective Comparative Study SETTING:: two academic Level 1 Regional Trauma Centers PATIENTS:: 510 patients treated surgically for an acutely displaced mid-shaft clavicle fracture between 2000-2013 were identified and reviewed retrospectively at a minimum of 24 months' follow-up (F/U).
  • INTERVENTION: Patients were treated either with AI or S clavicle plating at the treating surgeon's discretion.
  • RESULTS: Final analysis included 252 fractures/251 patients.
  • Seven patients/seven fractures (5.9%) in Group AI underwent a secondary surgery whereas 30 patients/30 fractures (22.3%) in group S required a secondary surgery.
  • Furthermore, because 80% of these subsequent interventions were a result of plate irritation with patient discomfort, the Odds Ratio for a second procedure was 5 times greater in those fractures treated with a superior plate.
  • Considering patient satisfaction and a reduced financial burden to the health care system, we recommend routine anterior-inferior plate application when ORIF of the clavicle is indicated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28548997.001).
  • [ISSN] 1531-2291
  • [Journal-full-title] Journal of orthopaedic trauma
  • [ISO-abbreviation] J Orthop Trauma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp RGJ, Mooijaart SP, Sattar N, Aubert CE, Aujesky D, Bauer DC, Baumgartner C, Blum MR, Browne JP, Byrne S, Collet TH, Dekkers OM, den Elzen WPJ, Du Puy RS, Ellis G, Feller M, Floriani C, Hendry K, Hurley C, Jukema JW, Kean S, Kelly M, Krebs D, Langhorne P, McCarthy G, McCarthy V, McConnachie A, McDade M, Messow M, O'Flynn A, O'Riordan D, Poortvliet RKE, Quinn TJ, Russell A, Sinnott C, Smit JWA, Van Dorland HA, Walsh KA, Walsh EK, Watt T, Wilson R, Gussekloo J, TRUST Study Group: Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. N Engl J Med; 2017 06 29;376(26):2534-2544
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 368 patients were assigned to receive levothyroxine (at a starting dose of 50 μg daily, or 25 μg if the body weight was <50 kg or the patient had coronary heart disease), with dose adjustment according to the thyrotropin level; 369 patients were assigned to receive placebo with mock dose adjustment.
  • RESULTS: The mean age of the patients was 74.4 years, and 396 patients (53.7%) were women.


9. Homcha BE, Mets EJ, Goldenberg MDF, Kong L, Vaida SJ: Development and Assessment of Pictorial Guide for Improved Accuracy of Visual Blood Loss Estimation in Cesarean Delivery. Simul Healthc; 2017 Jul 10;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and Assessment of Pictorial Guide for Improved Accuracy of Visual Blood Loss Estimation in Cesarean Delivery.
  • Blood loss estimation is further complicated during cesarean delivery (CD) by a large volume loss for a short period as well as the presence of amniotic fluid.
  • METHODS: A simulated CD scene was used to assess the ability of clinicians to estimate the amount of blood lost by a CD patient.
  • CONCLUSIONS: An institution-specific pictorial guide is effective at improving the accuracy of visual blood loss estimation in a simulation and may help improve clinical care in CD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28697055.001).
  • [ISSN] 1559-713X
  • [Journal-full-title] Simulation in healthcare : journal of the Society for Simulation in Healthcare
  • [ISO-abbreviation] Simul Healthc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Babiloni C, Del Percio C, Lizio R, Noce G, Cordone S, Lopez S, Soricelli A, Ferri R, Pascarelli MT, Nobili F, Arnaldi D, Aarsland D, Orzi F, Buttinelli C, Giubilei F, Onofrj M, Stocchi F, Stirpe P, Fuhr P, Gschwandtner U, Ransmayr G, Caravias G, Garn H, Sorpresi F, Pievani M, Frisoni GB, D'Antonio F, De Lena C, Güntekin B, Hanoğlu L, Başar E, Yener G, Emek-Savaş DD, Triggiani AI, Franciotti R, De Pandis MF, Bonanni L: Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. Neurobiol Aging; 2017 Jul;55:143-158

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study.
  • The aim of this retrospective exploratory study was that resting state eyes-closed electroencephalographic (rsEEG) rhythms might reflect brain arousal in patients with dementia due to Alzheimer's disease dementia (ADD), Parkinson's disease dementia (PDD), and dementia with Lewy body (DLB).
  • Demography, education, and Mini-Mental State Evaluation score were not different between the patient groups.
  • Furthermore, all patient groups showed lower posterior alpha 2 source activities.
  • The posterior delta and alpha sources allowed good classification accuracy (approximately 0.85-0.90) between the Nold subjects and patients, and between ADD and PDD patients.
  • In quiet wakefulness, delta and alpha sources unveiled different spatial and frequency features of the cortical neural synchronization underpinning brain arousal in ADD, PDD, and DLB patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28454845.001).
  • [ISSN] 1558-1497
  • [Journal-full-title] Neurobiology of aging
  • [ISO-abbreviation] Neurobiol. Aging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Alzheimer's disease dementia (ADD) / Dementia with Lewy body (DLB) / Exact low-resolution brain electromagnetic source tomography (eLORETA) / Parkinson's disease dementia (PDD) / Resting state electroencephalographic (rsEEG) rhythms
  •  go-up   go-down


11. Denis F, Lethrosne C, Pourel N, Molinier O, Pointreau Y, Domont J, Bourgeois H, Senellart H, Trémolières P, Lizée T, Bennouna J, Urban T, El Khouri C, Charron A, Septans AL, Balavoine M, Landry S, Solal-Céligny P, Letellier C: Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients. J Natl Cancer Inst; 2017 09 01;109(9)
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients.
  • Background: The use of web-based monitoring for lung cancer patients is growing in interest because of promising recent results suggesting improvement in cancer and resource utilization outcomes.
  • It remains an open question whether the overall survival (OS) in these patients could be improved by using a web-mediated follow-up rather than classical scheduled follow-up and imaging.
  • Methods: Advanced-stage lung cancer patients without evidence of disease progression after or during initial treatment were randomly assigned in a multicenter phase III trial to compare a web-mediated follow-up algorithm (experimental arm), based on weekly self-scored patient symptoms, with routine follow-up with CT scans scheduled every three to six months according to the disease stage (control arm).
  • Results: From June 2014 to January 2016, 133 patients were enrolled and 121 were retained in the intent-to-treat analysis; 12 deemed ineligible after random assignment were not subsequently followed.
  • Most of the patients (95.1%) had stage III or IV disease.
  • The performance status at first detected relapse was 0 to 1 for 75.9% of the patients in the experimental arm and for 32.5% of those in the control arm (two-sided P < .001).
  • Optimal treatment was initiated in 72.4% of the patients in the experimental arm and in 32.5% of those in the control arm (two-sided P < .001).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Diagnostic Self Evaluation. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Outcome Assessment (Health Care) / methods. Outcome Assessment (Health Care) / statistics & numerical data. Prospective Studies. Quality of Life. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28423407.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


12. Holcomb JB, Swartz MD, DeSantis SM, Greene TJ, Fox EE, Stein DM, Bulger EM, Kerby JD, Goodman M, Schreiber MA, Zielinski MD, O'Keeffe T, Inaba K, Tomasek JS, Podbielski JM, Appana SN, Yi M, Wade CE, PROHS Study Group: Multicenter observational prehospital resuscitation on helicopter study. J Trauma Acute Care Surg; 2017 Jul;83(1 Suppl 1):S83-S91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Earlier use of in-hospital plasma, platelets, and red blood cells (RBCs) has improved survival in trauma patients with severe hemorrhage.
  • Retrospective studies have associated improved early survival with prehospital blood product transfusion (PHT).
  • We hypothesized that PHT of plasma and/or RBCs would result in improved survival after injury in patients transported by helicopter.
  • METHODS: Adult trauma patients transported by helicopter from the scene to nine Level 1 trauma centers were prospectively observed from January to November 2015.
  • All patients meeting predetermined high-risk criteria were analyzed.
  • Patients receiving PHT were compared with patients not receiving PHT.
  • Our primary analysis compared mortality at 3 hours, 24 hours, and 30 days, using logistic regression to adjust for confounders and site heterogeneity to model patients who were matched on propensity scores.
  • RESULTS: Twenty-five thousand one hundred eighteen trauma patients were admitted, 2,341 (9%) were transported by helicopter, of which 1,058 (45%) met the highest-risk criteria.
  • Five hundred eighty-five of 1,058 patients were flown on helicopters carrying blood products.
  • Twenty-four percent of eligible patients received a PHT.
  • Of patients receiving PHT, 24% received only plasma, 7% received only RBCs, and 69% received both.
  • With few units transfused to each patient and small outcome differences between groups, it is likely large, multicenter, randomized studies will be required to detect survival differences in this important population.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28383476.001).
  • [ISSN] 2163-0763
  • [Journal-full-title] The journal of trauma and acute care surgery
  • [ISO-abbreviation] J Trauma Acute Care Surg
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / U01 HL077863
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J, Albert CM, Anderson CS, Antoniou S, Benjamin EJ, Boriani G, Brachmann J, Brandes A, Chao TF, Conen D, Engdahl J, Fauchier L, Fitzmaurice DA, Friberg L, Gersh BJ, Gladstone DJ, Glotzer TV, Gwynne K, Hankey GJ, Harbison J, Hillis GS, Hills MT, Kamel H, Kirchhof P, Kowey PR, Krieger D, Lee VWY, Levin LÅ, Lip GYH, Lobban T, Lowres N, Mairesse GH, Martinez C, Neubeck L, Orchard J, Piccini JP, Poppe K, Potpara TS, Puererfellner H, Rienstra M, Sandhu RK, Schnabel RB, Siu CW, Steinhubl S, Svendsen JH, Svennberg E, Themistoclakis S, Tieleman RG, Turakhia MP, Tveit A, Uittenbogaart SB, Van Gelder IC, Verma A, Wachter R, Yan BP, AF-Screen Collaborators: Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. Circulation; 2017 05 09;135(19):1851-1867
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During 2016, 60 expert members of AF-SCREEN, including physicians, nurses, allied health professionals, health economists, and patient advocates, were invited to prepare sections of a draft document.
  • Certain patient groups, such as those with recent embolic stroke of uncertain source (ESUS), require more intensive monitoring for AF.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28483832.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; atrial fibrillation (major topic) / screening (major topic) / stroke (major topic)
  • [Investigator] Al Awwad A; Al-Kalili F; Berge T; Breithardt G; Bury G; Caorsi WR; Chan NY; Chen SA; Christophersen I; Connolly S; Crijns H; Davis S; Dixen U; Doughty R; Du X; Ezekowitz M; Fay M; Frykman V; Geanta M; Gray H; Grubb N; Guerra A; Halcox J; Hatala R; Heidbuchel H; Jackson R; Johnson L; Kaab S; Keane K; Kim YH; Kollios G; Løchen ML; Ma C; Mant J; Martinek M; Marzona I; Matsumoto K; McManus D; Moran P; Naik N; Ngarmukos T; Prabhakaran D; Reidpath D; Ribeiro A; Rudd A; Savalieva I; Schilling R; Sinner M; Stewart S; Suwanwela N; Takahashi N; Topol E; Ushiyama S; Verbiest van Gurp N; Walker N; Wijeratne T
  •  go-up   go-down


14. Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C, Lusakowska A, Comi GP, Cuisset JM, Abitbol JL, Scherrer B, Ducray PS, Buchbjerg J, Vianna E, van der Pol WL, Vuillerot C, Blaettler T, Fontoura P, Olesoxime SMA Phase 2 Study Investigators: Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol; 2017 Jul;16(7):513-522
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial.
  • We investigated the safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 SMA.
  • METHODS: This randomised, double-blind, placebo-controlled, phase 2 study was done in 22 neuromuscular care centres in Belgium, France, Germany, Italy, Netherlands, Poland, and the UK.
  • Safety and efficacy of olesoxime were assessed in patients aged 3-25 years with genetically confirmed type 2 or non-ambulatory type 3 SMA.
  • A centralised, computerised randomisation process allocated patients (2:1 with stratification by SMA type and centre) to receive olesoxime (10 mg/kg per day) in an oral liquid suspension or placebo for 24 months.
  • Patients, investigators assessing outcomes, and sponsor study personnel were masked to treatment assignment.
  • A shorter, 20-item version of the MFM, which was specifically adapted for young children, was used to assess patients younger than 6 years.
  • Safety was assessed in all patients who received one or more doses of the study drug.
  • Of 198 patients screened, 165 were randomly assigned to olesoxime (n=108) or placebo (n=57).
  • Five patients in the olesoxime group were not included in the primary outcome analysis because of an absence of post-baseline assessments.
  • There were two patient deaths (one in each group), but these were not deemed to be related to the study treatment.
  • Although the primary endpoint was not met, secondary endpoints and sensitivity analyses suggest that olesoxime might maintain motor function in patients with type 2 or type 3 SMA over a period of 24 months.
  • Based on these results, olesoxime might provide meaningful clinical benefits for patients with SMA and, given its mode of action, might be used in combination with other drugs targeting other mechanisms of disease, although additional evidence is needed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28460889.001).
  • [ISSN] 1474-4465
  • [Journal-full-title] The Lancet. Neurology
  • [ISO-abbreviation] Lancet Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] André C; Bruno C; Chabrol B; Deconinck N; Estournet B; Fontaine-Carbonnel S; Goemans N; Gorni K; Govoni A; Guglieri M; Lochmuller H; Magri F; Mayer M; Müller-Felber W; Rivier F; Roper H; Schara U; Scoto M; van den Berg L; Vita G; Walter MC
  •  go-up   go-down


15. Sheedy SP, Bruining DH, Dozois EJ, Faubion WA, Fletcher JG: MR Imaging of Perianal Crohn Disease. Radiology; 2017 Mar;282(3):628-645
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Perianal fistulas are a leading cause of patient morbidity because closure often requires multimodality treatments over a prolonged period of time.
  • Different treatment modalities are selected based on fistula anatomy, patient factors, and management goals (closure versus sepsis control).
  • Radiologists can help maximize patient care by being familiar with MR imaging features of perianal Crohn disease and knowledgeable about what features may influence therapy decisions.

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28218881.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


16. Aliberti S, Morlacchi LC, Faverio P, Fernandez-Botran R, Cosentini R, Mantero M, Peyrani P, Ramirez J, Bordon J, Blasi F: Serum and exhaled breath condensate inflammatory cytokines in community-acquired pneumonia: a prospective cohort study. Pneumonia (Nathan); 2016;8:8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to evaluate pro- and anti-inflammatory cytokines at both local (lung) and systemic (blood) levels and their relationship with the severity of the disease on admission and time for a patient to reach clinical stability during hospitalisation.
  • METHODS: This was an observational, prospective, cohort study of hospitalised patients with a diagnosis of CAP at the IRCCS Policlinico Hospital, Milan, Italy, between April 2010 and January 2012.
  • RESULTS: A total of 74 patients (median age: 76 years; gender: 61 % male) were enrolled.
  • The anti- to pro-inflammatory cytokine ratio was reduced in patients with severe disease on admission and prolonged time to reach clinical stability.
  • CONCLUSIONS: Dis-regulation between pro- and anti-inflammatory pathways might be a part of the pathogenic mechanisms that lead to severe infection and worse early clinical outcomes in CAP patients.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 1996 Nov;174(5):994-1000 [8896500.001]
  • [Cites] Crit Care Med. 2008 Jan;36(1):296-327 [18158437.001]
  • [Cites] Lancet. 1997 May 24;349(9064):1498-504 [9167458.001]
  • [Cites] J Pathol. 2013 Sep;231(1):8-20 [23794437.001]
  • [Cites] Eur Respir J. 2013 Sep;42(3):742-9 [23143544.001]
  • [Cites] Eur Respir J. 2005 Sep;26(3):523-48 [16135737.001]
  • [Cites] Infect Dis Clin North Am. 2013 Mar;27(1):133-47 [23398870.001]
  • [Cites] Eur Respir J. 2002 Oct;20(4):990-5 [12412694.001]
  • [Cites] Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72 [17278083.001]
  • [Cites] Crit Care Med. 1999 Sep;27(9):1745-53 [10507593.001]
  • [Cites] Thorax. 2000 Jan;55(1):46-52 [10607801.001]
  • [Cites] Scand J Infect Dis. 1995;27(5):457-62 [8588135.001]
  • [Cites] Thorax. 1999 Jan;54(1):51-5 [10343632.001]
  • [Cites] Eur Respir J. 2005 Dec;26(6):1138-80 [16319346.001]
  • [Cites] J Crit Care. 2010 Mar;25(1):176.e7-13 [19592208.001]
  • [Cites] Natl Vital Stat Rep. 2009 Apr 17;57(14):1-134 [19788058.001]
  • [Cites] Pneumonol Alergol Pol. 2011;79(2):90-8 [21351059.001]
  • [Cites] Med Mycol. 2013 Oct;51(7):704-12 [23488973.001]
  • [Cites] J Allergy Clin Immunol. 2002 Jul;110(1):28-34 [12110814.001]
  • [Cites] N Engl J Med. 1997 Jan 23;336(4):243-50 [8995086.001]
  • [Cites] Eur Respir J. 2013 Jun;41(6):1378-85 [23258791.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1255-9 [16160134.001]
  • (PMID = 28702287.001).
  • [ISSN] 2200-6133
  • [Journal-full-title] Pneumonia (Nathan Qld.)
  • [ISO-abbreviation] Pneumonia (Nathan)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Community-acquired pneumonia / Exhaled breath condensate / Inflammation / Inflammatory cytokines / Serum
  •  go-up   go-down


17. Verwaal VJ, Rau B, Jamali F, Gilly FN, de Hingh I, Takala H, Syk I, Pelz J, Mulsow J, van der Speeten K, Shigeki K, Iversen LH, Mohamed F, Glehen O, Younan R, Yarema R, Gonzalez-Moreno S, O'Dwyer S, Yonemura Y, Sugarbaker P: Registries on peritoneal surface malignancies throughout the world, their use and their options. Int J Hyperthermia; 2017 Aug;33(5):528-533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: The treatment of peritoneal surface malignancies ranges from palliative care to full cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy, HIPEC.
  • Ongoing monitoring of patient recruitment and volume is usually carried out through dedicated registries.
  • The questionnaire covers: general purpose of the registry; inclusion criteria in the registry; the date the registry was first established; volume of patients in the registry and description of the data fields in the registries.
  • Most database collect data on patients who have undergone an attempt to CRS and HIPEC.
  • Two registries collect data on all patients with peritoneal carcinomatosis regardless the treatment.
  • When correlating the number of cases of CRS and HIPEC that are performed to the catchment area of the various registry, a large variation in the number of performed procedures related to the overall population was noted, ranging from 1.3 to 57 patients/million year with an average of 15 patients/1 million year.
  • The most striking difference is the proportion of HIPEC procedures per capita which ranges from 1.3 to 57 patients per million.
  • This suggests either a difference in patient selection, lack of access to HIPEC centres or lack of appropriate data collection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28540833.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; HIPEC / peritoneal surface malignancy / registration study
  •  go-up   go-down


18. Ferguson S, Ahmad S, Chen Y, Ferreira C, Islam M, Keeling V, Lau A, Jin H: SU-F-T-143: Implementation of a Correction-Based Output Model for a Compact Passively Scattered Proton Therapy System. Med Phys; 2016 Jun;43(6):3494-3495

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A previously published output prediction model (Sahoo et al, Med Phys, 35, 5088-5097, 2008) was commissioned for our Mevion S250 proton therapy system.
  • To minimize fluence perturbation, scattered dose from range compensator and patient was not considered.
  • However, great care should be taken when the field-size is less than 5×5 cm<sup>2</sup> where a direct output measurement is required due to substantial output change by irregular block shape.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2016 American Association of Physicists in Medicine.
  • (PMID = 28047467.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Computer modeling / Interpolation / Proton therapy
  •  go-up   go-down


19. Nguyen KT, Olgin JE, Pletcher MJ, Ng M, Kaye L, Moturu S, Gladstone RA, Malladi C, Fann AH, Maguire C, Bettencourt L, Christensen MA, Marcus GM: Smartphone-Based Geofencing to Ascertain Hospitalizations. Circ Cardiovasc Qual Outcomes; 2017 Mar;10(3)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ascertainment of hospitalizations is critical to assess quality of care and the effectiveness and adverse effects of various therapies.
  • An in-person study included consecutive consenting patients scheduled for electrophysiology and cardiac catheterization procedures.
  • Of 22 eligible in-person patients, 17 hospitalizations were detected (sensitivity 77%; 95% confidence interval, 55%-92%).
  • This first proof of concept may ultimately be applicable to geofencing other types of prespecified locations to facilitate healthcare research and patient care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [Cites] J Biomed Inform. 2009 Apr;42(2):377-81 [18929686.001]
  • [Cites] Telemed J E Health. 2016 Aug;22(8):655-65 [26958742.001]
  • [Cites] J Am Coll Cardiol. 2012 Aug 14;60(7):569-80 [22796257.001]
  • [Cites] J Vasc Surg. 2014 Jul;60(1):98-105 [24636641.001]
  • [Cites] Am J Epidemiol. 1998 May 15;147(10):969-77 [9596475.001]
  • [Cites] Med Care Res Rev. 2006 Apr;63(2):217-35 [16595412.001]
  • [Cites] J Clin Epidemiol. 1990;43(1):87-91 [2319285.001]
  • [Cites] Gerontologist. 2016 Oct;56(5):807-16 [26035900.001]
  • [Cites] Patient Prefer Adherence. 2016 Jan 27;10:99-106 [26869773.001]
  • [Cites] Am J Hypertens. 2007 Sep;20(9):942-8 [17765133.001]
  • [Cites] JMIR Mhealth Uhealth. 2016 Apr 19;4(2):e41 [27095507.001]
  • [Cites] Soc Sci Med. 2008 Jul;67(1):128-36 [18396367.001]
  • [Cites] AIDS. 2006 Jan 9;20(2):253-60 [16511419.001]
  • [Cites] Lancet. 2012 Dec 15;380(9859):2197-223 [23245608.001]
  • [Cites] Am J Epidemiol. 2004 Dec 15;160(12):1152-8 [15583367.001]
  • [Cites] Biotechnol Adv. 2016 May-Jun;34(3):291-304 [26952640.001]
  • [Cites] Lancet. 2014 Jul 5;384(9937):45-52 [24996589.001]
  • [Cites] Heart Rhythm. 2016 Jan;13(1):3-9 [26340844.001]
  • [Cites] JMIR Mhealth Uhealth. 2014 May 01;2(2):e19 [25099179.001]
  • [Cites] BMJ Open. 2015 Dec 23;5(12):e008896 [26700275.001]
  • [Cites] Health Serv Res. 2002 Jun;37(3):751-74 [12132604.001]
  • (PMID = 28325751.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Grant] United States / NIMHD NIH HHS / MD / R25 MD006832; United States / NCATS NIH HHS / TR / TL1 TR000144; United States / NIBIB NIH HHS / EB / U2C EB021881
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; fast food / hospitalization / internet / pharmacies / smartphone
  •  go-up   go-down


20. Temel JS, Greer JA, El-Jawahri A, Pirl WF, Park ER, Jackson VA, Back AL, Kamdar M, Jacobsen J, Chittenden EH, Rinaldi SP, Gallagher ER, Eusebio JR, Li Z, Muzikansky A, Ryan DP: Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial. J Clin Oncol; 2017 Mar 10;35(8):834-841
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial.
  • Purpose We evaluated the impact of early integrated palliative care (PC) in patients with newly diagnosed lung and GI cancer.
  • Patients and Methods We randomly assigned patients with newly diagnosed incurable lung or noncolorectal GI cancer to receive either early integrated PC and oncology care (n = 175) or usual care (n = 175) between May 2011 and July 2015.
  • Patients who were assigned to the intervention met with a PC clinician at least once per month until death, whereas those who received usual care consulted a PC clinician upon request.
  • Secondary end points included change in QOL from baseline to week 24, change in depression per the Patient Health Questionnaire-9, and differences in end-of-life communication.
  • Results Intervention patients ( v usual care) reported greater improvement in QOL from baseline to week 24 (1.59 v -3.40; P = .010) but not week 12 (0.39 v -1.13; P = .339).
  • Intervention patients also reported lower depression at week 24, controlling for baseline scores (adjusted mean difference, -1.17; 95% CI, -2.33 to -0.01; P = .048).
  • Intervention effects varied by cancer type, such that intervention patients with lung cancer reported improvements in QOL and depression at 12 and 24 weeks, whereas usual care patients with lung cancer reported deterioration.
  • Patients with GI cancers in both study groups reported improvements in QOL and mood by week 12.
  • Intervention patients versus usual care patients were more likely to discuss their wishes with their oncologist if they were dying (30.2% v 14.5%; P = .004).
  • Conclusion For patients with newly diagnosed incurable cancers, early integrated PC improved QOL and other salient outcomes, with differential effects by cancer type.
  • Early integrated PC may be most effective if targeted to the specific needs of each patient population.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Intern Med. 2001 Sep;16(9):606-13 [11556941.001]
  • [Cites] J Clin Oncol. 2011 Jun 10;29(17):2319-26 [21555700.001]
  • [Cites] N Engl J Med. 2012 Oct 25;367(17):1616-25 [23094723.001]
  • [Cites] Cancer. 2014 Jan 15;120(2):278-85 [24122784.001]
  • [Cites] J Palliat Med. 2013 Aug;16(8):894-900 [23786425.001]
  • [Cites] J Clin Oncol. 2012 Mar 10;30(8):880-7 [22312101.001]
  • [Cites] J Pain Symptom Manage. 2015 Dec;50(6):758-67 [26296261.001]
  • [Cites] J Pain Symptom Manage. 2007 Jun;33(6):737-44 [17531914.001]
  • [Cites] J Palliat Med. 2014 Nov;17(11):1244-8 [25390467.001]
  • [Cites] Acta Psychiatr Scand. 1983 Jun;67(6):361-70 [6880820.001]
  • [Cites] Mil Med. 2015 Apr;180(4):365-7 [25826339.001]
  • [Cites] JAMA. 2008 Oct 8;300(14):1665-73 [18840840.001]
  • [Cites] Stat Med. 2013 Apr 15;32(8):1394-406 [23001893.001]
  • [Cites] JAMA. 2008 Apr 9;299(14):1698-709 [18398082.001]
  • [Cites] J Clin Oncol. 2015 May 1;33(13):1438-45 [25800768.001]
  • [Cites] N Engl J Med. 2010 Aug 19;363(8):733-42 [20818875.001]
  • [Cites] Arch Intern Med. 2009 Mar 9;169(5):480-8 [19273778.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2377-82 [17557950.001]
  • [Cites] Lancet. 2014 May 17;383(9930):1721-30 [24559581.001]
  • [Cites] JAMA. 2016 Jul 5;316(1):51-62 [27380343.001]
  • [Cites] Prev Sci. 2013 Apr;14(2):111-20 [21562742.001]
  • [Cites] Qual Life Res. 2002 May;11(3):207-21 [12074259.001]
  • [Cites] JAMA. 2009 Aug 19;302(7):741-9 [19690306.001]
  • [Cites] Nat Rev Clin Oncol. 2016 Mar;13(3):159-71 [26598947.001]
  • (PMID = 28029308.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023108; United States / NINR NIH HHS / NR / R01 NR012735
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Backes D, Rinkel GJE, Greving JP, Velthuis BK, Murayama Y, Takao H, Ishibashi T, Igase M, terBrugge KG, Agid R, Jääskeläinen JE, Lindgren AE, Koivisto T, von Und Zu Fraunberg M, Matsubara S, Moroi J, Wong GKC, Abrigo JM, Igase K, Matsumoto K, Wermer MJH, van Walderveen MAA, Algra A, Vergouwen MDI: ELAPSS score for prediction of risk of growth of unruptured intracranial aneurysms. Neurology; 2017 Apr 25;88(17):1600-1606
MedlinePlus Health Information. consumer health - Brain Aneurysm.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From 10 cohorts of patients with unruptured intracranial aneurysms and follow-up imaging, we pooled individual data on sex, population, age, hypertension, history of subarachnoid hemorrhage, and aneurysm location, size, aspect ratio, and shape but not on smoking during follow-up and family history of intracranial aneurysms in 1,507 patients with 1,909 unruptured intracranial aneurysms and used aneurysm growth as outcome.
  • RESULTS: Aneurysm growth occurred in 257 patients (17%) and 267 aneurysms (14%) during 5,782 patient-years of follow-up.
  • CONCLUSIONS: The ELAPSS score consists of 6 easily retrievable predictors and can help physicians in decision making on the need for and timing of follow-up imaging in patients with unruptured intracranial aneurysms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Academy of Neurology.
  • (PMID = 28363976.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


22. Beckmann S, Nikolic N, Denhaerynck K, Binet I, Koller M, Boely E, De Geest S, Psychosocial Interest Group, Swiss Transplant Cohort Study: Evolution of body weight parameters up to 3 years after solid organ transplantation: The prospective Swiss Transplant Cohort Study. Clin Transplant; 2016 Dec 23;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 3 years, based on their BMI categories at 6 months, normal weight and obese liver Tx patients, as well as underweight kidney, lung and heart Tx patients had the highest weight gains.
  • Judged against international Tx patient data, the majority of our Swiss Tx recipients' experienced lower post-Tx weight gain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
  • (PMID = 28008650.001).
  • [ISSN] 1399-0012
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Keywords] NOTNLM ; body mass index / obesity / organ transplantation / prospective study / underweight / weight gain
  • [Investigator] Berben L; Burkhalter H; Claes V; Helmy R; Kirsch M; Leppla L; Mauthner O; Struker M; Boehler A; Gerull S; Huynh-Do U; Catana E; Simcox A; Seiler A; Klaghofer R; Künzler-Heule P; Achermann R; Amico P; Aubert JD; Banz V; Beldi G; Benden C; Berger C; Bochud PY; Bucher H; Bühler L; Carell T; Chalandon Y; de Rougemont O; Dickenmann M; Duchosal M; Elkrief L; Fehr T; Ferrari-Lacraz S; Garzoni C; Soccal PG; Gaudet C; Giostra E; Golshayan D; Hadaya K; Halter J; Heim D; Hess C; Hillinger S; Hirsch HH; Hofbauer G; Immer F; Laesser B; Lehmann R; Lovis C; Manuel O; Marti HP; Martin PY; Meylan P; Mohacsi P; Morel P; Mueller U; Mueller NJ; Mueller-McKenna H; Müller A; Müller T; Müllhaupt B; Nadal D; Pascual M; Passweg J; Rick J; Roosnek E; Rosselet A; Rothlin S; Ruschitzka F; Schanz U; Schaub S; Schnyder A; Seiler C; Stampf S; Steiger J; Stirnimann G; Toso C; Van Delden C; Venetz JP; Villard J; Wick M; Wilhelm M; Yerly P
  •  go-up   go-down


23. Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadié M, Parrens M, Vergier B, Copie-Bergman C, Fabiani B, Traverse-Glehen A, Brousse N, Copin MC, Tas P, Petrella T, Rousselet MC, Brière J, Charlotte F, Chassagne-Clement C, Rousset T, Xerri L, Moreau A, Martin A, Damotte D, Dartigues P, Soubeyran I, Peoch M, Dechelotte P, Michiels JF, de Mascarel A, Berger F, Bossard C, Arbion F, Quintin-Roué I, Picquenot JM, Patey M, Fabre B, Sevestre H, Le Naoures C, Chenard-Neu MP, Bastien C, Thiebault S, Martin L, Delage M, Filleron T, Salles G, Molina TJ, Delsol G, Brousset P, Gaulard P: Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. J Clin Oncol; 2017 Jun 20;35(18):2008-2017

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.
  • Materials and Methods From January 2010 to December 2013, 42,145 samples from patients with newly diagnosed or suspected lymphomas were reviewed, according to the 2008 WHO classification, in real time by experts through the Lymphopath Network.
  • Changes in diagnosis between referral and expert review were classified as major or minor according to their potential impact on patient care.
  • A diagnostic change between referral and expert review occurred in 19.7% of patients, with an estimated impact on patient care for 17.4% of patients.
  • This rate was significantly higher for patients sent with a provisional diagnosis seeking expert second opinion (37.8%) than for patients sent with a formal diagnosis (3.7%).
  • Conclusion To our knowledge, this study provides the largest ever description of the distribution of lymphoma entities in a western country and highlights how expert review significantly contributes to a precise lymphoma diagnosis and optimal clinical management in a proportion of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28459613.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Bourgeois H, Grudé F, Solal-Céligny P, Dupuis O, Voog E, Ganem G, Denis F, Zinger M, Juhel-Voog L, Lafond C, Maillart P, Capitain O, Delva R, Soulié P, Abadie-Lacourtoisie S, Guérin-Meyer V, Morin-Meschin ME, Commer JM, Gangler A, d'Aillières B, Zannetti A, Bourbouloux E, Berton-Rigault D, Lebouvier-Sadot S, Kaassis M, Baudon J, Lam YH, Bizieux A, Marcq M, Edeline J, Le Du F, Lefeuvre C, Deguiral P, Delecroix V, Blot E, Egreteau J, Goudier MJ, Lamy R, Ferec M, Artignan X, Corbinais S, Morel H, Hardy-Bessard AC, Alleaume C, Naudeix E, Cojocarasu O, Metges JP, Riché C, Déniel-Lagadec D, Marhuenda F, Ingrand P, Douillard JY: Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anti-cancer therapy: PRONOPALL study. Ann Oncol; 2017 May 04;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Background: In 2008, a study of the characteristics of hospitalised patients led to the development of a prognostic tool that distinguished three populations with significantly different two-month survival rates.
  • Patients and Methods: : PRONOPALL is a multicentre study of current care.
  • 302 adult patients who met one or more of the following criteria: life expectancy under six months, performance status ≥ 2, disease progression during the previous chemotherapy regimen, were included across 16 institutions between October 2009 and October 2010.
  • Afterwards, in order to validate the prognostic tool, the score was ciphered and correlated to patient survival.
  • Results: 262 patients (87%) were evaluable (27 patients excluded and 13 unknown score).
  • 32% of patients presented one metastatic site, 35% had two, and 31% had more than two.
  • According to the PRONOPALL prognostic tool, the two-month survival rate was 92% and the median survival rate was 301 days [209-348] for the 130 patients in population C, 66% and 79 days [71-114] for the 111 patients in population B, and 24% and 35 days for [14-56] the 21 patients in population A.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28472235.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Lactate DeHydrogenase / Perfomans Status (PS ECOG) / Prognostic tool / palliative care / serum albumin / survival at 2 months
  •  go-up   go-down


25. Negredo A, de la Calle-Prieto F, Palencia-Herrejón E, Mora-Rillo M, Astray-Mochales J, Sánchez-Seco MP, Bermejo Lopez E, Menárguez J, Fernández-Cruz A, Sánchez-Artola B, Keough-Delgado E, Ramírez de Arellano E, Lasala F, Milla J, Fraile JL, Ordobás Gavín M, Martinez de la Gándara A, López Perez L, Diaz-Diaz D, López-García MA, Delgado-Jimenez P, Martín-Quirós A, Trigo E, Figueira JC, Manzanares J, Rodriguez-Baena E, Garcia-Comas L, Rodríguez-Fraga O, García-Arenzana N, Fernández-Díaz MV, Cornejo VM, Emmerich P, Schmidt-Chanasit J, Arribas JR, Crimean Congo Hemorrhagic Fever@Madrid Working Group: Autochthonous Crimean-Congo Hemorrhagic Fever in Spain. N Engl J Med; 2017 07 13;377(2):154-161

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The index patient acquired the disease through a tick bite in the province of Ávila - 300 km away from the province of Cáceres, where viral RNA from ticks was amplified in 2010.
  • The second patient was a nurse who became infected while caring for the index patient.
  • Both were infected with the African 3 lineage of this virus. (Funded by Red de Investigación Cooperativa en Enfermedades Tropicales [RICET] and Efficient Response to Highly Dangerous and Emerging Pathogens at EU [European Union] Level [EMERGE].).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28700843.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Vázquez A; Hernández L; Herrero L; Molero F; Alami Tajri B; Alba Suarez AM; Aldeanueva Serrano ME; Alonso Domingo JJ; Aparicio Plaza E; Arabi Fernández O; Arsuaga Vicente M; Armijo Castillo MO; Avila Borja RM; Barrientos Martínez MI; Borrego Prieto P; Bretín Zornoza M; Cabildo Fajardo ML; Cachafeiro Fuciños L; Del Campo Ortún E; Campos Higueras JE; Casado Fernández L; Castaño Carmona AM; Castillo Portellano C; Cerón Serrano A; Cuesta Herrero Y; Del Carmen De Dompablo Ferrándiz M; Díaz Menendez M; Enriquez Calatrava V; Fernández Puntero B; Flores Cabeza EM; Galvez Charro M; García Hernandez R; García Expósito MA; Garcia Gonzalez C; García Sánchez M; Gómez Campos AM; Gómez Rodríguez E; Gómez Del Pulgar Carrillo E; González Herrero MA; González Herrezuelo I; González Navarro A; González Del Castillo AI; González Espinosa S; Gracia Pasamar JC; Granizo Lopez R; Gutierrez Plana C; Gutierrez Prieto M; Hermida Rodriguez J; Hernández Bernal M; Herrero Benito C; Herrero Alonso MT; Jara Orozco PA; Jiménez Castellano R; León Pérez M; López Lorente P; López Alvir C; López Díaz-Plaza Y; Lorenzo Velez C; Lucas Burgos V; Machón Rodríguez B; Mármol Martínez F; Marote Martín C; Martínez Corral C; Martínez Nieto SA; Martínez Quintana JI; Molins Bustamante C; Moreno Lozano E; Moreno Martinez C; Del Carmen Muñoz Gil M; Ortega Lucena C; Patrón Barambio PA; Perez Pacheco M; Del Rosario Rivero Gómez M; Rodriguez Diez R; San Juan Rodríguez A; Sanchez Arroyo V; Sanchez Villarejo M; Silva Montero AI; del Carmen Solera Martin De Nicolas M; Soriano Sánchez MA; Tapia García MR; Torres Hidalgo A; Robustillo Rodela A; Elola Vicente P; Arnalich F; Buño Soto A; García de Lorenzo A; Núñez C; Garcia-Pando CR; Martins Muñoz G; Velasquez-Alcala SG; Ángeles Sánchez-Castillo M; Rey-Cuevas E; Del Rosario Férnandez-Acevedo M; Borobia A; Aguirre Martín-Gil R; Alvarez-Castillo MC; Aragón-Peña A; de Burgos-Lunar C; Córdoba-Deorador E; Diezma-Criado JC; Domínguez-Berjón F; Esteban-Niveiro MJ; Bernardo-Ferrer Simó J; Fuentes-Rodriguez CY; Fuster F; Garcia-Mañosa I; Gil-Montalbán E; Ibáñez-Martí C; Insua Marisquerena E; Lasheras-Carbajo MD; Latasa-Zamalloa P; Angeles Lópaz-Perez M; Marino E; Martin-Martínez F; Martinez-Vidal M; de Miguel-Moro JI; Nieto-Juliá A; Noguerales-De la Obra R; Ortiz-Marrón H; Palomino-Lopez MT; Sanchez-Diaz J; Sánchez-Gómez A; Torrijano-Castillo MJ; Wijers I; Sierra-Matamoros MJ; Simón-Soria F; García Bordas J; Muñoz García P; Fernández RA; Goyanes MJ; Gijón Vidaurreta P; Martín-Rabadán P; Sánchez Carrillo C; Bouza E; Barrios JC; Guerrero JE; Bibiano C; Medina Iglesias P; Pacheco Puig R; Aguilar Huertas JL; Sanz de Miguel E; de Sansegundo Reyes M; Camacho Muñoz I; Cava F
  •  go-up   go-down


26. Cornejo-Olivas M, Torres L, Velit-Salazar MR, Inca-Martinez M, Mazzetti P, Cosentino C, Micheli F, Perandones C, Dieguez E, Raggio V, Tumas V, Borges V, Ferraz HB, Rieder CRM, Shumacher-Schuh A, Velez-Pardo C, Jimenez-Del-Rio M, Lopera F, Chang-Castello J, Andreé-Munoz B, Waldherr S, Yearout D, Zabetian CP, Mata IF: Variable frequency of &lt;i&gt;LRRK2&lt;/i&gt; variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry. NPJ Parkinsons Dis; 2017;3:19

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We screened 1734 Parkinson's disease patients and 1097 controls enrolled in the Latin American Research Consortium on the Genetics of Parkinson's disease (LARGE-PD), which includes sites in Argentina, Brazil, Colombia, Ecuador, Peru, and Uruguay.
  • We identified a total of 29 Parkinson's disease patients (1.7%) who carried p.G2019S and the frequency ranged from 0.2% in Peru to 4.2% in Uruguay.
  • Only two Parkinson's disease patients carried p.R1441G and one patient carried p.R1441C.
  • There was no significant difference in the frequency of p.Q1111H in patients (3.8%) compared to controls (3.1%; OR 1.02, <i>p</i> = 0.873).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Neurol. 2009 Aug;16(8):957-60 [19473361.001]
  • [Cites] Parkinsonism Relat Disord. 2011 Sep;17 (8):629-31 [21632271.001]
  • [Cites] J Neurol Sci. 2006 Dec 21;251(1-2):102-6 [17097110.001]
  • [Cites] Neurosci Lett. 2007 Jul 18;422(3):193-7 [17614198.001]
  • [Cites] Neurology. 2008 Apr 15;70(16 Pt 2):1456-60 [18337586.001]
  • [Cites] Am J Hum Genet. 2006 Oct;79(4):752-8 [16960813.001]
  • [Cites] Neurogenetics. 2005 Dec;6(4):171-7 [16172858.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2016 Oct;171(7):925-30 [27111571.001]
  • [Cites] Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S205-8 [20082991.001]
  • [Cites] Am J Hum Genet. 2005 Aug;77(2):330-2 [16145815.001]
  • [Cites] Neurology. 2007 Oct 30;69(18):1737-44 [17804834.001]
  • [Cites] Neurosci Lett. 2010 Nov 19;485(2):79-82 [20727385.001]
  • [Cites] J Geriatr Psychiatry Neurol. 2010 Dec;23 (4):228-42 [20938043.001]
  • [Cites] Parkinsonism Relat Disord. 2007 Dec;13(8):509-15 [17540608.001]
  • [Cites] Curr Opin Neurol. 2011 Aug;24(4):318-23 [21734494.001]
  • [Cites] Parkinsonism Relat Disord. 2009 Jun;15(5):370-3 [18980856.001]
  • [Cites] Eur J Neurol. 2010 Dec;17 (12 ):1479-81 [20443975.001]
  • [Cites] Colomb Med (Cali). 2015 Sep 30;46(3):117-21 [26600626.001]
  • [Cites] Neurosci Lett. 2005 Jul 15;382(3):309-11 [15925109.001]
  • [Cites] Neurogenetics. 2009 Oct;10 (4):347-53 [19308469.001]
  • [Cites] Arch Neurol. 2006 Mar;63(3):377-82 [16533964.001]
  • [Cites] Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S63-5 [22166457.001]
  • [Cites] Neurogenetics. 2009 Apr;10 (2):157-9 [19020907.001]
  • [Cites] Hum Mol Genet. 2010 May 15;19(10 ):1998-2004 [20197411.001]
  • [Cites] Neurobiol Aging. 2014 Nov;35(11):2656.e17-23 [24973808.001]
  • [Cites] Eur Neurol. 2010;63(6):321-5 [20413974.001]
  • [Cites] N Engl J Med. 2009 Oct 22;361(17):1651-61 [19846850.001]
  • [Cites] Neuron. 2004 Nov 18;44(4):601-7 [15541309.001]
  • [Cites] Parkinsonism Relat Disord. 2010 May;16(4):237-42 [19945904.001]
  • [Cites] J Hum Genet. 2013 Sep;58(9):627-34 [23863748.001]
  • [Cites] Mov Disord. 2010 Oct 30;25(14 ):2340-5 [20721916.001]
  • (PMID = 28649619.001).
  • [ISSN] 2373-8057
  • [Journal-full-title] NPJ Parkinson's disease
  • [ISO-abbreviation] NPJ Parkinsons Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Swanenburg J, Zurbrugg A, Straumann D, Hegemann SCA, Palla A, de Bruin ED: A pilot study investigating the association between chronic bilateral vestibulopathy and components of a clinical functional assessment tool. Physiother Theory Pract; 2017 Jun;33(6):454-461

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: This study aimed to analyze the association between prospectively assessed falls and functional abilities in patients with bilateral vestibulopathy (BVP).
  • METHODS: Nineteen BVP patients had functional abilities assessed at baseline with the expanded timed get-up-and-go (ETGUG) test.
  • RESULTS: Eight (45%) of 18 patients (61.11 ± 15.19 years, 12 male) reported 19 falls.
  • DISCUSSION: BVP patients classified as fallers demonstrated significant faster gait speed after a turning maneuver.
  • Future studies in larger BVP patient samples are needed to refute or confirm our findings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28594306.001).
  • [ISSN] 1532-5040
  • [Journal-full-title] Physiotherapy theory and practice
  • [ISO-abbreviation] Physiother Theory Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Falls / gait / prospective / validity / vestibular loss
  •  go-up   go-down


28. Raymondos K, Dirks T, Quintel M, Molitoris U, Ahrens J, Dieck T, Johanning K, Henzler D, Rossaint R, Putensen C, Wrigge H, Wittich R, Ragaller M, Bein T, Beiderlinden M, Sanmann M, Rabe C, Schlechtweg J, Holler M, Frutos-Vivar F, Esteban A, Hecker H, Rosseau S, von Dossow V, Spies C, Welte T, Piepenbrock S, Weber-Carstens S: Outcome of acute respiratory distress syndrome in university and non-university hospitals in Germany. Crit Care; 2017 May 30;21(1):122

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: This study investigates differences in treatment and outcome of ventilated patients with acute respiratory distress syndrome (ARDS) between university and non-university hospitals in Germany.
  • METHODS: This subanalysis of a prospective, observational cohort study was performed to identify independent risk factors for mortality by examining: baseline factors, ventilator settings (e.g., driving pressure), complications, and care settings-for example, case volume of ventilated patients, size/type of intensive care unit (ICU), and type of hospital (university/non-university hospital).
  • To control for potentially confounding factors at ARDS onset and to verify differences in mortality, ARDS patients in university vs non-university hospitals were compared using additional multivariable analysis.
  • RESULTS: Of the 7540 patients admitted to 95 ICUs from 18 university and 62 non-university hospitals in May 2004, 1028 received mechanical ventilation and 198 developed ARDS.
  • Although the characteristics of ARDS patients were very similar, hospital mortality was considerably lower in university compared with non-university hospitals (39.3% vs 57.5%; p = 0.012).
  • This was confirmed by additional independent comparisons between the two patient groups when controlling for confounding factors at ARDS onset.
  • CONCLUSIONS: Mortality risk of ARDS patients was considerably higher in non-university compared with university hospitals.
  • Differences in ventilatory care between hospitals might explain this finding and may at least partially imply regionalization of care and the export of ventilatory strategies to non-university hospitals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Intensive Care Med. 2011 Dec;37(12):1932-41 [21997128.001]
  • [Cites] Lancet. 2000 Jul 15;356(9225):185-9 [10963195.001]
  • [Cites] Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):818-24 [7509706.001]
  • [Cites] Am J Surg. 2000 Aug;180(2):144-54 [11044532.001]
  • [Cites] Chest. 2000 Jun;117(6):1690-6 [10858404.001]
  • [Cites] Anaesthesist. 2004 Mar;53(3):235-43 [14999396.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1685-93 [16236739.001]
  • [Cites] N Engl J Med. 2015 Feb 19;372(8):747-55 [25693014.001]
  • [Cites] Qual Saf Health Care. 2007 Oct;16(5):329-33 [17913772.001]
  • [Cites] JAMA. 2002 Jan 16;287(3):345-55 [11790214.001]
  • [Cites] JAMA. 2008 Feb 13;299(6):646-55 [18270353.001]
  • [Cites] JAMA. 2010 Mar 3;303(9):865-73 [20197533.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Jan 15;177(2):170-7 [17962636.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Apr;151(4):1121-5 [7697241.001]
  • [Cites] N Engl J Med. 1998 Feb 5;338(6):347-54 [9449727.001]
  • [Cites] Crit Care Med. 2015 Mar;43(3):519-26 [25479111.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):327-36 [15269312.001]
  • [Cites] Intensive Care Med. 2013 May;39(5):847-56 [23306584.001]
  • [Cites] Crit Care Med. 2002 Nov;30(11):2450-6 [12441753.001]
  • [Cites] Crit Care Med. 2005 Jan;33(1):21-30 [15644644.001]
  • [Cites] Intensive Care Med. 2016 May;42(5):889-96 [26942446.001]
  • [Cites] Intensive Care Med. 2004 Jan;30(1):51-61 [14569423.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):41-50 [16822995.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1301-8 [10793162.001]
  • [Cites] Am J Respir Crit Care Med. 2013 Jul 15;188(2):220-30 [23631814.001]
  • [Cites] JAMA. 2016 Feb 23;315(8):788-800 [26903337.001]
  • [Cites] Crit Care Med. 2008 May;36(5):1412-20 [18434894.001]
  • [Cites] Crit Care Med. 2008 Oct;36(10):2787-93, e1-9 [18766102.001]
  • [Cites] Intensive Care Med. 1992;18(6):319-21 [1469157.001]
  • [Cites] Crit Care Med. 1982 Nov;10(11):724-32 [6754260.001]
  • [Cites] JAMA. 2002 Nov 6;288(17):2151-62 [12413375.001]
  • [Cites] JAMA. 2008 Feb 13;299(6):637-45 [18270352.001]
  • [Cites] Am J Respir Crit Care Med. 2015 Jan 15;191(2):177-85 [25478681.001]
  • [Cites] Crit Care. 2006;10(2):R55 [16606435.001]
  • [Cites] N Engl J Med. 2008 Nov 13;359(20):2095-104 [19001507.001]
  • (PMID = 28554331.001).
  • [ISSN] 1466-609X
  • [Journal-full-title] Critical care (London, England)
  • [ISO-abbreviation] Crit Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Acute respiratory distress syndrome / Biphasic positive airway pressure / Care setting / Driving pressure / Mechanical ventilation
  •  go-up   go-down


29. Bagur R, Solo K, Alghofaili S, Nombela-Franco L, Kwok CS, Hayman S, Siemieniuk RA, Foroutan F, Spencer FA, Vandvik PO, Schäufele TG, Mamas MA: Cerebral Embolic Protection Devices During Transcatheter Aortic Valve Implantation: Systematic Review and Meta-Analysis. Stroke; 2017 May;48(5):1306-1315
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We conducted a comprehensive search to identify studies that evaluated patients undergoing TAVI with or without EPD.
  • RESULTS: Sixteen studies involving 1170 patients (865/305 with/without EPD) fulfilled the inclusion criteria.
  • The EPD delivery success rate was reported in all studies and was achieved in 94.5% of patients.
  • Subgroup analysis by type of valve showed an overall trend toward significant reduction in new lesions per patient using EPD (standardized mean difference, -0.41; 95% CI, -0.82 to 0.00; <i>P</i>=0.05), driven by self-expanding devices.
  • There was only very low quality of evidence showing no significant differences between patients undergoing TAVI with or without EPD with respect to clinically evident stroke and mortality.
  • [MeSH-major] Brain Ischemia / prevention & control. Embolic Protection Devices. Intracranial Embolism / prevention & control. Outcome and Process Assessment (Health Care). Stroke / prevention & control. Transcatheter Aortic Valve Replacement / standards

  • MedlinePlus Health Information. consumer health - Ischemic Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28411259.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; GRADE / TAVI / TAVR / aortic stenosis / embolic protection / stroke
  •  go-up   go-down


30. Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT: Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev; 2016 Dec;35(4):547-573
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient-derived xenograft (PDX) models in basic and translational breast cancer research.
  • Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long-established traditional cell lines as preferred models for conducting basic and translational preclinical research.
  • Many of these models are well-characterized with respect to genomic, transcriptomic, and proteomic features, metastatic behavior, and treatment response to a variety of standard-of-care and experimental therapeutics.
  • This review summarizes current experiences related to PDX generation across participating groups, efforts to develop data standards for annotation and dissemination of patient clinical information that does not compromise patient privacy, efforts to develop complementary data standards for annotation of PDX characteristics and biology, and progress toward "credentialing" of PDX models as surrogates to represent individual patients for use in preclinical and co-clinical translational research.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microsc Res Tech. 2001 Jan 15;52(2):224-30 [11169869.001]
  • [Cites] Nature. 2015 Feb 19;518(7539):422-6 [25470049.001]
  • [Cites] J Infect Dis. 2013 Nov;208 Suppl 2:S125-30 [24151318.001]
  • [Cites] Mol Oncol. 2014 Mar;8(2):431-43 [24394560.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4307-16 [9192753.001]
  • [Cites] Breast Cancer Res Treat. 2015 Nov;154(1):13-22 [26438141.001]
  • [Cites] Nat Protoc. 2006;1(1):206-14 [17406234.001]
  • [Cites] Cancer J Sci Am. 1996 Sep-Oct;2(5):291-300 [9166547.001]
  • [Cites] Breast Cancer Res. 2002;4(4):155-64 [12100741.001]
  • [Cites] Am J Pathol. 1985 Sep;120(3):464-77 [2412448.001]
  • [Cites] Curr Protoc Mouse Biol. 2013 Mar 01;3(1):21-9 [26069021.001]
  • [Cites] Nat Med. 2008 Dec;14(12):1384-9 [19029987.001]
  • [Cites] Ann Oncol. 2016 Jul;27(7):1190-8 [26912558.001]
  • [Cites] Nat Commun. 2016 Jun 06;7:11908 [27264733.001]
  • [Cites] Leukemia. 1998 Dec;12(12):2029-33 [9844934.001]
  • [Cites] Methods Mol Biol. 2010;596:33-45 [19949919.001]
  • [Cites] Breast Cancer Res Treat. 2010 Jun;121(2):301-9 [19603265.001]
  • [Cites] Stem Cells. 2015 Jun;33(6):1696-704 [25694194.001]
  • [Cites] Cell. 2010 Jan 8;140(1):62-73 [20074520.001]
  • [Cites] Anticancer Res. 1995 Jan-Feb;15(1):1-7 [7733618.001]
  • [Cites] Breast Cancer Res. 2015 Jan 09;17:3 [25572662.001]
  • [Cites] Cancer Res. 1983 May;43(5):2223-39 [6831445.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3175-82 [12384415.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Biochim Biophys Acta. 2010 Jan;1805(1):105-17 [19931353.001]
  • [Cites] Br J Cancer. 1985 Mar;51(3):347-56 [3970811.001]
  • [Cites] Oncotarget. 2015 May 30;6(15):12890-908 [25973541.001]
  • [Cites] Breast Cancer Res Treat. 2010 May;121(1):53-64 [19593635.001]
  • [Cites] Cancer Res. 2013 Aug 1;73(15):4885-97 [23737486.001]
  • [Cites] Breast Cancer Res Treat. 2010 Jul;122(1):35-43 [19701706.001]
  • [Cites] Cancer Res. 2012 Jun 15;72(12):3010-9 [22523036.001]
  • [Cites] Nature. 1994 Nov 3;372(6501):103-7 [7969402.001]
  • [Cites] Expert Rev Mol Diagn. 2013 Mar;13(2):151-65 [23477556.001]
  • [Cites] J Natl Cancer Inst. 1960 Apr;24:953-69 [13821714.001]
  • [Cites] Blood. 2010 Jul 15;116(2):193-200 [20404133.001]
  • [Cites] Br J Cancer. 1980 Oct;42(4):524-9 [6254552.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3989-98 [17606733.001]
  • [Cites] J Natl Cancer Inst. 1979 Dec;63(6):1331-7 [92586.001]
  • [Cites] Proc Natl Acad Sci U S A. 2012 Feb 21;109 (8):2766-71 [21768359.001]
  • [Cites] Development. 2000 Jun;127(11):2269-82 [10804170.001]
  • [Cites] Eur J Immunol. 1995 Feb;25(2):631-4 [7875225.001]
  • [Cites] Contemp Top Lab Anim Sci. 2003 Nov;42(6):33-5 [14615958.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2649-56 [17363585.001]
  • [Cites] Breast Care (Basel). 2016 Apr;11(2):108-15 [27239172.001]
  • [Cites] PLoS One. 2015 Sep 01;10(9):e0136851 [26325287.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1160-7 [19204204.001]
  • [Cites] Hum Immunol. 2009 May;70(5):325-30 [19236898.001]
  • [Cites] J Pathol. 2016 Nov;240(3):256-261 [27447842.001]
  • [Cites] Nature. 2014 Aug 14;512(7513):155-60 [25079324.001]
  • [Cites] Nature. 2011 Apr 7;472(7341):90-4 [21399628.001]
  • [Cites] Breast Cancer Res Treat. 2012 Sep;135(2):415-32 [22821401.001]
  • [Cites] Cancer. 2015 Jan 1;121(1):8-16 [25043972.001]
  • [Cites] Oncotarget. 2016 Jul 26;7(30):48206-48219 [27374081.001]
  • [Cites] Cancer Res. 1959 Jun;19(5):515-20 [13663040.001]
  • [Cites] Arch Pathol Lab Med. 2014 Feb;138(2):241-56 [24099077.001]
  • [Cites] Int J Cancer. 2003 Jul 1;105(4):444-53 [12712433.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):529-41 [17157792.001]
  • [Cites] J Exp Med. 1988 Mar 1;167(3):1016-33 [3280724.001]
  • [Cites] Blood. 2013 Mar 21;121(12):e90-7 [23349390.001]
  • [Cites] Genet Res. 1966 Dec;8(3):295-309 [5980117.001]
  • [Cites] Breast Cancer Res. 2015 Feb 10;17:17 [25849559.001]
  • [Cites] Cell. 1995 Mar 10;80(5):813-23 [7889575.001]
  • [Cites] Adv Exp Med Biol. 2016;882:169-89 [26987535.001]
  • [Cites] J Exp Med. 1971 Sep 1;134(3 Pt 1):681-92 [15776569.001]
  • [Cites] Nature. 2010 Apr 15;464(7291):999-1005 [20393555.001]
  • [Cites] Nature. 2009 Jun 18;459(7249):1005-9 [19421193.001]
  • [Cites] Oncotarget. 2016 May 3;7(18):26107-19 [27034166.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S375-9 [16507413.001]
  • [Cites] Breast Cancer Res. 2009;11(5):R66 [19735549.001]
  • [Cites] N Engl J Med. 2012 Mar 22;366(12):1090-8 [22417201.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):142-6 [10702024.001]
  • [Cites] Cancer Discov. 2014 Sep;4(9):998-1013 [25185190.001]
  • [Cites] Stem Cells. 2011 Jan;29(1):11-9 [21280155.001]
  • [Cites] PLoS One. 2016 Mar 08;11(3):e0151121 [26953790.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R21 [16611371.001]
  • [Cites] Nat Protoc. 2016 Mar;11(3):616 [26914320.001]
  • [Cites] Cell. 2012 May 25;149(5):994-1007 [22608083.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Curr Protoc Pharmacol. 2012 Dec;Chapter 14:Unit 14.22 [23258598.001]
  • [Cites] J Immunol. 1995 Jan 1;154(1):180-91 [7995938.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):917-23 [11830552.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1424-31 [11355958.001]
  • [Cites] Cancer Lett. 2014 Mar 1;344(1):13-9 [24513265.001]
  • [Cites] Clin Exp Metastasis. 1995 Jan;13(1):3-15 [7820953.001]
  • [Cites] Cancer Res. 2014 Mar 1;74(5):1463-74 [24425047.001]
  • [Cites] Mol Oncol. 2011 Feb;5(1):5-23 [21147047.001]
  • [Cites] Cancer Discov. 2011 Jun;1(1):54-67 [22039576.001]
  • [Cites] Curr Opin Immunol. 2010 Apr;22(2):231-7 [20144856.001]
  • [Cites] Neoplasia. 2015 Sep;17(9):735-41 [26476081.001]
  • [Cites] Nat Protoc. 2012 May 03;7(6):1024-41 [22555242.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):888-902 [7717456.001]
  • [Cites] Mol Cell Biol. 1992 Nov;12(11):5152-8 [1406687.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13081-6 [18723673.001]
  • [Cites] Nat Med. 2011 Oct 23;17(11):1514-20 [22019887.001]
  • [Cites] PLoS One. 2008 Apr 02;3(4):e1908 [18382681.001]
  • [Cites] PLoS One. 2016 Jun 16;11(6):e0157368 [27310713.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2062-71 [17332335.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1328-34 [10604729.001]
  • [Cites] Cell Rep. 2013 Sep 26;4(6):1116-30 [24055055.001]
  • [Cites] Genome Res. 2013 Dec;23(12):2115-25 [24056532.001]
  • [Cites] Cancer Lett. 1981 Dec;14(3):309-16 [7332907.001]
  • [Cites] Nat Med. 2010 Sep;16(9):974-5 [20823880.001]
  • [Cites] PLoS One. 2010 Aug 16;5(8):e12180 [20808935.001]
  • [Cites] Cancer Res. 1980 Jan;40(1):95-100 [6243091.001]
  • [Cites] Nat Biotechnol. 2014 Apr;32(4):364-72 [24633240.001]
  • [Cites] Nat Med. 2016 Aug;22(8):933-9 [27322743.001]
  • [Cites] Cancer Lett. 1980 Aug;10(2):177-89 [7459836.001]
  • [Cites] Br J Cancer. 1988 Jan;57(1):19-31 [3348947.001]
  • [Cites] Cancer Biol Ther. 2009 Jun;8(11):1010-7 [19398888.001]
  • [Cites] J Natl Cancer Inst. 2008 May 7;100(9):672-9 [18445819.001]
  • [Cites] Exp Cell Biol. 1979;47(4):281-93 [467773.001]
  • [Cites] Breast Cancer Res. 2014 May 20;16(3):210 [25928070.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):845-51 [15120040.001]
  • [Cites] Nature. 1979 Mar 29;278(5703):451-3 [313007.001]
  • [Cites] Cancer Immunol Immunother. 2007 Mar;56(3):271-85 [16819631.001]
  • [Cites] Cell Cycle. 2009 Aug;8(15):2317-8 [19625762.001]
  • [Cites] Cancer Cell. 2013 Jul 8;24(1):120-9 [23845444.001]
  • [Cites] Cell Growth Differ. 1993 Jul;4(7):563-9 [8398896.001]
  • [Cites] Cancer Res. 2013 Dec 15;73(24):7290-300 [24142344.001]
  • [Cites] Nature. 2009 Oct 8;461(7265):809-13 [19812674.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):379-91 [14973383.001]
  • [Cites] Nature. 2012 Apr 04;486(7403):395-9 [22495314.001]
  • [Cites] Am J Pathol. 1977 Nov;89(2):413-30 [200144.001]
  • [Cites] Trends Immunol. 2016 Jul;37(7):462-76 [27216414.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2016 Dec;21(3-4):99-109 [27680982.001]
  • [Cites] Cancer Res. 2012 Jun 1;72(11):2705-13 [22467173.001]
  • [Cites] Cancer Res. 1985 Feb;45(2):584-90 [3967234.001]
  • [Cites] Int J Cancer. 1988 May 15;41(5):713-9 [3366492.001]
  • [Cites] J Immunol. 1993 May 1;150(9):3817-24 [8473734.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Immunol Lett. 2012 Aug 30;146(1-2):1-7 [22507217.001]
  • [Cites] Nat Rev Drug Discov. 2010 Apr;9(4):253-4 [20369394.001]
  • [Cites] Cell Immunol. 1996 Aug 1;171(2):186-99 [8806787.001]
  • [Cites] Clin Cancer Res. 2015 Apr 1;21(7):1688-98 [25208879.001]
  • [Cites] Cell. 2012 Mar 2;148(5):873-85 [22385957.001]
  • [Cites] Nature. 2014 Oct 2;514(7520):54-8 [25079331.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):71-8 [17049443.001]
  • [Cites] Cancer Cell. 2016 Mar 14;29(3):407-22 [26947176.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;119(1):35-40 [1400563.001]
  • [Cites] Nat Med. 2006 Nov;12(11):1294-300 [17057710.001]
  • [Cites] Nat Rev Immunol. 2007 Feb;7(2):118-30 [17259968.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] J Cancer. 2014 Jan 23;5(2):156-65 [24563670.001]
  • [Cites] Breast Cancer Res. 2014 Apr 07;16(2):R36 [24708766.001]
  • [Cites] Nature. 1983 Feb 10;301(5900):527-30 [6823332.001]
  • [Cites] Genome Res. 2014 Nov;24(11):1881-93 [25060187.001]
  • [Cites] Cancer Cell. 2008 May;13(5):394-406 [18455123.001]
  • [Cites] Prostate. 2015 May;75(6):585-92 [25585936.001]
  • [Cites] Cancer. 1978 Jan;41(1):239-44 [626933.001]
  • [Cites] Nature. 2012 Apr 18;486(7403):346-52 [22522925.001]
  • [Cites] Lancet Oncol. 2007 Dec;8(12):1071-8 [18024211.001]
  • [Cites] Nature. 2012 Oct 4;490(7418):61-70 [23000897.001]
  • [Cites] J Endocrinol. 2006 Mar;188(3):589-601 [16522738.001]
  • [Cites] Nature. 2012 May 16;486(7403):400-4 [22722201.001]
  • [Cites] Arch Pathol Lab Med. 2010 Jun;134(6):907-22 [20524868.001]
  • [Cites] Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18708-13 [22068913.001]
  • [Cites] Cancer Discov. 2011 Nov;1(6):508-23 [22586653.001]
  • [Cites] Breast Dis. 2006-2007;26:139-47 [17473372.001]
  • [Cites] Nat Commun. 2016 May 10;7:11479 [27161491.001]
  • [Cites] Cancer Cell. 2008 Jan;13(1):23-35 [18167337.001]
  • [Cites] Breast Cancer Res. 2010;12(5):R68 [20813035.001]
  • [Cites] Nature. 1988 Sep 15;335(6187):256-9 [2970594.001]
  • [Cites] Genome Res. 2009 Feb;19(2):167-77 [19056696.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):370-8 [18223211.001]
  • [Cites] Clin Chem. 2014 Jan;60(1):122-33 [24298072.001]
  • [Cites] Nat Med. 2015 Nov;21(11):1318-25 [26479923.001]
  • [Cites] J Cell Physiol. 1995 Apr;163(1):51-60 [7896900.001]
  • [Cites] Nature. 2012 Jun 20;486(7403):405-9 [22722202.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Adv Immunol. 2006;90:1-50 [16730260.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 16;89(14):1059-65 [9230888.001]
  • [Cites] J Clin Oncol. 2014 Jul 20;32(21):2255-69 [24868023.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1725-32 [8411256.001]
  • [Cites] Curr Protoc Pharmacol. 2013 Mar;Chapter 14:Unit14.23 [23456611.001]
  • [Cites] Cancer Cell. 2010 Nov 16;18(5):485-98 [21035406.001]
  • [Cites] Blood. 1996 Nov 15;88(10):3731-40 [8916937.001]
  • [Cites] Cell. 1992 Mar 6;68(5):869-77 [1547488.001]
  • [Cites] Nat Med. 2009 Aug;15(8):907-13 [19648928.001]
  • [Cites] Breast Cancer Res Treat. 2012 Oct;135(3):913-22 [22941572.001]
  • [Cites] Cancer. 1980 Apr 15;45(8):2160-5 [7370957.001]
  • [Cites] Clin Cancer Res. 2010 Feb 1;16(3):876-87 [20103682.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6477-89 [15879151.001]
  • [Cites] BMC Cancer. 2003 Apr 24;3:13 [12713671.001]
  • [Cites] Clin Cancer Res. 2016 Aug 1;22(15):3764-73 [26957554.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] J Clin Oncol. 2014 Jul 1;32(19):2100-8 [24799487.001]
  • [Cites] Breast Cancer Res. 2004;6(1):22-30 [14680482.001]
  • [Cites] Nat Methods. 2014 Apr;11(4):396-8 [24633410.001]
  • [Cites] Cancer Metastasis Rev. 2010 Jun;29(2):309-16 [20405169.001]
  • [Cites] Int J Cancer. 2011 Nov 1;129(9):2194-206 [21544806.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] J Clin Oncol. 2015 Jun 10;33(17 ):1974-82 [25605845.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1299-311 [9588898.001]
  • [Cites] Breast Cancer Res. 2016 Jan 27;18(1):13 [26818199.001]
  • [Cites] Curr Drug Targets. 2010 Sep;11(9):1041-2 [20545615.001]
  • [Cites] Breast Cancer Res Treat. 2012 Jun;133(2):595-606 [22002565.001]
  • [Cites] Breast Cancer Res. 2016 Jun 28;18(1):68 [27349894.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):966-80 [16795075.001]
  • [Cites] Cancer Res. 2011 Jan 15;71(2):614-24 [21224357.001]
  • [Cites] J Natl Cancer Inst. 1975 Dec;55(6):1461-6 [1206764.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(1):69-86 [8738607.001]
  • [Cites] BioDrugs. 2009;23(5):277-87 [19754218.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • (PMID = 28025748.001).
  • [ISSN] 1573-7233
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112305; United States / NCI NIH HHS / CA / R01 CA172764; United States / NCI NIH HHS / CA / R01 CA173903; United States / NCI NIH HHS / CA / R01 CA129765; United States / NCI NIH HHS / CA / K08 CA164048; United States / NCI NIH HHS / CA / R01 CA140985; United States / NCI NIH HHS / CA / P30 CA034196; United States / NCRR NIH HHS / RR / UL1 RR024992; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / P30 CA125123; United States / NCI NIH HHS / CA / R01 CA166422; United States / NCI NIH HHS / CA / R21 CA185460; United States / NCI NIH HHS / CA / R01 CA101860; United States / NCI NIH HHS / CA / P50 CA058183; United States / NCATS NIH HHS / TR / UL1 TR000448; United States / NCI NIH HHS / CA / U01 CA214172; United States / NCI NIH HHS / CA / U54 CA149196; United States / NCI NIH HHS / CA / R21 CA187890; United States / NCI NIH HHS / CA / P50 CA186784
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Breast cancer / Immunocompromised/immunodeficient mice / PDX consortium / Patient-derived xenograft / Translational research
  •  go-up   go-down


31. Atri M, Zhang Z, Dehdashti F, Lee SI, Marques H, Ali S, Koh WJ, Mannel RS, DiSilvestro P, King SA, Pearl M, Zhou X, Plante M, Moxley KM, Gold M: Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial. Radiology; 2017 May;283(2):450-459
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients underwent PET/CT and pelvic and abdominal lymphadenectomy.
  • Two hundred seven of 215 enrolled patients had PET/CT and pathologic examination results for the abdomen and pelvis.
  • Mean patient age was 62.7 years ± 9.6 (standard deviation).
  • Data in all 23 patients with a positive abdominal examination and in 26 randomly selected patients with a negative abdominal examination were used for this central reader study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Abdom Imaging. 2015 Oct;40(7):2472-85 [25680500.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):486-92 [18201753.001]
  • [Cites] Eur Radiol. 2009 Jun;19(6):1529-36 [19184037.001]
  • [Cites] Am J Obstet Gynecol. 1999 Jul;181(1):31-4 [10411790.001]
  • [Cites] Obstet Gynecol. 2010 Nov;116(5):1141-9 [20966700.001]
  • [Cites] J Obstet Gynaecol (Tokyo 1995). 1995 Dec;21(6):551-6 [8640464.001]
  • [Cites] Int J Gynecol Cancer. 2013 Nov;23 (9):1536-43 [24172090.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):546-51 [15581961.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jul-Aug;17 (4):890-6 [17343574.001]
  • [Cites] Radiology. 2004 May;231(2):372-8 [15031434.001]
  • [Cites] J Nucl Med. 2008 Dec;49(12):1928-35 [18997054.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jun;190(6):1652-8 [18492920.001]
  • [Cites] Ann Oncol. 2010 May;21 Suppl 5:v41-5 [20555100.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2813-21 [15837995.001]
  • [Cites] Cancer. 1987 Oct 15;60(8 Suppl):2035-41 [3652025.001]
  • [Cites] Gynecol Oncol. 2013 Aug;130(2):306-11 [23707673.001]
  • [Cites] J Bone Joint Surg Am. 2003 Apr;85-A(4):760; author reply 760 [12672856.001]
  • [Cites] Obstet Gynecol. 2000 May;95(5):692-6 [10775731.001]
  • [Cites] Biometrics. 1988 Sep;44(3):837-45 [3203132.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):112-7 [12468351.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):188-96 [17291252.001]
  • [Cites] J Nucl Med. 2009 Jul;50(7):1187-93 [19525463.001]
  • [Cites] Radiology. 1991 Jun;179(3):829-32 [2028000.001]
  • [Cites] Eur J Radiol. 2012 Nov;81(11):3511-7 [22305013.001]
  • [Cites] Anticancer Res. 2014 Feb;34(2):585-92 [24510987.001]
  • [Cites] Radiology. 2006 Jan;238(1):272-9 [16304090.001]
  • (PMID = 28051912.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / U10 CA079778; United States / NCI NIH HHS / CA / U10 CA080098
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


32. Ataide R, Ashley EA, Powell R, Chan JA, Malloy MJ, O'Flaherty K, Takashima E, Langer C, Tsuboi T, Dondorp AM, Day NP, Dhorda M, Fairhurst RM, Lim P, Amaratunga C, Pukrittayakamee S, Hien TT, Htut Y, Mayxay M, Faiz MA, Beeson JG, Nosten F, Simpson JA, White NJ, Fowkes FJ: Host immunity to &lt;i&gt;Plasmodium falciparum&lt;/i&gt; and the assessment of emerging artemisinin resistance in a multinational cohort. Proc Natl Acad Sci U S A; 2017 Mar 28;114(13):3515-3520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibodies specific to 12 <i>Plasmodium falciparum</i> sporozoite and blood-stage antigens were determined in 959 patients (from 11 sites in Southeast Asia) participating in a multinational cohort study assessing parasite clearance half-life (PCt<sub>1/2</sub>) after artesunate treatment and <i>kelch13</i> mutations.
  • Linear mixed-effects modeling of pooled individual patient data assessed the association between antibody responses and PCt<sub>1/2.
  • Naturally acquired immunity accelerates the clearance of artemisinin-resistant parasites in patients with falciparum malaria and may confound the current working definition of artemisinin resistance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2014 Jul 31;371(5):411-23 [25075834.001]
  • [Cites] N Engl J Med. 2009 Jul 30;361(5):455-67 [19641202.001]
  • [Cites] Malar J. 2012 Mar 22;11:79 [22439695.001]
  • [Cites] Immunity. 2015 Mar 17;42(3):580-90 [25786180.001]
  • [Cites] BMC Med. 2014 Jul 01;12:108 [24980799.001]
  • [Cites] N Engl J Med. 2008 Dec 11;359(24):2619-20 [19064625.001]
  • [Cites] Trends Parasitol. 2013 Jul;29(7):313-7 [23623760.001]
  • [Cites] Blood. 2011 Jan 13;117(2):381-92 [20852127.001]
  • [Cites] PLoS One. 2011;6(11):e26005 [22102856.001]
  • [Cites] Nature. 2014 Jan 2;505(7481):50-5 [24352242.001]
  • [Cites] BMC Med. 2015 Sep 07;13:212 [26343145.001]
  • [Cites] Malar J. 2007 Nov 16;6:153 [18021388.001]
  • [Cites] PLoS Med. 2010 Jan 19;7(1):e1000218 [20098724.001]
  • [Cites] Lancet Infect Dis. 2012 Nov;12(11):851-8 [22940027.001]
  • [Cites] Malar J. 2009 Nov 18;8:258 [19922664.001]
  • [Cites] Cell Mol Life Sci. 2014 Oct;71(19):3633-57 [24691798.001]
  • [Cites] Lancet Infect Dis. 2015 Apr;15(4):415-21 [25704894.001]
  • [Cites] Infect Immun. 2006 May;74(5):2887-93 [16622227.001]
  • [Cites] Am J Trop Med Hyg. 2003 Nov;69(5):558-63 [14695097.001]
  • [Cites] Malar J. 2011 Sep 22;10:278 [21939506.001]
  • [Cites] PLoS One. 2012;7(12):e52571 [23285095.001]
  • [Cites] Am J Trop Med Hyg. 2001 Dec;65(6):918-23 [11791999.001]
  • [Cites] Malar J. 2011 Nov 10;10:339 [22074219.001]
  • [Cites] Clin Exp Immunol. 1982 Mar;47(3):635-44 [7044626.001]
  • [Cites] J Infect Dis. 2013 Jun 1;207(11):1655-63 [23448727.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1084-92 [15085184.001]
  • [Cites] PLoS One. 2013;8(3):e57689 [23520478.001]
  • [Cites] J Exp Med. 1990 Dec 1;172(6):1633-41 [2258697.001]
  • [Cites] Nat Genet. 2015 Mar;47(3):226-34 [25599401.001]
  • [Cites] Infect Immun. 2005 Apr;73(4):2116-22 [15784553.001]
  • [Cites] Clin Microbiol Rev. 2009 Jan;22(1):13-36, Table of Contents [19136431.001]
  • [Cites] Lancet. 2012 May 26;379(9830):1960-6 [22484134.001]
  • [Cites] J Infect Dis. 2015 Jan 15;211(2):290-7 [25183768.001]
  • [Cites] J Infect Dis. 2009 Jul 15;200(2):299-306 [19500037.001]
  • [Cites] PLoS Biol. 2015 Apr 22;13(4):e1002132 [25901609.001]
  • [Cites] J Infect Dis. 2002 May 15;185(10):1538-41 [11992295.001]
  • [Cites] Clin Microbiol Rev. 2011 Apr;24(2):377-410 [21482730.001]
  • [Cites] Malar J. 2012 Aug 16;11:278 [22898135.001]
  • (PMID = 28289193.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; artemisinin / drug resistance / immunity / malaria / serology
  •  go-up   go-down


33. Iskandar H, Gray DM 2nd, Vu H, Mirza F, Rude MK, Regan K, Abdalla A, Gaddam S, Almaskeen S, Mello M, Marquez E, Meyer C, Bolkhir A, Kanuri N, Sayuk G, Gyawali CP: Coeliac disease screening is suboptimal in a tertiary gastroenterology setting. Postgrad Med J; 2017 Jan 09;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Coeliac disease (CD) is widely prevalent in North America, but case-finding techniques currently used may not be adequate for patient identification.
  • RESULTS: 616 consecutive patients (49±0.6 years, range 16-87 years, 58.5% females, 94% Caucasian) fulfilled inclusion criteria.
  • Of 145 patients screened, 4 patients (2.4%) had serology consistent with CD, of which 2 were proven by duodenal biopsy.
  • Using this proportion, an additional 5 patients might have been diagnosed in 191 untested patients with indications for CD screening.
  • CONCLUSIONS: More than 50% of patients in a tertiary GI clinic have indications for CD screening, but <50% of indicated cases are screened.
  • Case-finding techniques therefore are suboptimal, constituting a gap in patient care and an important target for future quality improvement initiatives.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
  • [Cites] Curr Gastroenterol Rep. 2006 Oct;8(5):383-9 [16968605.001]
  • [Cites] Am J Gastroenterol. 2007 Jul;102(7):1454-60 [17355413.001]
  • [Cites] J Gen Intern Med. 2005 Jul;20(7):644-6 [16050861.001]
  • [Cites] Gut. 2010 Apr;59(4):547-57 [20332526.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2012 Oct;22(4):661-77 [23083985.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2012 Oct;22(4):613-21 [23083982.001]
  • [Cites] Am J Gastroenterol. 2013 May;108(5):656-76; quiz 677 [23609613.001]
  • [Cites] Gastroenterology. 2014 Sep;147(3):610-617.e1 [24837306.001]
  • [Cites] Dig Liver Dis. 2006 Jul;38(7):461-7 [16737857.001]
  • [Cites] Am J Gastroenterol. 2010 Dec;105(12):2520-4 [21131921.001]
  • [Cites] Am J Gastroenterol. 2013 May;108(5):818-24 [23511460.001]
  • [Cites] Gastroenterol Rep (Oxf). 2015 Feb;3(1):3-11 [25326000.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1981-2002 [17087937.001]
  • [Cites] Arch Intern Med. 2003 Feb 10;163(3):286-92 [12578508.001]
  • [Cites] Scand J Gastroenterol. 2014 Nov;49(11):1304-10 [25139307.001]
  • [Cites] Gastrointest Endosc. 2012 Oct;76(4):779-85 [22732871.001]
  • [Cites] BMC Gastroenterol. 2011 Dec 16;11:136 [22176557.001]
  • [Cites] Am J Gastroenterol. 2012 Oct;107(10):1538-44; quiz 1537, 1545 [22850429.001]
  • (PMID = 28069744.001).
  • [ISSN] 1469-0756
  • [Journal-full-title] Postgraduate medical journal
  • [ISO-abbreviation] Postgrad Med J
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K23 DK084113; United States / NIDDK NIH HHS / DK / T32 DK007130; United States / NCATS NIH HHS / TR / UL1 TR000448
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. Breitenstein C, Grewe T, Flöel A, Ziegler W, Springer L, Martus P, Huber W, Willmes K, Ringelstein EB, Haeusler KG, Abel S, Glindemann R, Domahs F, Regenbrecht F, Schlenck KJ, Thomas M, Obrig H, de Langen E, Rocker R, Wigbers F, Rühmkorf C, Hempen I, List J, Baumgaertner A, FCET2EC study group: Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting. Lancet; 2017 Apr 15;389(10078):1528-1538
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting.
  • METHODS: In this multicentre, parallel group, superiority, open-label, blinded-endpoint, randomised controlled trial, patients aged 70 years or younger with aphasia after stroke lasting for 6 months or more were recruited from 19 inpatient or outpatient rehabilitation centres in Germany.
  • FINDINGS: We randomly assigned 158 patients between April 1, 2012, and May 31, 2014.
  • The modified intention-to-treat population comprised 156 patients (78 per group).
  • Eight patients had adverse events during therapy or treatment deferral (one car accident [in the control group], two common cold [one patient per group], three gastrointestinal or cardiac symptoms [all intervention group], two recurrent stroke [one in intervention group before initiation of treatment, and one before group assignment had occurred]); all were unrelated to study participation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28256356.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Villringer A; Bley M; Jöbges M; Halm K; Schulz J; Werner C; Goldenberg G; Klingenberg G; König E; Müller F; Gröne B; Knecht S; Baake R; Knauss J; Miethe S; Steller U; Sudhoff R; Schillikowski E; Pfeiffer G; Billo K; Hoffmann H; Ferneding FJ; Runge S; Keck T; Middeldorf V; Krüger S; Wilde B; Krakow K; Berghoff C; Reinhuber F; Maser I; Hofmann W; Sous-Kulke C; Schupp W; Oertel A; Bätz D; Hamzei F; Schulz K; Meyer A; Kartmann A; Som O; Schipke SB; Bamborschke S
  •  go-up   go-down


35. Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ, Conference Participants: Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int; 2017 Mar;91(3):539-551
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to help guide clinicians who are caring for such patients, recommendations for best treatment strategies were discussed at length, providing the evidence base underpinning current treatment options.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 27989322.001).
  • [ISSN] 1523-1755
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G1002528
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; C3 glomerulopathy / anti-complement therapies / atypical hemolytic uremic syndrome / complement / glomerulonephritis / kidney disease
  • [Investigator] Alpers CE; Appel GB; Ardissino G; Ariceta G; Arici M; Bagga A; Bajema IM; Blasco M; Burke L; Cairns TD; Carratala M; D'Agati VD; Daha MR; De Vriese AS; Dragon-Durey MA; Fogo AB; Galbusera M; Gale DP; Haller H; Johnson S; Józsi M; Karpman D; Lanning L; Le Quintrec M; Licht C; Loirat C; Monfort F; Morgan BP; Noël LH; O'Shaughnessy MM; Rabant M; Rondeau E; Ruggenenti P; Sheerin NS; Smith J; Spoleti F; Thurman JM; van de Kar NC; Vivarelli M; Zipfel PF
  •  go-up   go-down


36. Anderson CS, Arima H, Lavados P, Billot L, Hackett ML, Olavarría VV, Muñoz Venturelli P, Brunser A, Peng B, Cui L, Song L, Rogers K, Middleton S, Lim JY, Forshaw D, Lightbody CE, Woodward M, Pontes-Neto O, De Silva HA, Lin RT, Lee TH, Pandian JD, Mead GE, Robinson T, Watkins C, HeadPoST Investigators and Coordinators: Cluster-Randomized, Crossover Trial of Head Positioning in Acute Stroke. N Engl J Med; 2017 06 22;376(25):2437-2447
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We wanted to determine whether outcomes in patients with acute ischemic stroke could be improved by positioning the patient to be lying flat (i.e., fully supine with the back horizontal and the face upwards) during treatment to increase cerebral perfusion.
  • METHODS: In a pragmatic, cluster-randomized, crossover trial conducted in nine countries, we assigned 11,093 patients with acute stroke (85% of the strokes were ischemic) to receive care in either a lying-flat position or a sitting-up position with the head elevated to at least 30 degrees, according to the randomization assignment of the hospital to which they were admitted; the designated position was initiated soon after hospital admission and was maintained for 24 hours.
  • Patients in the lying-flat group were less likely than patients in the sitting-up group to maintain the position for 24 hours (87% vs. 95%, P<0.001).
  • In a proportional-odds model, there was no significant shift in the distribution of 90-day disability outcomes on the global modified Rankin scale between patients in the lying-flat group and patients in the sitting-up group (unadjusted odds ratio for a difference in the distribution of scores on the modified Rankin scale in the lying-flat group, 1.01; 95% confidence interval, 0.92 to 1.10; P=0.84).
  • Mortality within 90 days was 7.3% among the patients in the lying-flat group and 7.4% among the patients in the sitting-up group (P=0.83).
  • CONCLUSIONS: Disability outcomes after acute stroke did not differ significantly between patients assigned to a lying-flat position for 24 hours and patients assigned to a sitting-up position with the head elevated to at least 30 degrees for 24 hours. (Funded by the National Health and Medical Research Council of Australia; HeadPoST ClinicalTrials.gov number, NCT02162017 .).
  • [MeSH-major] Patient Positioning. Posture. Stroke / therapy

  • MedlinePlus Health Information. consumer health - Stroke.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28636854.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT02162017
  • [Publication-type] Journal Article; Multicenter Study; Pragmatic Clinical Trial; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Preto R; Heritier S; Lindley R; Jan S; Boaden E; Herbert R; Chen CPLH; Forster A; Scaria A; Espinosa N; McEvoy L; Blackburn L; Richtering SS; You S; Ladwig S; Merritt GP; Thomsen B; Jenson K; Gordon P; Nguyen DR; Quan WW; Lo TP; Lim J; Goh S; Ivanova E; Liu L; Baig MA; Singh R; Donnelly P; Armenis M; Van Zyl M; Monaghan H; Smith P; Glass P; Zhou F; Shen Y; Lei L; Li D; Zhang T; Zhang X; Peng Y; Feng L; Ye Z; Gregory P; Arora D; Gonzalez F; Portales B; Pontes-Neto O; Santos-Pontelli T; Rimoli B; Braga M; Hoffmeister L; Vidal C; Benadof D; Rivas RJ; Carvallo L; Carvallo P; Miranda R; Pileggi. B; Weerawardena S; Jeevarajah T; Dharmawardena D; Ranasinghe D; Dharshana M; Shafras MMM; Nandadeva N; Nawarathna. S; Yin JH; Yeh SJ; Ma RJ; Whiteley G; Cox J; Fitzgerald J; Heney JF; Byfield H; Finley S; Tyrer HE; Bruce C; Gibbon A; Jones B; Siracusa E; Gowda K; Cowans S; Forman B; Jacob S; Caprecho K; Khatri R; Wan PY; Lopez M; Vanika S; Bleeker W; Ireland M; Jala S; Day S; Ha E; Krause M; Passer M; Giaccari S; Burkolter N; Braithwaite M; Tastula K; Ghia D; Musuka T; Alvaro A; Edmonds G; O'Loughin N; Phair R; Kaoutal J; Blacker DJ; Saint BL; Parrey K; Coad M; Kinchington M; Senanayake N; Alaban J; Kuehne I; Camilo M; Libardi M; Martins S; Carlos B; Martins M; Carbonera L; Almeida A; Kelin M; Martins G; Pauli C; Lunardi M; Silveira L; Chagas O; Souza D; Bazan R; Braga G; Ribeiro P; Luvizutto G; Polin M; Winckler. F; Liu J; Wang Z; Wang H; Lin S; Dong J; Zhou J; Qin S; Zhan H; Xue Y; Tian D; Yang D; Yin Y; Li H; Geng C; Liu J; Jiang X; Wu Y; Sun W; Yu B; Guan Y; Wang Q; Wei B; Wang H; Wang Y; Tai L; Zhang W; Zhao W; Wang X; Li G; Ni Z; Guo F; Cen L; Lu J; Chen Z; Yin G; Wang Y; Zheng J; Zhou Z; Wang H; Zou R; Xue B; Li A; Guo J; Guo Y; Jiang X; Tan X; Zhang C; Shao B; Niu X; Liu C; Chen D; Liang P; Zhang X; Zhang C; Gong W; Huang Z; Liu H; Huang J; Shi R; Wang C; Liu Y; Wang J; Wu G; Gao Z; Lin Q; Xu C; Zheng H; Ye X; Jin X; Liu J; Cao X; Zhang Y; Wang J; Xu Y; Li Y; Ma X; Kong Q; Hao Y; Qiao B; Yan H; Huang Z; Chang B; Yan J; Liao P; Zhang W; Liu L; Zhu T; Liu X; Li Y; Dong R; Chen M; Ge X; Wang H; Dai L; Liu J; Wang S; Du J; Song A; Li Y; Feng J; Yu C; Feng H; Sun X; Sun R; Liu W; Liu J; Lu X; Chen E; Gao W; Liu H; Wang H; Wang Y; Song J; Liu D; Du W; Li G; Li C; Liang Y; Cai X; Zhang J; Tao X; An P; Tang R; Qin X; Wang Y; Zhang W; Ma R; Huang X; Liu Y; Wang Y; Fan P; Yang H; Feng L; Zhi J; Zhang J; Zhou Y; Wu D; He H; Chen X; Hou Y; Su X; Fan S; Suárez L; de Dios Polanco J; Sotomayor P; Urzúa R; Urrutia D; Conejan N; Escobar A; Gonzalez M; Vargas D; Constante A; Vásquez E; Godoy E; Figueroa C; San Martin V; Vidal N; Muñoz M; Spencer M; Almeida J; Acosta I; Guerrero R; Lozano P; Aguayo C; Pizarro J; Soto A; Bonilla F; García P; Del Castillo C; Grandjean M; Von Johnn A; Gutierrez I; Rivero F; López I; Silva F; Pachón M; Mendoza J; Pabón A; Kate M; Akhtar N; Narang GS; Deepak A; Huded V; De Sowza R; Sigamani A; Rajendran K; Vishwanath A; K A; Kumaravelu S; Rahamath S; Kannneganti S; Khurana D; Katoch C; Kaur T; Karadan U; Kuriakose A; John J; Basheer M; Padmavathy N S; Sreedharan SE; Gunasekara HH; De Silva GCU; Ubeywickrama PHL; Silva KC; De Silva EA; Ranawaka U; Mettananda C; Nanayakkara Y; Mendis T; Fernando G; Imthikab A; Pieris K; Gunatilake SB; Madanayake PMW; Paranavitane SA; Senanayake B; Vishwanathan V; Sivapalan M; Murage RU; Chandradeva U; Liu YH; Lin CL; Lin HF; Liu KT; Chen CF; Wu MN; Tsai SH; Chen CC; Chen LY; Chang CH; Chang YJ; Huang KL; Chang TY; Liu CH; Seak CJ; Lin YL; Luo JY; Yang HY; Wang CY; Chan L; Hu CJ; Chi NF; Wu D; Huang YH; Kuan YC; Hong CT; Chen YC; Sun Y; Lin CH; Lu CJ; Chu HJ; Lo YC; Chang WH; Lin WJ; Su HC; Lin TY; Cho CH; Lu SL; Hsueh YF; Lai. CY; Jarrett D; James C; Valentine S; Whistler C; Butler R; Browning S; Watchurst C; Erande R; Elliott E; Patel K; Brezitski M; Hogan C; Banaras A; Crook L; Ahmed R; Potter L; Laird R; Patel B; Clarke N; Loosemore A; Godber J; Gawned S; Hamilton KA; Jones R; Guyler P; Tysoe S; Prabakaran R; Shah S; Calver J; Sztriha LK; Fitzpatrick M; Drysdale S; Aeron-Thomas J; McKenzie E; Chitando B; Willcoxson P; Iveson E; Wanklyn P; Dyer N; Keeling M; Rodriguez R; Elliott K; Porteous M; O'Neill M; Orme S; Richardson C; Tomlinson J; Hawkins S; Bester D; Jeffs C; Howard J; Brown P; Ward D; Turfrey J; Raybould L; Bates A; O'Connell S; O'Connor M; Williams S; Emsley HCA; McLoughlin A; Raj S; Gregary B; Doyle D; Courtauld GM; Schofield C; Lucas L; Lydon A; James A; Saastamoinen K; Howaniec L; Daboo P; Ali AN; Richards E; Howe J; Kamara C; Stocks K; Lindert R; Day DJ; Finlay S; McGee J; Mitchell J; Amis E; Macey R; Tauro S; Henry L; Cuddy S; Steele A; Mullen K; Kirker S; Bhattad M; Carpenter M; Datta P; Needle A; Jackson L; Ball J; Beckitt R; Devon R; Chivers N; Bowring A; Eddy S; Thorpe K; Keenan S; Griffin A; Maguire S; Patterson C; Ramadan H; Bellfield R; Hooley M; Stewart K; Williams L; Gurney C; Oliver D; Gardiner M; Grayland S; Bhandari M; Collas DM; Adesina T; Sundayi S; Harvey R; Pope E; Lam A; Walker E; Merrill C; Banerjee S; Harvey KH; Mashate S; Wilding P; Johnson L; Namushi R; Jacob P; Andole S; Dunne K; Gadapa N; King S; Patel R; Siliuzaite S; Dealing S; Attwood K; Sanmuganathan S; Woods A; Sandhu B; Mamun M; Mahmood A; Jones J; Ojo A; Carter-Evans D; Fitzsimmons P; Manoj A; Fletcher G; Lopez P; Rana PS; Greig J; Robinson M; Jones P; Jones S; Jones L; West C; Tench H; Potter S; Gascoyne R; Whileman A; Hall E; Wright S; Toms J; Sekaran L; Phiri D; Sethuraman S; Mohammed N; Justin F; Tate ML; Chauhan M; Chatterjee K; Haider SI; Nallasivan A; Webster T; Leason S; Seagrave S; Subramonian S; Owksu-Agyei P; Temple N; Butterworth-Cowin N; Magezi F; Turner E; Khan S; Stephens C; Mistri A; Murphy A; Lam M; Underwood P; Thompson C; Smith C; Buckley C; Wood D; Board S; Howard L; Johnson S; Ahmed A; Oates B; Jenkinson DF; Leonard S; Jupp BJ; Thavanesan K; Dharmasiri M; Logianathan S; Ovington C; Hann G; Cox C; McCormick MT; Douglas C; Goggin M; Fearon P; Gilpin S; O'Hagan M; Mangion DM; Hardwick A; Netherton K; Ni H; Quinn J; Bozkaplan T; Jose J
  •  go-up   go-down


37. McCord J, Cabrera R, Lindahl B, Giannitsis E, Evans K, Nowak R, Frisoli T, Body R, Christ M, deFilippi CR, Christenson RH, Jacobsen G, Alquezar A, Panteghini M, Melki D, Plebani M, Verschuren F, French J, Bendig G, Weiser S, Mueller C, TRAPID-AMI Investigators: Prognostic Utility of a Modified HEART Score in Chest Pain Patients in the Emergency Department. Circ Cardiovasc Qual Outcomes; 2017 Feb;10(2)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic Utility of a Modified HEART Score in Chest Pain Patients in the Emergency Department.
  • METHODS AND RESULTS: Twelve centers evaluated 1282 patients in the emergency department for possible AMI from 2011 to 2013.
  • Low-risk patients had an m-HS≤3 and had either hs-cTnT<14 ng/L over serial testing or had AMI excluded by the 1-hour protocol.
  • By the 1-hour protocol, 777 (60%) patients had an AMI excluded.
  • Of those 777 patients, 515 (66.3%) patients had an m-HS≤3, with 1 (0.2%) patient having a MACE, and 262 (33.7%) patients had an m-HS≥4, with 6 (2.3%) patients having MACEs (P=0.007).
  • Over 4 to 14 hours, 661 patients had a hs-cTnT<14 ng/L.
  • Of those 661 patients, 413 (62.5%) patients had an m-HS≤3, with 1 (0.2%) patient having a MACE, and 248 (37.5%) patients had an m-HS≥4, with 5 (2.0%) patients having MACEs (P=0.03).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28167641.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / PDF-2012-05-193
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; mortality / myocardial i / nfarction / patient discharge / prognosis / troponin-T
  • [Investigator] Twerenbold R; Katus HA; Popp S; Ordóñez-Llanos J; Santalo-Bel M; Horner D; Dolci A; Jernberg T; Zaninotto M; Manara A; Dinkel C; Menassanch-Volker S; Jarausch J; Zaugg C
  •  go-up   go-down


38. Andersen V, Holmskov U, Sørensen SB, Jawhara M, Andersen KW, Bygum A, Hvid L, Grauslund J, Wied J, Glerup H, Fredberg U, Villadsen JA, Kjær SG, Fallingborg J, Moghadd SAGR, Knudsen T, Brodersen J, Frøjk J, Dahlerup JF, Nielsen OH, Christensen R, Bojesen AB, Sorensen GL, Thiel S, Færgeman NJ, Brandslund I, Stensballe A, Schmidt EB, Franke A, Ellinghaus D, Rosenstiel P, Raes J, Heitmann B, Boye M, Nielsen CL, Werner L, Kjeldsen J, Ellingsen T: A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine. Nutrients; 2017 May 15;9(5)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Approximately one-third of the patients do not respond to the treatment.
  • Clinical data including lifestyle and treatment response and biological specimens (blood, faeces, urine, and, in IBD patients, intestinal biopsies) are sampled prior to and while on TNF inhibitor therapy.
  • The final purpose is to improve the lives of patients suffering from CIDs, by providing tools facilitating treatment selection and dietary recommendations likely to improve the clinical outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nutr J. 2005 Feb 10;4:7 [15705205.001]
  • [Cites] Gastroenterology. 1995 May;108(5):1434-44 [7729636.001]
  • [Cites] Digestion. 2008;77(1):57-64 [18349539.001]
  • [Cites] Int J Epidemiol. 2011 Jun;40(3):602-10 [20338891.001]
  • [Cites] Scand J Public Health. 2007;35(4):432-41 [17786808.001]
  • [Cites] Gastroenterology. 2010 Dec;139(6):1912-7 [20950616.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2012 Jan 1;302(1):G1-9 [22016433.001]
  • [Cites] Cell. 2016 Nov 17;167(5):1339-1353.e21 [27863247.001]
  • [Cites] Lancet. 2002 May 4;359(9317):1541-9 [12047962.001]
  • [Cites] Am J Clin Nutr. 2014 Sep;100(3):959-67 [25030783.001]
  • [Cites] Nat Commun. 2015 Feb 05;6:6046 [25651891.001]
  • [Cites] Int J Epidemiol. 1992 Aug;21(4):770-7 [1521982.001]
  • [Cites] Gut. 2009 Dec;58(12 ):1606-11 [19628674.001]
  • [Cites] J Crohns Colitis. 2010 Feb;4(1):28-62 [21122489.001]
  • [Cites] Ann Rheum Dis. 2014 Jul;73(7):1316-22 [24550173.001]
  • [Cites] Nat Genet. 2012 Dec;44(12 ):1341-8 [23143594.001]
  • [Cites] J Physiol Pharmacol. 2013 Apr;64(2):143-55 [23756389.001]
  • [Cites] Nature. 2016 Dec 12;:null [27951586.001]
  • [Cites] Lancet. 2007 May 12;369(9573):1627-40 [17499605.001]
  • [Cites] Nat Commun. 2015 Jan 19;6:5890 [25597830.001]
  • [Cites] Lancet. 2007 May 12;369(9573):1641-57 [17499606.001]
  • [Cites] N Engl J Med. 2013 Aug 22;369(8):754-62 [23964937.001]
  • [Cites] Am J Gastroenterol. 2013 Apr;108(4):575-82 [23318483.001]
  • [Cites] Am J Gastroenterol. 2015 Sep;110(9):1324-38 [26303131.001]
  • [Cites] Aliment Pharmacol Ther. 2016 Sep;44(6):554-67 [27417569.001]
  • [Cites] Nature. 2013 Aug 29;500(7464):541-6 [23985870.001]
  • [Cites] Rheumatol Int. 2015 Mar;35(3):533-9 [25428595.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):514-21 [17332878.001]
  • [Cites] Curr Pharm Des. 2011;17(29):3141-54 [21864263.001]
  • [Cites] J Rheumatol Suppl. 2012 Jul;89:97-9 [22751605.001]
  • [Cites] J Rheumatol. 2004 Jul;31(7):1310-9 [15229949.001]
  • [Cites] PLoS One. 2015 Oct 06;10(10):e0139781 [26440629.001]
  • [Cites] Nucleic Acids Res. 2012 Jan;40(Database issue):D930-4 [22064851.001]
  • [Cites] Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17059-64 [24062455.001]
  • [Cites] Ann Rheum Dis. 2011 May;70(5):722-6 [21257615.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):52-65 [17241859.001]
  • [Cites] Pharmacogenomics J. 2014 Dec;14(6):526-34 [24776844.001]
  • [Cites] Gastroenterology. 2017 May 12;:null [28506689.001]
  • [Cites] Expert Opin Drug Saf. 2011 Jul;10 (4):655-73 [21554150.001]
  • [Cites] J Rheumatol. 2016 Jan;43(1):187-93 [25877496.001]
  • [Cites] Aliment Pharmacol Ther. 2014 Apr;39(8):834-42 [24611981.001]
  • [Cites] Mayo Clin Proc. 2006 Nov;81(11):1462-71 [17120402.001]
  • [Cites] Int J Epidemiol. 2015 Dec;44(6):1995-2005 [26546032.001]
  • [Cites] Clin Epidemiol. 2016 Oct 25;8:737-742 [27822121.001]
  • [Cites] Bioinformatics. 2015 Mar 1;31(5):761-3 [25338716.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2014 Jan;26(1):11-8 [24216567.001]
  • [Cites] Nutrients. 2017 Mar 15;9(3): [28294972.001]
  • [Cites] Gastroenterology. 2012 Mar;142(3):482-9 [22155183.001]
  • [Cites] World J Gastroenterol. 2014 Jan 7;20(1):64-77 [24415859.001]
  • [Cites] BMC Med Genet. 2010 May 28;11:82 [20509889.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2010 May;22(5):602-6 [20216220.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2462-76 [16339095.001]
  • [Cites] Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7 [26323879.001]
  • [Cites] Pharmacogenomics. 2013 May;14(7):727-34 [23651021.001]
  • [Cites] Gut. 2014 May;63(5):776-84 [23828881.001]
  • [Cites] Nature. 2014 Feb 20;506(7488):376-81 [24390342.001]
  • [Cites] Nature. 2013 Aug 29;500(7464):585-8 [23985875.001]
  • [Cites] Nat Genet. 2013 Jul;45(7):730-8 [23749187.001]
  • [Cites] Ann Rheum Dis. 2014 Jan;73(1):219-26 [23505230.001]
  • [Cites] Gastroenterology. 2013 Nov;145(5):970-7 [23912083.001]
  • [Cites] Dig Liver Dis. 2012 Mar;44(3):185-94 [22055893.001]
  • [Cites] Nat Genet. 2010 Dec;42(12):1118-25 [21102463.001]
  • [Cites] Gut. 1993 Apr;34(4):437-9 [8491386.001]
  • [Cites] Am J Epidemiol. 2012 Mar 1;175(5):402-13 [22247049.001]
  • [Cites] Semin Immunol. 2011 Apr;23(2):92-8 [21376627.001]
  • [Cites] Am J Gastroenterol. 2012 Sep;107(9):1399-406 [22777340.001]
  • [Cites] Inflamm Bowel Dis. 2015 May;21(5):1063-71 [25723616.001]
  • [Cites] J Invest Dermatol. 2013 Feb;133(2):377-85 [23014338.001]
  • [Cites] Hum Mol Genet. 2008 Oct 15;17(R2):R116-21 [18852199.001]
  • [Cites] Acta Derm Venereol. 2009;89(5):492-7 [19734975.001]
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):239-50 [17634459.001]
  • [Cites] Clin Nutr. 2017 Apr;36(2):321-347 [28131521.001]
  • [Cites] Nat Genet. 2015 Sep;47(9):979-86 [26192919.001]
  • [Cites] Clin Gastroenterol Hepatol. 2014 Aug;12(8):1315-23.e2 [24183956.001]
  • [Cites] Nature. 2011 Jun 15;474(7351):298-306 [21677746.001]
  • [Cites] Clin Rev Allergy Immunol. 2015 Jun;48(2-3):182-91 [24828903.001]
  • [Cites] PLoS One. 2014 Jun 27;9(6):e98815 [24971461.001]
  • [Cites] Front Genet. 2015 Mar 19;6:81 [25852737.001]
  • [Cites] Nat Commun. 2015 Jan 21;6:6131 [25607885.001]
  • [Cites] Am J Med. 2007 Nov;120(11):953-9 [17976422.001]
  • [Cites] J Crohns Colitis. 2012 Dec;6(10):991-1030 [23040451.001]
  • [Cites] Nutrients. 2016 Sep 30;8(10 ): [27706028.001]
  • [Cites] Trends Mol Med. 2016 Mar;22(3):190-9 [26852376.001]
  • [Cites] Aliment Pharmacol Ther. 2013 Nov;38(10):1156-71 [24102340.001]
  • [Cites] Am J Med. 2006 Jun;119(6):503.e1-9 [16750964.001]
  • [Cites] Scand J Rheumatol. 2006 May-Jun;35(3):169-74 [16766362.001]
  • [Cites] Inflamm Bowel Dis. 2013 Aug;19(9):1921-7 [23751398.001]
  • [Cites] Int J Epidemiol. 1991 Dec;20(4):906-12 [1800429.001]
  • [Cites] Curr Clin Pharmacol. 2012 Nov;7(4):271-5 [22794157.001]
  • [Cites] Mol Nutr Food Res. 2012 Jan;56(1):184-96 [22121108.001]
  • [Cites] Inflamm Bowel Dis. 2016 Jun;22(6):1403-11 [27120568.001]
  • [Cites] Inflamm Bowel Dis. 2014 Nov;20(11):2013-21 [25265262.001]
  • [Cites] Gut. 2004 Oct;53(10):1479-84 [15361498.001]
  • [Cites] Br J Dermatol. 2011 May;164(5):1091-6 [21219290.001]
  • [Cites] Surv Ophthalmol. 2015 Nov-Dec;60(6):575-89 [26164735.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Dec;64(12 ):1829-36 [22744978.001]
  • [Cites] Inflamm Bowel Dis. 2015 Oct;21(10 ):2311-9 [26236952.001]
  • [Cites] Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30 [22001864.001]
  • [Cites] Cytokine. 2016 Jan;77:44-9 [26520877.001]
  • [Cites] Clin Exp Immunol. 2014 Jun;176(3):301-9 [24528300.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3812-4 [12824425.001]
  • [Cites] Arthritis Rheum. 2004 Dec;50(12 ):3804-12 [15593211.001]
  • [Cites] Immunol Rev. 2008 Jun;223:7-19 [18613827.001]
  • [Cites] Int Immunopharmacol. 2015 Dec;29(2):947-9 [26563541.001]
  • [Cites] Br J Dermatol. 2014 Feb;170(2):304-14 [24117435.001]
  • [Cites] Pharmacogenomics J. 2016 Oct 04;:null [27698401.001]
  • [Cites] Pharmacogenomics J. 2017 Jan 31;:null [28139755.001]
  • [Cites] Nat Genet. 2016 May;48(5):510-8 [26974007.001]
  • [Cites] Clin Ther. 2004 Dec;26(12):1960-75 [15823761.001]
  • [Cites] Science. 2015 May 8;348(6235):648-60 [25954001.001]
  • (PMID = 28505128.001).
  • [ISSN] 2072-6643
  • [Journal-full-title] Nutrients
  • [ISO-abbreviation] Nutrients
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; biomarker / exercise / food / molecular epidemiology / patient related outcome measures (PROMs) / personalized medicine / red meat / smoking / treatment outcome / western style diet (WSD)
  •  go-up   go-down


39. Strandberg AY, Khanfir H, Mäkimattila S, Saukkonen T, Strandberg TE, Hoti F: Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults. Ann Med; 2017 Jun;49(4):357-364

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Risk of severe hypoglycemia requiring hospital care was compared between insulin types.
  • RESULTS: A total of 16,985 persons initiated basal insulin treatment (5586, 7499, and 3900 patients started NPH, glargine, and detemir, respectively) during follow-up.
  • Absolute rate (per 1000 patient-years) was 20.6 (95% CI 17.9, 23.8), 17.8 (15.6, 20.3), and 12.4 (9.9, 15.5) for NPH, glargine, and detemir initiators, respectively.
  • Large reductions in the incidence of severe hypoglycemia were seen among real-life patients who started insulin detemir, as compared to patients who initiated glargine or especially NPH insulin.
  • Given the large amount of patients using insulin, these findings may have considerable clinical consequences at the population level.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28042719.001).
  • [ISSN] 1365-2060
  • [Journal-full-title] Annals of medicine
  • [ISO-abbreviation] Ann. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Hypoglycemia / NPH insulin / basal insulin therapy / insulin detemir / insulin glargine / working-age population
  •  go-up   go-down


40. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A: Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol; 2017 Jun 24;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
  • CONCLUSIONS: The presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available, including disease extent and location, prior therapies regardless of type, host factors including comorbidities, as well as patient preferences, current and emerging evidence, and logistical and economic constraints.
  • PATIENT SUMMARY: The second Advanced Prostate Cancer Consensus Conference APCCC 2017 did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer.
  • The aim of the conference is to bring the expertise of world experts to care givers around the world who see less patients with prostate cancer.
  • The results of these expert opinion votes are embedded in the clinical context of current treatment of men with advanced prostate cancer and provide a practical guide to clinicians to assist in the discussions with men with prostate cancer as part of a shared and multidisciplinary decision-making process.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 28655541.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Advanced and high-risk localized prostate cancer / Castration-naive and castration-resistant prostate cancer / Consensus / Oligometastatic prostate cancer / Therapeutics
  •  go-up   go-down


41. Udy AA, Dulhunty JM, Roberts JA, Davis JS, Webb SAR, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Starr T, Paul SK, Lipman J, BLING-II Investigators, ANZICS Clinical Trials Group: Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. Int J Antimicrob Agents; 2017 May;49(5):624-630

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial.
  • This substudy of the BLING-II trial aimed to explore the association between ARC and patient outcomes in a large randomised clinical trial.
  • Patients receiving any form of renal replacement therapy were excluded.
  • A total of 254 patients were included, among which 45 (17.7%) manifested ARC [median (IQR) CL<sub>Cr</sub> 165 (144-198) mL/min].
  • ARC patients were younger (P <0.001), more commonly male (P = 0.04) and had less organ dysfunction (P <0.001).
  • There were no statistically significant differences in clinical outcomes in ARC patients according to the dosing strategy employed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
  • (PMID = 28286115.001).
  • [ISSN] 1872-7913
  • [Journal-full-title] International journal of antimicrobial agents
  • [ISO-abbreviation] Int. J. Antimicrob. Agents
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Augmented renal clearance / Critical illness / Sepsis / β-Lactams
  • [Investigator] Bellomo R; Eastwood G; Peck L; Young H; Boschert C; Fletcher J; Smith J; Nand K; Sara T; Shirwadkar C; Harney A; Rodgers H; Van Haren F; Clarke S; Durham D; Hannan C; Matheson E; Schwartz K; Thomas K; Bone A; Cattigan C; Elderkin T; Salerno T; Cameron R; Ellis K; Hatter S; Davis J; Sanap M; Soar N; Wood J; Chan K; Heffernan A; Lai NA; Moss C; Sheehy K; Duroux M; Ratcliffe M; Shone S; Warhurst T; Dulhunty J; Dunlop R; Lipman J; Paterson D; Roberts J; Starr T; Stuart J; Udy A; Cooper D; McAllister R; Webb S; Cheng A; Inskip D; Miller J; Myburgh J; Knowles S; Reynolds C; Rudham S; Baker S; Hepburn K; Roberts B; Woods P; Chatterjee I; Smith J; Cullen M; Kong J; Nayyar V; Whitehead C; Gomersall C; Leung P; Gilder E; McCarthy L; McGuiness S; Parke R; Benefield K; Chen Y; McArthur C; Newby L; Henderson S; Mehrtens J; Noble S; Chadwick L; Freebain R; Hogan C; Kazemi A; Rust L; Song R; Tilsley A; Williams A; Durning J; Frengley R; La Pine M; McCracken G; Sharma SB; Andrews L; Dinsdale R; Hunt A; Hurford S; Mackle D; Ongley J; Young P; Lipman J; Bellomo R; Davis J; Dulhunty J; Eastwood G; Gomersall C; Myburgh J; Paterson D; Roberts J; Shirwadkar C; Starr T; Webb S; Kollef M; Turnidge J; Paul S
  •  go-up   go-down


42. Silverman P, Colella F, McQuigg B, Hines H, Ciarallo S, Whittington L, Belcher S: Elective chemotherapy admission pilot and work-flow improvements to reduce excess days. J Clin Oncol; 2012 Dec;30(34_suppl):101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 101 Background: The Inpatient (Inpt) Oncology Service at University Hospitals Seidman Cancer Center, a large urban academic NCI Comprehensive Cancer Center was charged with identifying opportunities to link patient (pt) quality improvement and decreased length of stay (LOS) in pts admitted for elective chemotherapy (EC).
  • METHODS: A 2-month pilot was conducted, using an intervention group (IG) and control (C) group representing usual care (UC).
  • Census was taken above cap to accommodate IG patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28146956.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Hirose T, Kimbara F, Shinozaki M, Mizushima Y, Yamamoto H, Kishi M, Kiguchi T, Shiono S, Noborio M, Fuke A, Akimoto H, Kimura T, Kaga S, Horiuchi T, Shimazu T: Screening for hereditary angioedema (HAE) at 13 emergency centers in Osaka, Japan: A prospective observational study. Medicine (Baltimore); 2017 Feb;96(6):e6109
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective is to study the incidence of HAE among patients who visit the emergency department.This was a 3-year prospective observational screening study involving 13 urban tertiary emergency centers in Osaka prefecture, Japan.
  • Patients were included if they met the following criteria: unexplained edema of the body, upper airway obstruction accompanied by edema, anaphylaxis, acute abdomen with intestinal edema (including ileus and acute pancreatitis), or asthma attack.
  • C1-INH activity and C4 level were measured at the time of emergency department admission during the period between July 2011 and June 2014.This study comprised 66 patients with a median age of 54.0 (IQR: 37.5-68.3) years.
  • Three patients were newly diagnosed as having HAE, and 1 patient had already been diagnosed as having HAE.
  • C1-INH activity levels of the patients with HAE were below the detection limit (<25%), whereas those of non-HAE patients (n = 62) were 106% (IQR: 85.5%-127.0%) (normal range, 70%-130%).
  • The median level of C4 was significantly lower in the patients with HAE compared with those without HAE (1.2 [IQR: 1-3] mg/dL vs 22 [IQR: 16.5-29.5] mg/dL, P < 0.01) (normal range, 17-45 mg/dL).Three patients with undiagnosed HAE were diagnosed as having HAE in the emergency department during the 3-year period.
  • If patients have signs and symptoms suspicious of HAE, the levels of C1-INH activity and C4 should be measured.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Complement C1 Inhibitor Protein / analysis. Complement C4 / analysis. Female. Humans. Japan. Male. Middle Aged. Prospective Studies. Tertiary Care Centers

  • Genetic Alliance. consumer health - Hereditary angioedema.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Immunol. 1988;6:595-628 [3289579.001]
  • [Cites] Arerugi. 2014 Jun;63(6):749-53 [24953732.001]
  • [Cites] Am J Med Sci. 2012 Mar;343(3):210-4 [21934598.001]
  • [Cites] Eur Ann Allergy Clin Immunol. 2013 Feb;45(1):7-16 [23678554.001]
  • [Cites] N Engl J Med. 1996 Jun 20;334(25):1666-7 [8628365.001]
  • [Cites] Ann Allergy Asthma Immunol. 2010 Mar;104(3):211-4 [20377110.001]
  • [Cites] Eur J Emerg Med. 2012 Aug;19(4):271-4 [22008588.001]
  • [Cites] Mayo Clin Proc. 2000 Apr;75(4):349-54 [10761488.001]
  • [Cites] Clin Rev Allergy Immunol. 2016 Oct;51(2):183-92 [27207174.001]
  • [Cites] Ann Allergy Asthma Immunol. 2013 Nov;111(5):329-36 [24125136.001]
  • [Cites] Allergy Asthma Clin Immunol. 2014 Oct 24;10(1):50 [25352908.001]
  • [Cites] Lancet. 2012 Aug 25;380(9843):730 [22920751.001]
  • [Cites] Allergy Asthma Proc. 2004 Mar-Apr;25(2):127-31 [15176498.001]
  • [Cites] N Engl J Med. 2008 Sep 4;359(10):1027-36 [18768946.001]
  • [Cites] Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):24 [20667127.001]
  • [Cites] Am J Emerg Med. 2015 Dec;33(12):1840.e1-2 [25913082.001]
  • [Cites] Arch Intern Med. 2001 Nov 12;161(20):2417-29 [11700154.001]
  • [Cites] J Allergy Clin Immunol. 2012 Sep;130(3):692-7 [22841766.001]
  • [Cites] BMC Gastroenterol. 2013 Aug 02;13:123 [23915279.001]
  • [Cites] Allergol Int. 2012 Dec;61(4):559-62 [23093794.001]
  • [Cites] J Allergy Clin Immunol. 2004 Sep;114(3 Suppl):S51-131 [15356535.001]
  • [Cites] Am J Med. 2006 Mar;119(3):267-74 [16490473.001]
  • [Cites] Transfusion. 2014 Nov;54(11):2989-96; quiz 2988 [24735226.001]
  • (PMID = 28178173.001).
  • [ISSN] 1536-5964
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Observational Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Complement C1 Inhibitor Protein; 0 / Complement C4
  •  go-up   go-down


44. Silva S, Ait Aissa D, Cocquet P, Hoarau L, Ruiz J, Ferre F, Rousset D, Mora M, Mari A, Fourcade O, Riu B, Jaber S, Bataille B: Combined Thoracic Ultrasound Assessment during a Successful Weaning Trial Predicts Postextubation Distress. Anesthesiology; 2017 Jun 23;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent studies suggest that isolated sonographic assessment of the respiratory, cardiac, or neuromuscular functions in mechanically ventilated patients may assist in identifying patients at risk of postextubation distress.
  • METHODS: Longitudinal ultrasound data from 136 patients who were extubated after passing a trial of pressure support ventilation were measured immediately after the start and at the end of this trial.
  • In case of postextubation distress (31 of 136 patients), an additional combined ultrasound assessment was performed while the patient was still in acute respiratory failure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28650414.001).
  • [ISSN] 1528-1175
  • [Journal-full-title] Anesthesiology
  • [ISO-abbreviation] Anesthesiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Blecha S, Harth M, Schlachetzki F, Zeman F, Blecha C, Flora P, Burger M, Denzinger S, Graf BM, Helbig H, Pawlik MT: Changes in intraocular pressure and optic nerve sheath diameter in patients undergoing robotic-assisted laparoscopic prostatectomy in steep 45° Trendelenburg position. BMC Anesthesiol; 2017 Mar 11;17(1):40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in intraocular pressure and optic nerve sheath diameter in patients undergoing robotic-assisted laparoscopic prostatectomy in steep 45° Trendelenburg position.
  • BACKGROUND: To evaluate changes in intraocular pressure (IOP) and intracerebral pressure (ICP) reflected by the optic nerve sheath diameter (ONSD) in patients undergoing robotic-assisted laparoscopic prostatectomy (RALP) in permanent 45° steep Trendelenburg position (STP).
  • METHODS: Fifty-one patients undergoing RALP under a standardised anaesthesia.
  • IOP was perioperatively measured in awake patients (T0) and IOP and ONSD 20 min after induction of anaesthesia (T1), after insufflation of the abdomen in supine position (T2), after 30 min in STP (T3), when controlling Santorini's plexus in STP (T4) and before awakening while supine (T5).
  • We investigated the influence of respiratory and circulatory parameters as well as patient-specific and time-dependent factors on IOP and ONSD.
  • Patients aged <63 years showed a 0.21 mm wider ONSD on average (p = 0.017) and greater variations in diameter than older patients.
  • Differences in the ONSD were age-related, showing higher output values as well as better autoregulation and compliance in STP for patients aged <63 years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2016 Jul;196(1):9-10 [27086181.001]
  • [Cites] J Neuroophthalmol. 2007 Dec;27(4):285-7 [18090562.001]
  • [Cites] BMC Anesthesiol. 2015 Mar 31;15:43 [25861241.001]
  • [Cites] Acta Anaesthesiol Scand. 2011 Jul;55(6):644-52 [21463263.001]
  • [Cites] J Neurosurg Anesthesiol. 2015 Apr;27(2):155-9 [25105824.001]
  • [Cites] Br J Ophthalmol. 2014 Mar;98(3):305-8 [24064941.001]
  • [Cites] Anesth Analg. 2009 Aug;109(2):473-8 [19608821.001]
  • [Cites] Eur Urol. 2009 May;55(5):1037-63 [19185977.001]
  • [Cites] J Endourol. 2014 Jul;28(7):801-6 [24517270.001]
  • [Cites] Emerg Med J. 2009 Sep;26(9):630-4 [19700575.001]
  • [Cites] J Clin Ultrasound. 2003 Jun;31(5):258-73 [12767021.001]
  • [Cites] J Neurosurg Anesthesiol. 2009 Jan;21(1):16-20 [19098619.001]
  • [Cites] PLoS One. 2015 Apr 23;10(4):e0123361 [25906167.001]
  • [Cites] Br J Anaesth. 1998 Feb;80(2):243-4 [9602594.001]
  • [Cites] Ultraschall Med. 2014 Oct;35(5):422-31 [24647767.001]
  • [Cites] Anesth Analg. 1985 May;64(5):520-30 [3158256.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2016 Jun;87(6):650-5 [26285586.001]
  • [Cites] Minerva Anestesiol. 2012 May;78(5):596-604 [22415437.001]
  • [Cites] AANA J. 2011 Apr;79(2):115-21 [21560974.001]
  • [Cites] Curr Opin Anaesthesiol. 2013 Jun;26(3):375-81 [23614957.001]
  • [Cites] AANA J. 2014 Jun;82(3):203-11 [25109158.001]
  • [Cites] Acta Anaesthesiol Scand. 2002 Jul;46(6):703-6 [12059895.001]
  • [Cites] Eur Urol. 2013 Apr;63(4):606-14 [22840353.001]
  • [Cites] Acta Ophthalmol. 2011 Sep;89(6):e528-32 [21518306.001]
  • [Cites] J Urol. 2016 Jul;196(1):76-81 [26860793.001]
  • [Cites] J Urol. 2015 Apr;193(4):1213-9 [25444990.001]
  • [Cites] Intensive Care Med. 2008 Nov;34(11):2062-7 [18509619.001]
  • (PMID = 28284189.001).
  • [ISSN] 1471-2253
  • [Journal-full-title] BMC anesthesiology
  • [ISO-abbreviation] BMC Anesthesiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Intraocular pressure / Optic nerve sheath diameter / Robotic-assisted laparoscopic prostatectomy / steep Trendelenburg position
  •  go-up   go-down


46. Bosnic-Anticevich S, Callan C, Chrystyn H, Lavorini F, Nikolaou V, Kritikos V, Dekhuijzen PNR, Roche N, Bjermer L, Rand C, Zwar N, Price DB: Inhaler technique mastery and maintenance in healthcare professionals trained on different devices. J Asthma; 2017 Mar 23;:1-10
figshare. supplemental materials - Supporting Data and Materials for the article .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Healthcare professionals (HCPs) are required to assess and train patients in the correct use of inhalers but are often unable to demonstrate correct technique themselves.
  • METHODS: We conducted a randomized, un-blinded, crossover study in undergraduate HCPs who undertook a six-step training procedure (intuitive use, patient information leaflet, instructional video, individual tuition from expert, then two repeats of individual tuition) for the use of Turbuhaler® (an established device) and Spiromax® (a newer device, reportedly easier to use).
  • The implications on clinical practice, device education delivery, and patient outcomes require further evaluation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28332886.001).
  • [ISSN] 1532-4303
  • [Journal-full-title] The Journal of asthma : official journal of the Association for the Care of Asthma
  • [ISO-abbreviation] J Asthma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Asthma / clinical trial / device mastery / device mastery maintenance / dry powder inhaler / handling errors
  •  go-up   go-down


47. Kadokura M, Ishida Y, Tatsumi A, Takahashi E, Shindo H, Amemiya F, Takano S, Fukasawa M, Sato T, Enomoto N: Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer. J Gastrointest Oncol; 2016 Dec;7(6):982-988

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer.
  • BACKGROUND: The usefulness of various prognostic factors for pancreatic cancer (PC) has been reported, but the number of elderly patients in these studies is disproportionately fewer compared with those in everyday practice.
  • The purpose of this study was to investigate the prognostic factors for unresectable PC in elderly patients.
  • METHODS: We retrospectively analyzed 67 elderly (age ≥75 years) patients with unresectable PC who underwent chemotherapy between January 2006 and December 2014 at our hospital.
  • CONCLUSIONS: The two prognostic factors identified herein are useful in the identification of patients with a poor prognosis and subsequent administration of supportive care alone, which may help avoid the unnecessary adverse effects and complications of systemic chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2015 Mar 1;136(5):E359-86 [25220842.001]
  • [Cites] JAMA. 1986 Jun 27;255(24):3385-90 [3712698.001]
  • [Cites] J Clin Invest. 2010 Apr;120(4):1151-64 [20237412.001]
  • [Cites] Hepatogastroenterology. 2013 Sep;60(126):1479-83 [23933941.001]
  • [Cites] Cancer Chemother Pharmacol. 2011 Oct;68(4):1017-26 [21327930.001]
  • [Cites] Oncologist. 2015 Feb;20(2):143-50 [25582141.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2014 Oct;13(5):474-81 [25308357.001]
  • [Cites] Pancreas. 2015 Apr;44(3):471-7 [25423560.001]
  • [Cites] J Gastrointest Cancer. 2013 Dec;44(4):404-9 [23765155.001]
  • [Cites] Mol Clin Oncol. 2013 Jul;1(4):788-792 [24649248.001]
  • [Cites] PLoS One. 2014 Aug 18;9(8):e104730 [25133546.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [Cites] Cancer Cell. 2009 Sep 8;16(3):183-94 [19732719.001]
  • [Cites] PLoS One. 2013 Nov 04;8(11):e78225 [24223776.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1671-7 [8635074.001]
  • [Cites] Jpn J Clin Oncol. 2015 Jan;45(1):61-6 [25341546.001]
  • [Cites] Yonsei Med J. 2013 May 1;54(3):643-9 [23549809.001]
  • [Cites] Pancreas. 2008 Apr;36(3):e16-21 [18362833.001]
  • [Cites] J Clin Oncol. 2013 May 1;31(13):1640-8 [23547081.001]
  • [Cites] Br J Cancer. 2013 Jul 23;109(2):416-21 [23799847.001]
  • [Cites] World J Gastroenterol. 2014 Aug 21;20(31):10802-12 [25152583.001]
  • [Cites] J Gastrointest Cancer. 2016 Mar;47(1):15-9 [26545612.001]
  • [Cites] CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 [24399786.001]
  • [Cites] Cancer Med. 2014 Apr;3(2):406-15 [24519894.001]
  • [Cites] J Am Geriatr Soc. 1985 Sep;33(9):585-9 [4031335.001]
  • [Cites] Oncology. 2011;80(3-4):175-80 [21701231.001]
  • [Cites] Pancreas. 2016 Feb;45(2):211-7 [26495775.001]
  • [Cites] Sci Rep. 2015 Jul 31;5:11026 [26226887.001]
  • [Cites] Pancreas. 2014 Mar;43(2):306-10 [24518512.001]
  • [Cites] J BUON. 2012 Jan-Mar;17(1):102-5 [22517701.001]
  • [Cites] Med Oncol. 2012 Dec;29(5):3101-7 [22729400.001]
  • [Cites] Br J Cancer. 2014 Jan 7;110(1):183-8 [24201751.001]
  • [Cites] Int J Clin Oncol. 2013 Oct;18(5):839-46 [22996141.001]
  • [Cites] Cytokine Growth Factor Rev. 2007 Feb-Apr;18(1-2):171-82 [17329145.001]
  • [Cites] Jpn J Clin Oncol. 2008 Nov;38(11):755-61 [18845521.001]
  • [Cites] World J Gastroenterol. 2011 Aug 14;17(30):3497-502 [21941416.001]
  • (PMID = 28078122.001).
  • [ISSN] 2078-6891
  • [Journal-full-title] Journal of gastrointestinal oncology
  • [ISO-abbreviation] J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Keywords] NOTNLM ; Pancreatic cancer (PC) / elderly patient / neutrophil-lymphocyte ratio (NLR) / prognostic factor
  •  go-up   go-down


48. Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekbom A, Svenningsson P, Chen H, Wirdefeldt K: Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study. Neurology; 2017 May 23;88(21):1996-2002
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Using data from nationwide Swedish registers, we conducted a matched-cohort study of 9,430 vagotomized patients (3,445 truncal and 5,978 selective) identified between 1970 and 2010 and 377,200 reference individuals from the general population individually matched to vagotomized patients by sex and year of birth with a 40:1 ratio.
  • Vagotomy and PD were identified from the Swedish Patient Register.
  • PD incidence (per 100,000 person-years) was 61.8 among vagotomized patients (80.4 for truncal and 55.1 for selective) and 67.5 among reference individuals.
  • However, there was a suggestion of lower risk among patients with truncal vagotomy (HR 0.78, 95% CI 0.55-1.09), which may be driven by truncal vagotomy at least 5 years before PD diagnosis (HR 0.59, 95% CI 0.37-0.93).

  • Genetic Alliance. consumer health - Parkinson Disease.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
  • [Cites] PLoS One. 2010 Jan 19;5(1):e8762 [20098733.001]
  • [Cites] BMC Public Health. 2011 Jun 09;11:450 [21658213.001]
  • [Cites] Sci Rep. 2012;2:898 [23205266.001]
  • [Cites] Nat Med. 2008 May;14(5):501-3 [18391963.001]
  • [Cites] Lancet Neurol. 2015 Jun;14(6):625-39 [25987282.001]
  • [Cites] Mov Disord. 2010 Oct 30;25(14):2355-60 [20721917.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Mov Disord. 2008 Jun 15;23(8):1076-84 [18442121.001]
  • [Cites] Ann Neurol. 2015 Dec;78(6):1011-2 [26418122.001]
  • [Cites] Med Care. 2005 Nov;43(11):1130-9 [16224307.001]
  • [Cites] Nat Med. 2008 May;14(5):504-6 [18391962.001]
  • [Cites] Cell Tissue Res. 2004 Oct;318(1):121-34 [15338272.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13010-5 [19651612.001]
  • [Cites] Neurosci Lett. 2006 Mar 20;396(1):67-72 [16330147.001]
  • [Cites] Acta Neuropathol. 2014 Feb;127(2):235-41 [24240814.001]
  • [Cites] Acta Neuropathol. 2010 Jun;119(6):689-702 [20306269.001]
  • [Cites] Neurology. 2009 Nov 3;73(18):1462-8 [19776374.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Neuroepidemiology. 2012;38(3):186-93 [22472568.001]
  • [Cites] Transl Neurodegener. 2015 Jan 08;4(1):1 [25671103.001]
  • [Cites] Acta Neuropathol. 2014 Dec;128(6):805-20 [25296989.001]
  • [Cites] Ann Neurol. 2016 Jun;79(6):940-9 [27015771.001]
  • [Cites] Lancet Neurol. 2010 Nov;9(11):1128-38 [20846907.001]
  • [Cites] Ann Neurol. 2015 Oct;78(4):522-9 [26031848.001]
  • [Cites] J Neurol Sci. 2011 Nov 15;310(1-2):9-11 [21600591.001]
  • [Cites] J Neural Transm (Vienna). 2003 May;110(5):517-36 [12721813.001]
  • (PMID = 28446653.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Bartlett CH, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M: PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. J Clin Oncol; 2015 Jun 20;33(18_suppl):LBA502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Resistance to endocrine treatment remains a major clinical problem for patients with hormone receptor positive breast cancer.
  • METHODS: In this double-blind phase 3 study women with HR positive/HER2 negative advanced metastatic BC whose cancer had relapsed or progressed on prior endocrine therapy, were randomized 2:1 to palbociclib (Palbo, 125 mg/d orally for 3 wk followed by 1 wk off) and fulvestrant (F, 500 mg per standard of care) or placebo (PLB) and F.
  • Secondary endpoints included overall survival (OS), response assessment, patient-reported outcomes, and safety and tolerability.
  • CONCLUSIONS: Palbociclib combined with fulvestrant improved progression free survival in hormone receptor positive advanced breast cancer that had progressed on prior endocrine therapy, and can be considered as a treatment option for these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28147719.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Bailly S, Leroy O, Azoulay E, Montravers P, Constantin JM, Dupont H, Guillemot D, Lortholary O, Mira JP, Perrigault PF, Gangneux JP, Timsit JF, AmarCAND2 Study Group: Impact of echinocandin on prognosis of proven invasive candidiasis in ICU: A post-hoc causal inference model using the AmarCAND2 study. J Infect; 2017 Jan 16;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: guidelines recommend first-line systemic antifungal therapy (SAT) with echinocandins in invasive candidiasis (IC), especially in critically ill patients.
  • This study aimed at assessing the impact of echinocandins compared to azoles as initial SAT on the 28-day prognosis in adult ICU patients.
  • METHODS: From the prospective multicenter AmarCAND2 cohort (835 patients), we selected those with documented IC and treated with echinocandins (ECH) or azoles (AZO).
  • RESULTS: 397 patients were selected, treated with echinocandins (242 patients, 61%) or azoles (155 patients, 39%); septic shock: 179 patients (45%).
  • However, echinocandin tended to benefit patients with septic shock (HR: 0.46 [0.19; 1.07]; p = 0.07).
  • CONCLUSION: Patients who received echinocandins were more severely ill.
  • Echinocandin use was associated with a non-significant 7% decrease of 28-day mortality and a trend to a beneficial effect for patient with septic shock.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 28104387.001).
  • [ISSN] 1532-2742
  • [Journal-full-title] The Journal of infection
  • [ISO-abbreviation] J. Infect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Echinocandin / Fluconazole / IPTW estimator / Invasive candidiasis / Patient prognosis
  • [Investigator] Aait H; Adda; Allaouchiche; Ammenouche; Angel; Argaud; Badetti; Baldesi; Barthet; Bastien; Baudin; Bellec; Blasco; Bollaert; Bonadona; Bretonnière; Brocas; Brua; Bruder; Brunin; Cabaret; Carpentier; Cartier; Cerf; Chabanne; Charles; Cheval; Cinotti; Cohen; Constantin; Cousson; Delpierre; Demory; Diconne; Du Cheyron; Dubost; Dumenil; Durand; Duroy; Forel; Foucher-Lezla; Fratea; Gally; Gaudard; Geffe; Gergaud; Gette; Girault; Goubaux; Gouin; Grenot; Grossmith; Guelon; Guerin-Robardey; Guervilly; Hayl-Slayman; Hilbert; Houissa; Hraiech; Ichai; Jung; Kaidomar; Karoubi; Kherchache; Lambiotte; Lamhaut; Launoy; Lebreton; Lefrant; Lemaire; Lepape; Lepoivre; Leroy; Lesieur; Levy; Luyt; Mahe; Mahul; Mateu; Megarbane; Merle; Mira; Montcriol; Mootien; Navellou; Ouattara; Page; Perrigault; Petitpas; Plantefeve; Quinart; Quintard; Ragonnet; Roquilly; Ruiz; Saliba; Samba; Schmitt; Seguin; Sejourne; Tellier; Thevenot; Tonnelier; Van Grunderbeek; Vincent; Wiramus; Zogheib
  •  go-up   go-down


51. Mittal R, Harris IA, Adie S, Naylor JM, CROSSBAT Study Group: Surgery for Type B Ankle Fracture Treatment: a Combined Randomised and Observational Study (CROSSBAT). BMJ Open; 2017 Mar 27;7(3):e013298

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary outcomes Patient-reported ankle function using the American Academy of Orthopaedic Surgeons Foot and Ankle Outcomes Questionnaire (FAOQ) and the physical component score (PCS) of the SF-12v2 General Health Survey at 12 months postinjury.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
  • [Cites] J Orthop Surg (Hong Kong). 2011 Dec;19(3):309-13 [22184160.001]
  • [Cites] J Bone Joint Surg Am. 2004 May;86-A(5):902-9 [15118030.001]
  • [Cites] J Bone Joint Surg Am. 1985 Jan;67(1):67-78 [3881447.001]
  • [Cites] Foot Ankle Clin. 2008 Dec;13(4):593-610 [19013398.001]
  • [Cites] J Bone Joint Surg Br. 2001 May;83(4):525-9 [11380123.001]
  • [Cites] Acta Orthop Scand. 1998 Feb;69(1):43-7 [9524517.001]
  • [Cites] J Bone Joint Surg Am. 1995 Jan;77(1):142-52 [7822349.001]
  • [Cites] Clin Orthop Relat Res. 1985 Oct;(199):17-27 [3930121.001]
  • [Cites] J Orthop Trauma. 2007 Aug;21(7):449-55 [17762475.001]
  • [Cites] J Bone Joint Surg Am. 2004 Nov;86-A(11):2393-8 [15523008.001]
  • [Cites] Injury. 2011 Nov;42(11):1226-9 [20869055.001]
  • [Cites] J Bone Joint Surg Am. 2002 Feb;84-A(2):208-15 [11861726.001]
  • [Cites] Injury. 2004 Aug;35(8):805-8 [15246805.001]
  • [Cites] J Orthop Trauma. 2012 Mar;26(3):129-34 [22330975.001]
  • [Cites] J Bone Joint Surg Am. 2009 May;91(5):1042-9 [19411451.001]
  • [Cites] Arch Orthop Trauma Surg. 2012 Feb;132(2):257-63 [21959696.001]
  • [Cites] Cochrane Database Syst Rev. 2012 Aug 15;(8):CD008470 [22895975.001]
  • [Cites] Health Aff (Millwood). 2005 Jan-Feb;24(1):18-28 [15647212.001]
  • [Cites] Cochrane Database Syst Rev. 2012 Nov 14;11:CD005595 [23152232.001]
  • [Cites] J Orthop Trauma. 2007 May;21(5):307-15 [17485995.001]
  • [Cites] Foot Ankle Int. 2014 Oct;35(10):988-95 [24962527.001]
  • [Cites] Osteoporos Int. 1999;9(1):29-37 [10367027.001]
  • [Cites] Med Care. 1996 Mar;34(3):220-33 [8628042.001]
  • [Cites] Injury. 2011 Apr;42(4):403-7 [21163480.001]
  • [Cites] Bone Joint J. 2014 Aug;96-B(8):1062-9 [25086122.001]
  • [Cites] Foot Ankle Int. 2011 Dec;32(12 ):1103-9 [22381193.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] J Nurs Meas. 2001 Fall;9(2):151-61 [11696939.001]
  • [Cites] Injury. 2006 Aug;37(8):691-7 [16814787.001]
  • [Cites] J Bone Joint Surg Br. 1986 Aug;68(4):610-3 [3090049.001]
  • [Cites] J Orthop Trauma. 2012 Nov;26(11):652-8 [22473067.001]
  • (PMID = 28348185.001).
  • [ISSN] 2044-6055
  • [Journal-full-title] BMJ open
  • [ISO-abbreviation] BMJ Open
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; ORTHOPAEDIC & TRAUMA SURGERY
  • [Investigator] Allcock P; Alttahir M; Balogh Z; Bhimani A; Bourne R; Boyle R; Broe D; Bucknill A; Chehade M; Chin R; Clout A; Connon F; Cooke C; Dave C; Dave J; Dekkers M; Drobetz H; Farrugia R; Fritsch B; Gupta S; Hoffman C; Holt M; Horseley M; Hutchinson S; Jeyaprakash P; Kent S; King D; Ko V; Kulkarni V; Laird M; Lieu D; Loefler A; Lunz D; Lynch G; Malisano L; Meakin I; Molnar R; Morrey C; Mulford J; Munsif A; Muscio P; Narayan A; Nicholls A; Nouh F; O'Carrigan T; O'Leary E; Lorentzos P; Pant S; Perriman D; Petchell J; Pirpiris M; Pohl T; Punjabi V; Randhawa S; Rau M; Scarvell J; Schuetz M; Scwartz B; Smith P; Sivakumar B; Solomon B; Spencer J; Stalley P; Steele M; Suthersan M; Szomor Z; Tamblyn P; Tarrant S; Tetsworth K; Viswanathan S; Walker R
  •  go-up   go-down


52. Taqui A, Cerejo R, Itrat A, Briggs FB, Reimer AP, Winners S, Organek N, Buletko AB, Sheikhi L, Cho SM, Buttrick M, Donohue MM, Khawaja Z, Wisco D, Frontera JA, Russman AN, Hustey FM, Kralovic DM, Rasmussen P, Uchino K, Hussain MS, Cleveland Pre-Hospital Acute Stroke Treatment (PHAST) Group: Reduction in time to treatment in prehospital telemedicine evaluation and thrombolysis. Neurology; 2017 Apr 04;88(14):1305-1312
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To compare the times to evaluation and thrombolytic treatment of patients treated with a telemedicine-enabled mobile stroke treatment unit (MSTU) vs those among patients brought to the emergency department (ED) via a traditional ambulance.
  • A vascular neurologist evaluated each patient via telemedicine and a neuroradiologist and vascular neurologist remotely assessed images obtained by the MSTU CT.
  • The evaluation and treatment of the first 100 MSTU patients (July 18, 2014-November 1, 2014) was compared to a control group of 53 patients brought to the ED via a traditional ambulance in 2014.
  • RESULTS: Patient and stroke severity characteristics were similar between 100 MSTU and 53 ED control patients (initial NIH Stroke Scale score 6 vs 7, <i>p</i> = 0.679).
  • Sixteen patients evaluated on MSTU received thrombolysis, 25% of whom received it within 60 minutes of symptom onset.

  • MedlinePlus Health Information. consumer health - Emergency Medical Services.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Academy of Neurology.
  • (PMID = 28275084.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Investigator] Taqui A; Cerejo R; Itrat A; Briggs FB; Reimer AP; Winners S; Organek N; Buletko AB; Sheikhi L; Cho SM; Buttrick M; Donohue MM; Khawaja Z; Wisco D; Frontera J; Russman A; Hustey FM; Kralovic D; Rasmussen P; Uchino K; Hussain MS
  •  go-up   go-down


53. Baynam G, Broley S, Bauskis A, Pachter N, McKenzie F, Townshend S, Slee J, Kiraly-Borri C, Vasudevan A, Hawkins A, Schofield L, Helmholz P, Palmer R, Kung S, Walker CE, Molster C, Lewis B, Mina K, Beilby J, Pathak G, Poulton C, Groza T, Zankl A, Roscioli T, Dinger ME, Mattick JS, Gahl W, Groft S, Tifft C, Taruscio D, Lasko P, Kosaki K, Wilhelm H, Melegh B, Carapetis J, Jana S, Chaney G, Johns A, Owen PW, Daly F, Weeramanthri T, Dawkins H, Goldblatt J: Initiating an undiagnosed diseases program in the Western Australian public health system. Orphanet J Rare Dis; 2017 May 03;12(1):83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: New approaches are required to address the needs of complex undiagnosed diseases patients.
  • However, complementary cross-disciplinary approaches are also critical to address those patients with multisystem disorders who traverse the bounds of multiple specialties and remain undiagnosed despite existing intra-specialty and genomic-focused approaches.
  • Herein, we describe the initiation and summary outcomes of a public health system approach for complex undiagnosed patients - the Undiagnosed Diseases Program-Western Australia (UDP-WA).
  • ii) delivered within a public health system to support equitable access to health care, including for those from remote and regional areas;.
  • iii) providing diagnoses and improved patient care;.
  • vii) designed to integrate with clinical translational research; and viii) is supporting greater connectedness for patients, families and medical staff.
  • The UDP-WA supports the provision of equitable and sustainable diagnostics and simultaneously supports capacity building in clinical care and translational research, for those with undiagnosed, typically rare, conditions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2015 Nov 3;314(17):1797-8 [26375289.001]
  • [Cites] Mol Genet Metab. 2015 Dec;116(4):223-5 [26596705.001]
  • [Cites] Orphanet J Rare Dis. 2016 Jun 11;11(1):77 [27287197.001]
  • [Cites] Orphanet J Rare Dis. 2016 Mar 24;11:30 [27012247.001]
  • [Cites] JAMA. 2014 Nov 12;312(18):1880-7 [25326637.001]
  • [Cites] Curr Opin Pediatr. 2014 Dec;26(6):626-33 [25313974.001]
  • [Cites] Genet Med. 2016 Nov;18(11):1102-1110 [27031083.001]
  • (PMID = 28468665.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Clinical best practice / Diagnosis / Diagnostic odyssey / Genomics / Phenomics / Policy / Precision public health / Undiagnosed
  •  go-up   go-down


54. d'Esterre CD, Trivedi A, Pordeli P, Boesen M, Patil S, Hwan Ahn S, Najm M, Fainardi E, Shankar JJ, Rubiera M, Almekhlafi MA, Mandzia J, Khaw AV, Barber P, Coutts S, Hill MD, Demchuk AM, Sajobi T, Forkert ND, Goyal M, Lee TY, Menon BK: Regional Comparison of Multiphase Computed Tomographic Angiography and Computed Tomographic Perfusion for Prediction of Tissue Fate in Ischemic Stroke. Stroke; 2017 Apr;48(4):939-945
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with M1-middle cerebral artery occlusions were prospectively included in this multicenter study.
  • Regional analysis was performed for each patient within Alberta Stroke Program Early CT Score regions M2 to M6.
  • RESULTS: Seventy-seven patients were included. mCTA parameter washout and CTP parameter Tmax were significantly associated with follow-up infarction in all models (<i>P</i><0.05).
  • CONCLUSIONS: Similar to CTP, multiphase CTA can be used to predict tissue fate regionally in acute ischemic stroke patients.
  • [MeSH-major] Brain Ischemia / diagnostic imaging. Infarction, Middle Cerebral Artery / diagnostic imaging. Outcome Assessment (Health Care). Stroke / diagnostic imaging. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Ischemic stroke.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Ischemic Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28292870.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Keywords] NOTNLM ; infarction (major topic) / logistic models (major topic) / magnetic resonance imaging (major topic) / stroke (major topic) / tomography (major topic)
  •  go-up   go-down


55. Korteland NM, Ahmed Y, Koolbergen DR, Brouwer M, de Heer F, Kluin J, Bruggemans EF, Klautz RJ, Stiggelbout AM, Bucx JJ, Roos-Hesselink JW, Polak P, Markou T, van den Broek I, Ligthart R, Bogers AJ, Takkenberg JJ: Does the Use of a Decision Aid Improve Decision Making in Prosthetic Heart Valve Selection? A Multicenter Randomized Trial. Circ Cardiovasc Qual Outcomes; 2017 Feb;10(2)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A Dutch online patient decision aid to support prosthetic heart valve selection was recently developed.
  • A multicenter randomized controlled trial was conducted to assess whether use of the patient decision aid results in optimization of shared decision making in prosthetic heart valve selection.
  • METHODS AND RESULTS: In a 5-center randomized controlled trial, patients were allocated to receive either standard preoperative care (control group) or additional access to the patient decision aid (intervention group).
  • Legally capable adult patients accepted for elective isolated or combined aortic and mitral valve replacement were included.
  • Primary outcome was preoperative decisional conflict (Decisional Conflict Scale); secondary outcomes included patient knowledge, involvement in valve selection, anxiety and depression, (valve-specific) quality of life, and regret.
  • Out of 306 eligible patients, 155 were randomized (78 control and 77 intervention).
  • Intervention patients felt better informed (median Decisional Conflict Scale informed subscore: 8 versus 17; <i>P</i>=0.046) and had a better knowledge of prosthetic valves (85% versus 68%; <i>P</i>=0.004).
  • Intervention patients experienced less anxiety and depression (median Hospital Anxiety and Depression Scale score: 6 versus 9; <i>P</i>=0.015) and better mental well-being (mean Short Form Health Survey score: 54 versus 50; <i>P</i>=0.032).
  • CONCLUSIONS: A patient decision aid to support shared decision making in prosthetic heart valve selection does not lower decisional conflict.
  • It does result in more knowledgeable, better informed, and less anxious and depressed patients, with a better mental well-being.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28228452.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; anxiety / cardiovascular diseases / decision making / heart valves / randomized controlled trial
  •  go-up   go-down


56. Kedhi E, Fabris E, van der Ent M, Kennedy MW, Buszman P, von Birgelen C, Cook S, Wedel H, Zijlstra F: A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial". Am Heart J; 2017 Jun;188:11-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount importance.
  • No other randomized controlled trials have evaluated the safety of shorter DAPT duration in ST-elevation myocardial infarction (STEMI) patients treated with second-generation DESs and latest P2Y12 platelet receptor inhibitors.
  • HYPOTHESIS: Six months of DAPT after Resolute Integrity stent implantation in STEMI patients is not inferior to 12 months of DAPT in clinical outcomes.
  • STUDY DESIGN: The Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation In ST-elevation Myocardial Infarction (DAPT-STEMI) trial is a randomized, multicenter, international, open-label trial designed to examine the safety (noninferiority) of 6-month DAPT after Resolute Integrity stent implantation in STEMI patients compared with 12-month DAPT.
  • Event-free patients on DAPT at 6month will be randomized (1:1 fashion) between single (aspirin only) versus DAPT for an additional 6 months and followed until 2 years after primary percutaneous coronary intervention.
  • The primary end point is a patient-oriented composite endpoint of all-cause mortality, any myocardial infarction, any revascularization, stroke, and major bleeding (net adverse clinical events [NACE]) at 18 months after randomization.
  • To achieve a power of 85% for a noninferiority limit of 1.66, a total of 1100 enrolled patients are required.
  • SUMMARY: The DAPT-STEMI trial aims to assess in STEMI patients treated with second-generation DESs whether discontinuation of DAPT after 6 months of event-free survival is noninferior to routine 12-month DAPT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28577666.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Vinant P, Joffin I, Serresse L, Grabar S, Jaulmes H, Daoud M, Abitbol G, Fouassier P, Triol I, Rostaing S, Brette MD, Colombet I, INSIGHT investigators: Integration and activity of hospital-based palliative care consultation teams: the INSIGHT multicentric cohort study. BMC Palliat Care; 2017 May 30;16(1):36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integration and activity of hospital-based palliative care consultation teams: the INSIGHT multicentric cohort study.
  • BACKGROUND: Hospital-based Palliative Care Consultation Teams (PCCTs) have a consulting role to specialist services at their request.
  • Referral of patients is often late.
  • Early palliative care in oncology has shown its effectiveness in improving quality of life, thereby questioning the "on request" model of PCCTs.
  • This multicentre prospective cohort study aims to describe the activity and integration of PCCTs at the patient level.
  • METHODS: For consecutive patients newly referred to participating PCCTs, the team collected the following data: circumstances of first referral, problems identified, number of interventions, patient's survival after first evaluation and place of death.
  • RESULTS: Seventeen PCCTs based in university hospitals in Paris area, recruited 744 newly referred adult patients, aged 72 ± 15 years, 52% males, and 504(68%) with cancer as primary diagnosis.
  • At first evaluation, 12% patients were outpatients, 88% were inpatients.
  • Symptoms represented the main reasons for referral and problems identified; 79% of patients had altered performance status; 24% encountered the PCCT only once.
  • Median survival (1st-3rd quartile) after first evaluation by the PCCT was 22 (5-82) days for overall patients, and respectively 31 (8-107) days and 9 (3-34) days for cancer versus noncancer patients (p < 0.0001).
  • Place of death was acute care hospital for 51.7% patients, and home or Palliative Care Unit for 35%.
  • Patients referred earlier died more often in PCU.
  • Cancer patients represent their predominant activity.
  • The integrated palliative care model seems to emerge besides the "on request" model which originally characterised their missions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4823-8 [15570085.001]
  • [Cites] J Pain Symptom Manage. 2014 Mar;47(3):579-587.e6 [23972575.001]
  • [Cites] Support Care Cancer. 2012 Sep;20(9):2199-203 [22552357.001]
  • [Cites] BMC Palliat Care. 2012 Dec 03;11:25 [23206428.001]
  • [Cites] Cancer J. 2010 Sep-Oct;16(5):423-35 [20890138.001]
  • [Cites] Oncologist. 2015 Jan;20(1):77-83 [25480826.001]
  • [Cites] J Clin Oncol. 2010 Sep 1;28(25):4013-7 [20660825.001]
  • [Cites] JAMA. 2010 Mar 17;303(11):1054-61 [20233823.001]
  • [Cites] J Clin Oncol. 2012 Mar 10;30(8):880-7 [22312101.001]
  • [Cites] J Natl Cancer Inst. 2011 Nov 2;103(21):1613-20 [21972226.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2538-43 [18487571.001]
  • [Cites] Palliat Med. 2004 Sep;18(6):525-42 [15453624.001]
  • [Cites] Presse Med. 2015 Jan;44(1):e1-e11 [25499252.001]
  • [Cites] Soc Sci Med. 2013 Feb;78:9-16 [23219848.001]
  • [Cites] Nutr J. 2010 Dec 22;9:69 [21176210.001]
  • [Cites] JAMA. 2008 Apr 9;299(14):1698-709 [18398082.001]
  • [Cites] J Clin Oncol. 2015 May 1;33(13):1438-45 [25800768.001]
  • [Cites] N Engl J Med. 2010 Aug 19;363(8):733-42 [20818875.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2377-82 [17557950.001]
  • [Cites] Lancet. 2014 May 17;383(9930):1721-30 [24559581.001]
  • [Cites] J Oncol Pract. 2011 Jan;7(1):48-53 [21532811.001]
  • [Cites] Arch Intern Med. 2008 Apr 28;168(8):867-75 [18443263.001]
  • (PMID = 28558731.001).
  • [ISSN] 1472-684X
  • [Journal-full-title] BMC palliative care
  • [ISO-abbreviation] BMC Palliat Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Cohort study / Health services evaluation / Multicenter study / Palliative care
  • [Investigator] Abel A; Abitbol G; Bauby A; de Corbière B; Brette MD; Chaillot N; Daoud M; Edda-Messi B; Ferry A; Fouassier P; Gauthier P; Guillard MY; Jeaulmes H; Jousselin C; Levi-Soussan M; Mercier D; Montheil V; Moreau N; Prenat-Molimard D; Morize V; Raffray Y; Tocheport P; Trabuc E; Varin D; Weiler F
  •  go-up   go-down


58. Kato A, Fujimaki Y, Fujimori S, Isogawa A, Onishi Y, Suzuki R, Yamauchi T, Ueki K, Kadowaki T, Hashimoto H: Psychological and behavioural patterns of stigma among patients with type 2 diabetes: a cross-sectional study. BMJ Open; 2017 Mar 29;7(3):e013425

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychological and behavioural patterns of stigma among patients with type 2 diabetes: a cross-sectional study.
  • OBJECTIVES: The aim of this study was to test the psychological and behavioural patterns of stigma (self-esteem and social participation) and their relationship to self-stigma, patient activation for engaging in self-care and glycaemic control among patients with type 2 diabetes mellitus (T2DM).
  • OUTCOME MEASURES: Study measures included a self-administered questionnaire to assess the Rosenberg Self-Esteem Scale (SES), the 3 subscales of 36-question Short Form Health Survey (SF-36; Social Function, Role Physical, Role Emotional), Self-Stigma Scale and Patient Activation Measure (PAM-13).
  • In our previous qualitative study, we found that psychological and behavioural patterns of stigma varied according to patients' levels of illness-related self-esteem as well as attitudes towards social participation.
  • CONCLUSIONS: The psychological and behavioural pattern of group D was found to be associated with higher levels of self-stigma and poorer patient activation for self-care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
  • [Cites] Diabetes Educ. 2015 Feb;41(1):86-94 [25398722.001]
  • [Cites] Diabetes Educ. 2009 Mar-Apr;35(2):285-92 [19204101.001]
  • [Cites] Health Qual Life Outcomes. 2014 Dec 12;12:179 [25495723.001]
  • [Cites] J Psychosom Res. 2007 May;62(5):589-94 [17467414.001]
  • [Cites] J Clin Nurs. 2003 Jan;12(1):149-50 [12519263.001]
  • [Cites] Occup Med (Lond). 2015 Jan;65(1):67-71 [25342711.001]
  • [Cites] BMJ Open. 2013 Nov 18;3(11):e003384 [24247325.001]
  • [Cites] Patient Educ Couns. 2016 Jul;99(7):1233-1239 [27873575.001]
  • [Cites] Res Nurs Health. 2007 Oct;30(5):508-17 [17893932.001]
  • [Cites] J Diabetes Investig. 2014 Mar 23;5(2):162-9 [24843756.001]
  • [Cites] J Ambul Care Manage. 2005 Jul-Sep;28(3):262-73 [15968219.001]
  • [Cites] Eur Psychiatry. 2005 Dec;20(8):529-39 [16171984.001]
  • [Cites] Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26 [15230939.001]
  • [Cites] Health Commun. 2016 Jul;31(7):806-14 [26605947.001]
  • [Cites] Psychiatr Serv. 2001 Dec;52(12):1621-6 [11726753.001]
  • [Cites] Health Serv Res. 2007 Aug;42(4):1443-63 [17610432.001]
  • [Cites] Diabet Med. 2015 Jan;32(1):120-8 [25081181.001]
  • [Cites] Am J Orthopsychiatry. 2010 Apr;80(2):267-81 [20553520.001]
  • [Cites] Health Serv Res. 2005 Dec;40(6 Pt 1):1918-30 [16336556.001]
  • [Cites] Patient. 2013;6(1):1-10 [23322536.001]
  • [Cites] BMJ Open. 2012 Nov 14;2(6):null [23151392.001]
  • [Cites] BMJ Open Diabetes Res Care. 2016 Jan 05;4(1):e000156 [26835138.001]
  • (PMID = 28360238.001).
  • [ISSN] 2044-6055
  • [Journal-full-title] BMJ open
  • [ISO-abbreviation] BMJ Open
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Diabetes education / Psychosocial, behavioral medicine / Stigma
  •  go-up   go-down


59. Desilles JP, Consoli A, Redjem H, Coskun O, Ciccio G, Smajda S, Labreuche J, Preda C, Ruiz Guerrero C, Decroix JP, Rodesch G, Mazighi M, Blanc R, Piotin M, Lapergue B, ETIS (Endovascular Treatment in Ischemic Stroke) Research Investigators: Successful Reperfusion With Mechanical Thrombectomy Is Associated With Reduced Disability and Mortality in Patients With Pretreatment Diffusion-Weighted Imaging-Alberta Stroke Program Early Computed Tomography Score ≤6. Stroke; 2017 Apr;48(4):963-969
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful Reperfusion With Mechanical Thrombectomy Is Associated With Reduced Disability and Mortality in Patients With Pretreatment Diffusion-Weighted Imaging-Alberta Stroke Program Early Computed Tomography Score ≤6.
  • BACKGROUND AND PURPOSE: In acute ischemic stroke patients, diffusion-weighted imaging (DWI)-Alberta Stroke Program Early Computed Tomography Score (ASPECTS) is correlated with infarct volume and is an independent factor of functional outcome.
  • Patients with pretreatment DWI-ASPECTS ≤6 were excluded or under-represented in the recent randomized mechanical thrombectomy trials.
  • Our aim was to assess the impact of reperfusion in pretreatment DWI-ASPECTS ≤6 patients treated with mechanical thrombectomy.
  • METHODS: We analyzed data collected between January 2012 and August 2015 in a bicentric prospective clinical registry of consecutive acute ischemic stroke patients treated with mechanical thrombectomy.
  • Every patient with a documented internal carotid artery or middle cerebral artery occlusion with pretreatment DWI-ASPECTS ≤6 was eligible for this study.
  • RESULTS: Two hundred and eighteen patients with a DWI-ASPECTS ≤6 were included.
  • Among them, 145 (66%) patients had successful reperfusion at the end of mechanical thrombectomy.
  • Reperfused patients had an increased rate of favorable outcome (38.7% versus 17.4%; <i>P</i>=0.002) and a decreased rate of mortality at 3 months (22.5% versus 39.1%; <i>P</i>=0.013) compared with nonreperfused patients.
  • However, in patients with DWI-ASPECTS <5, favorable outcome was low (13.0% versus 9.5%; <i>P</i>=0.68) with a high mortality rate (45.7% versus 57.1%; <i>P</i>=0.38) with or without successful reperfusion.
  • CONCLUSIONS: Successful reperfusion is associated with reduced mortality and disability in patients with a pretreatment DWI-ASPECTS ≤6.
  • Further data from randomized studies are needed, particularly in patients with DWI-ASPECTS <5.
  • [MeSH-major] Brain Ischemia / diagnostic imaging. Brain Ischemia / surgery. Mechanical Thrombolysis / methods. Outcome Assessment (Health Care). Registries. Reperfusion / methods. Severity of Illness Index. Stroke / diagnostic imaging. Stroke / surgery

  • MedlinePlus Health Information. consumer health - Ischemic Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [ErratumIn] Stroke. 2017 Apr;48(4):e120 [28348132.001]
  • [ErratumIn] Stroke. 2017 May;48(5):e138 [28439045.001]
  • (PMID = 28235960.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Keywords] NOTNLM ; ischemic stroke (major topic) / large ischemic lesion (major topic) / outcome (major topic) / reperfusion (major topic) / thrombectomy (major topic)
  • [Investigator] Wang A; Evrard S; Tchikviladzé M; Bourdain F; Gonzalez-Valcarcel J; Di Maria F; Pico F; Rakotoharinandrasana H; Tassan P; Poll R; Corabianu O; de Broucker T; Smadja D; Alamowitch S; Obadia M; Ille O; Manchon E; Garcia PY
  •  go-up   go-down


60. Murthy SB, Awad I, Harnof S, Aldrich F, Harrigan M, Jallo J, Caron JL, Huang J, Camarata P, Lara LR, Dlugash R, McBee N, Eslami V, Hanley DF, Ziai WC, CLEAR III Trial Investigators: Permanent CSF shunting after intraventricular hemorrhage in the CLEAR III trial. Neurology; 2017 Jun 28;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among the 500 patients with IVH, CSF shunting was performed in 90 (18%) patients at a median of 18 (interquartile range [IQR] 13-30) days.
  • Patient demographics and IVH characteristics were similar among patients with and without shunts.
  • Patients who had CSF shunts had similar odds of 180-day mortality, while survivors with shunts had increased odds of poor functional outcome, compared to survivors without shunts.
  • CONCLUSIONS: Among patients with spontaneous IVH requiring emergency CSF diversion, those with early elevated intracranial pressure, high CSF output, and placement of more than one EVD are at increased odds of permanent ventricular shunting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Academy of Neurology.
  • (PMID = 28659429.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Investigator] John S; Lopez G; Varelas P; Ansari S; LeDoux D; Adeoye O; Adams H; Bosel J; Hoffer A; Seder DB; Wartenberg K; Wechsler L; Tayal A; Venkatasubramanian C; Vespa P; Tetsai F; Kerz T; Arikan F; Moheet A; Rosenthal G; Cockroft K; Leonardo J; Bulters D; Torres Díaz BA; Agarwal S; Margalit N; Butcher K; Decker D; Markowski M; Kureshi I; Antezana D; Crabtree HM; Csiba L; Michalski D; Szapary L; Shah QA; Mirsen T; Freeman W; Lazaridis C; Torbey M; Latorre JG; Ardelt A; Poli S; Graham RS; Tucker K; Greer D; Sinclair D; Tuhrim S; Weaver M; Huttner H; Barzo P; Hall C; Froehler M; Silva GS; Cougo Pinto PT; Marti-Fabregas J; Helms A; Cruz-Flores S; Reinert M; Luft A; Shahi K; Gizzi M; Mendelow D; Lovick D; Emanuel B; Newman G; Ugorec I; Holsapple J; Bazso P; Juttler E; James ML; Longo AL; Marcondes de Souza J; Ouriques Martins SC; Kern M; Concha M; Boulton M; Schneck M; Ogilvy C; Aguilar M; Santiago F; Zaaroor M; Jacoby M; Patel H; Newell D
  •  go-up   go-down


61. Rantner B, Kollerits B, Roubin GS, Ringleb PA, Jansen O, Howard G, Hendrikse J, Halliday A, Gregson J, Eckstein HH, Calvet D, Bulbulia R, Bonati LH, Becquemin JP, Algra A, Brown MM, Mas JL, Brott TG, Fraedrich G, Carotid Stenosis Trialists’ Collaboration: Early Endarterectomy Carries a Lower Procedural Risk Than Early Stenting in Patients With Symptomatic Stenosis of the Internal Carotid Artery: Results From 4 Randomized Controlled Trials. Stroke; 2017 Jun;48(6):1580-1587

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early Endarterectomy Carries a Lower Procedural Risk Than Early Stenting in Patients With Symptomatic Stenosis of the Internal Carotid Artery: Results From 4 Randomized Controlled Trials.
  • BACKGROUND AND PURPOSE: Patients undergoing carotid endarterectomy (CEA) for symptomatic stenosis of the internal carotid artery benefit from early intervention.
  • METHODS: We investigated the association between timing of treatment (0-7 days and >7 days after the qualifying neurological event) and the 30-day risk of stroke or death after CAS or CEA in a pooled analysis of individual patient data from 4 randomized trials by the Carotid Stenosis Trialists' Collaboration.
  • RESULTS: Among a total of 4138 patients, a minority received their allocated treatment within 7 days after symptom onset (14% CAS versus 11% CEA).
  • Among patients treated within 1 week of symptoms, those treated by CAS had a higher risk of stroke or death compared with those treated with CEA: 8.3% versus 1.3%, risk ratio, 6.7; 95% confidence interval, 2.1 to 21.9 (adjusted for age at treatment, sex, and type of qualifying event).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28455318.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; carotid artery / carotid artery diseases / endarterectomy, carotid / stent / stroke
  •  go-up   go-down


62. Haldane V, Legido-Quigley H, Chuah FLH, Sigfrid L, Murphy G, Ong SE, Cervero-Liceras F, Watt N, Balabanova D, Hogarth S, Maimaris W, Buse K, McKee M, Piot P, Perel P: Integrating cardiovascular diseases, hypertension, and diabetes with HIV services: a systematic review. AIDS Care; 2017 Jul 05;:1-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Health services for HIV and NCDs require health systems that provide for people's chronic care needs, which present an opportunity to coordinate efforts and create synergies between programs to benefit people living with HIV and/or AIDS and NCDs.
  • Models also looked at integration from micro (patient focused integration) to macro (system level integrations).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28679283.001).
  • [ISSN] 1360-0451
  • [Journal-full-title] AIDS care
  • [ISO-abbreviation] AIDS Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; HIV / Integration / cardiovascular disease / chronic disease / diabetes / hypertension
  •  go-up   go-down


63. Tzoran I, Papadakis M, Brenner B, Fidalgo Á, Rivas A, Wells PS, Gavín O, Adarraga MD, Moustafa F, Monreal M, Registro Informatizado de Enfermedad TromboEmbólica Investigators: Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation. Am J Med; 2017 Apr;130(4):482.e1-482.e9
MedlinePlus Health Information. consumer health - Blood Thinners.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.
  • However, the influence of these polymorphisms on patient outcome during anticoagulant therapy has not been consistently explored.
  • METHODS: We used the Registro Informatizado de Enfermedad TromboEmbólica database to compare rates of venous thromboembolism recurrence and bleeding events occurring during the anticoagulation course in factor V Leiden carriers, prothrombin mutation carriers, and noncarriers.
  • RESULTS: Between March 2001 and December 2015, 10,139 patients underwent thrombophilia testing.
  • During the anticoagulation course, 160 patients developed recurrent deep vein thrombosis and 94 patients developed pulmonary embolism (16 died); 154 patients had major bleeding (10 died), and 291 patients had nonmajor bleeding.

  • Genetic Alliance. consumer health - Prothrombin.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017. Published by Elsevier Inc.
  • (PMID = 27986523.001).
  • [ISSN] 1555-7162
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / factor V Leiden; 9001-24-5 / Factor V; 9001-26-7 / Prothrombin; Thrombophilia due to Activated Protein C Resistance
  • [Keywords] NOTNLM ; Anticoagulant therapy / Bleeding / Thrombophilia / Venous thromboembolism
  • [Investigator] Decousus H; Prandoni P; Brenner B; Barba R; Di Micco P; Bertoletti L; Tzoran I; Reis A; Bosevski M; Bounameaux H; Malý R; Wells P; Papadakis M; Adarraga MD; Aibar MA; Alfonso M; Arcelus JI; Barba R; Barrón M; Barrón-Andrés B; Bascuñana J; Blanco-Molina A; Bueso T; Cañada G; Cañas I; Chic N; Del Pozo R; Del Toro J; Díaz-Pedroche MC; Díaz-Peromingo JA; Falgá C; Fernández-Capitán C; Fidalgo MA; Font C; Font L; Gallego P; García A; García MA; García-Bragado F; García-Brotons P; Gavín O; Gómez C; Gómez V; González J; González-Marcano D; Grau E; Grimón A; Guijarro R; Gutiérrez J; Hernández-Comes G; Hernández-Blasco L; Hermosa-Los Arcos MJ; Jara-Palomares L; Jaras MJ; Jiménez D; Joya MD; Llamas P; Lecumberri R; Lobo JL; López P; López-Jiménez L; López-Reyes R; López-Sáez JB; Lorente MA; Lorenzo A; Maestre A; Marchena PJ; Martín-Martos F; Monreal M; Nieto JA; Nieto S; Núñez A; Núñez MJ; Odriozola M; Otero R; Pedrajas JM; Pérez G; Pérez-Ductor C; Peris ML; Porras JA; Reig O; Riera-Mestre A; Riesco D; Rivas A; Rodríguez C; Rodríguez-Dávila MA; Rosa V; Ruiz-Giménez N; Sahuquillo JC; Sala-Sainz MC; Sampériz A; Sánchez-Martínez R; Sánchez Simón-Talero R; Sanz O; Soler S; Suriñach JM; Torres MI; Trujillo-Santos J; Uresandi F; Valero B; Valle R; Vela J; Vicente MP; Villalobos A; Vanassche T; Verhamme P; Wells P; Hirmerova J; Malý R; Tomko T; Del Pozo G; Salgado E; Sánchez GT; Bertoletti L; Bura-Riviere A; Mahé I; Merah A; Moustafa F; Papadakis M; Braester A; Brenner B; Tzoran I; Antonucci G; Barillari G; Bilora F; Bortoluzzi C; Cattabiani C; Ciammaichella M; Di Biase J; Di Micco P; Duce R; Ferrazzi P; Giorgi-Pierfranceschi M; Grandone E; Imbalzano E; Lodigiani C; Maida R; Mastroiacovo D; Pace F; Pesavento R; Pinelli M; Poggio R; Prandoni P; Rota L; Tiraferri E; Tonello D; Tufano A; Visonà A; Zalunardo B; Gibietis V; Skride A; Vitola B; Monteiro P; Ribeiro JL; Sousa MS; Bosevski M; Zdraveska M; Bounameaux H; Calanca L; Erdmann A; Mazzolai L
  •  go-up   go-down


64. Bruns BR, Morris DS, Zielinski M, Mowery NT, Miller PR, Arnold K, Phelan HA, Murry J, Turay D, Fam J, Oh JS, Gunter OL, Enniss T, Love JD, Skarupa D, Benns M, Fathalizadeh A, Leung PS, Carrick MM, Jewett B, Sakran J, O'Meara L, Herrera AV, Chen H, Scalea TM, Diaz JJ: Stapled versus hand-sewn: A prospective emergency surgery study. An American Association for the Surgery of Trauma multi-institutional study. J Trauma Acute Care Surg; 2017 Mar;82(3):435-443

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Data from the trauma patient population suggests handsewn (HS) anastomoses are superior to stapled (ST).
  • A recent retrospective study in emergency general surgery (EGS) patients had similar findings.
  • The aim of the current study was to evaluate HS and ST anastomoses in EGS patients undergoing urgent/emergent operations.
  • Patients undergoing urgent/emergent bowel resection for EGS pathology were prospectively enrolled from July 22, 2013 to December 31, 2015.
  • Patients were grouped by HS/ST anastomoses, and variables were collected.
  • RESULTS: Fifteen institutions enrolled a total of 595 patients with 649 anastomoses (253 HS and 396 ST).
  • Hospital and intensive care unit days, as well as mortality, were greater in the HS group.
  • On multivariate regression, the presence of contamination at initial resection (odds ratio, 1.965; 95% confidence interval, 1.183-3.264) and the patient being managed with open abdomen (odds ratio, 2.529; 95% confidence interval, 1.492-4.286) were independently associated with anastomotic failure, while the type of anastomosis was not.
  • CONCLUSION: EGS patients requiring bowel resection and anastomosis are at high risk for anastomotic failure.
  • The current study illustrates an apparent bias among acute care surgeons to perform HS techniques in higher-risk patients.
  • Despite the individualized application of technique for differing patient populations, the risk of anastomotic failure was equivalent when comparing HS and ST anastomoses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28030492.001).
  • [ISSN] 2163-0763
  • [Journal-full-title] The journal of trauma and acute care surgery
  • [ISO-abbreviation] J Trauma Acute Care Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


65. Katz BS, Adeoye O, Sucharew H, Broderick JP, McMullan J, Khatri P, Widener M, Alwell KS, Moomaw CJ, Kissela BM, Flaherty ML, Woo D, Ferioli S, Mackey J, Martini S, De Los Rios la Rosa F, Kleindorfer DO: Estimated Impact of Emergency Medical Service Triage of Stroke Patients on Comprehensive Stroke Centers: An Urban Population-Based Study. Stroke; 2017 Jul 12;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimated Impact of Emergency Medical Service Triage of Stroke Patients on Comprehensive Stroke Centers: An Urban Population-Based Study.
  • BACKGROUND AND PURPOSE: The American Stroke Association recommends that Emergency Medical Service bypass acute stroke-ready hospital (ASRH)/primary stroke center (PSC) for comprehensive stroke centers (CSCs) when transporting appropriate stroke patients, if the additional travel time is ≤15 minutes.
  • METHODS: Stroke patients ≥20 years old who were transported from home to an ASRH/PSC or CSC via Emergency Medical Service in 2010 were identified in the Greater Cincinnati area population of 1.3 million.
  • Addresses of all patients' residences and hospitals were geocoded, and estimated travel times were calculated.
  • We estimated the mean differences between the travel time for patients taken to an ASRH/PSC and the theoretical time had they been transported directly to the region's CSC.
  • RESULTS: Of 929 patients with geocoded addresses, 806 were transported via Emergency Medical Service directly to an ASRH/PSC.
  • Triage of all stroke patients to the CSC would have added 727 patients to the CSC's census in 2010.
  • Limiting triage to the CSC to patients with National Institutes of Health Stroke Scale score of ≥10 within 6 hours of onset would have added 116 patients (2.2 per week) to the CSC's annual census.
  • The impact on stroke systems of care and patient outcomes remains to be determined and requires prospective evaluation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28701576.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Emergency Medical Services / hospitals / stroke / triage
  •  go-up   go-down


66. Aytaman A, Ojike N, Zizi S, Pandi-Perumal SR, Lukolic I, Bhanvadia A, Nwamaghinna F, Kamran H, Akivis A, Bankole O, Salifu MO, McFarlane SI: Hepatitis B Vaccination Rate in Patients with Diabetes: Assessment of Racial and Socioeconomic Disparity. Int J Clin Endocrinol Metab; 2016;2(1):024-27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis B Vaccination Rate in Patients with Diabetes: Assessment of Racial and Socioeconomic Disparity.
  • INTRODUCTION: Less hygienic use of blood glucose monitoring equipment such as blood glucose meters, lancets, finger stick devices or other diabetes-care equipment such as syringes or insulin pens by self-administration often exposes the diabetic patient to Hepatitis B infection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Investig Med. 2013 Oct;61(7):1121-8 [24006083.001]
  • [Cites] Epidemiol Infect. 2011 Mar;139(3):327-35 [20478083.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2000 Jul 14;49(27):616-9 [10914928.001]
  • [Cites] J Community Health. 2012 Oct;37(5):1071-80 [22302652.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2011 Dec 23;60(50):1709-11 [22189894.001]
  • [Cites] Arch Public Health. 2014 Feb 27;72(1):6 [24576356.001]
  • [Cites] Am J Prev Med. 2014 Dec;47(6):722-33 [25300733.001]
  • [Cites] J Clin Gastroenterol. 2004 Nov-Dec;38(10 Suppl 3):S132-3 [15602159.001]
  • [Cites] JAMA. 2012 Apr 4;307(13):1353-4 [22474190.001]
  • [Cites] Hepatology. 2013 Sep;58(3):856-62 [23359276.001]
  • [Cites] Diabetes Care. 2013 Jan;36(1):63-9 [22933435.001]
  • [Cites] Euro Surveill. 2008 Jul 03;13(27):null [18761934.001]
  • [Cites] Vaccine. 2012 Aug 31;30(40):5844-8 [22828587.001]
  • [Cites] Hepatology. 2009 May;49(5 Suppl):S28-34 [19399791.001]
  • [Cites] J Viral Hepat. 2012 Sep;19(9):674-6 [22863272.001]
  • [Cites] J Infect Dis. 2010 Jul 15;202(2):192-201 [20533878.001]
  • [Cites] Hepatology. 2007 Oct;46(4):1034-40 [17654490.001]
  • [Cites] J Diabetes Sci Technol. 2010 Sep 01;4(5):1027-31 [20920422.001]
  • [Cites] Vital Health Stat 2. 2014 Apr;(165):1-53 [24775908.001]
  • (PMID = 28638894.001).
  • [Journal-full-title] International journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] Int J Clin Endocrinol Metab
  • [Language] eng
  • [Grant] United States / NIMHD NIH HHS / MD / P20 MD006875
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


67. Gilbody S, Lewis H, Adamson J, Atherton K, Bailey D, Birtwistle J, Bosanquet K, Clare E, Delgadillo J, Ekers D, Foster D, Gabe R, Gascoyne S, Haley L, Hamilton J, Hargate R, Hewitt C, Holmes J, Keding A, Lilley-Kelly A, Meer S, Mitchell N, Overend K, Pasterfield M, Pervin J, Richards DA, Spilsbury K, Traviss-Turner G, Trépel D, Woodhouse R, Ziegler F, McMillan D: Effect of Collaborative Care vs Usual Care on Depressive Symptoms in Older Adults With Subthreshold Depression: The CASPER Randomized Clinical Trial. JAMA; 2017 02 21;317(7):728-737
MedlinePlus Health Information. consumer health - Depression.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Collaborative Care vs Usual Care on Depressive Symptoms in Older Adults With Subthreshold Depression: The CASPER Randomized Clinical Trial.
  • Objective: To evaluate whether a collaborative care intervention can reduce depressive symptoms and prevent more severe depression in older people.
  • Design, Setting, and Participants: Randomized clinical trial conducted from May 24, 2011, to November 14, 2014, in 32 primary care centers in the United Kingdom among 705 participants aged 65 years or older with Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) subthreshold depression; participants were followed up for 12 months.
  • Interventions: Collaborative care (n=344) was coordinated by a case manager who assessed functional impairments relating to mood symptoms.
  • The control group received usual primary care (n=361).
  • Main Outcomes and Measures: The primary outcome was self-reported depression severity at 4-month follow-up on the 9-item Patient Health Questionnaire (PHQ-9; score range, 0-27).
  • Four-month retention was 83%, with higher loss to follow-up in collaborative care (82/344 [24%]) vs usual care (37/361 [10%]).
  • Collaborative care resulted in lower PHQ-9 scores vs usual care at 4-month follow-up (mean score with collaborative care, 5.36 vs with usual care, 6.67; mean difference, -1.31; 95% CI, -1.95 to -0.67; P < .001).
  • Treatment differences remained at 12 months (mean PHQ-9 score with collaborative care, 5.93 vs with usual care, 7.25; mean difference, -1.33; 95% CI, -2.10 to -0.55).
  • Conclusions and Relevance: Among older adults with subthreshold depression, collaborative care compared with usual care resulted in a statistically significant difference in depressive symptoms at 4-month follow-up, of uncertain clinical importance.
  • [MeSH-minor] Aged. Antidepressive Agents / therapeutic use. Comorbidity. Female. Follow-Up Studies. Humans. Male. Patient Care Team. Patient Dropouts / statistics & numerical data. Primary Health Care. Psychiatry. Quality of Life. Sample Size. Self Report. Time Factors. United Kingdom

  • Genetic Alliance. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2017 Feb 21;317(7):702-704 [28241337.001]
  • (PMID = 28241357.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN02202951
  • [Publication-type] Journal Article; Multicenter Study; Pragmatic Clinical Trial; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents
  •  go-up   go-down


68. Krupchanka D, Khalifeh H, Abdulmalik J, Ardila-Gómez S, Armiya'u AY, Banjac V, Baranov A, Bezborodovs N, Brecic P, Čavajda Z, de Girolamo G, Denisenko M, Dickens HA, Dujmovic J, Ergovic Novotny D, Fedotov I, Fernández MA, Frankova I, Gasparovic M, Giurgi-Oncu C, Grahovac T, James BO, Jomli R, Kekin I, Knez R, Lanfredi M, Lassman F, Mehta N, Nacef F, Nawka A, Nemirovsky M, Ola BA, Oshodi YO, Ouali U, Peharda T, Razic Pavicic A, Rojnic Kuzman M, Roventa C, Shamenov R, Smirnova D, Smoljanic D, Spikina A, Thornicroft A, Tomicevic M, Vidovic D, Williams P, Yakovleva Y, Zhabenko O, Zhilyaeva T, Zivkovic M, Thornicroft G, Sartorius N: Satisfaction with psychiatric in-patient care as rated by patients at discharge from hospitals in 11 countries. Soc Psychiatry Psychiatr Epidemiol; 2017 Mar 11;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Satisfaction with psychiatric in-patient care as rated by patients at discharge from hospitals in 11 countries.
  • PURPOSE: There is disregard in the scientific literature for the evaluation of psychiatric in-patient care as rated directly by patients.
  • In this context, we aimed to explore satisfaction of people treated in mental health in-patient facilities.
  • The research team at each study site approached a consecutive target sample of 30 discharged patients to measure their satisfaction using the five-item study-specific questionnaire.
  • After taking clustering into account, the only independent correlates of low satisfaction were schizophrenia diagnosis and low psychiatrist to patient ratio.
  • CONCLUSION: Further studies on patients' satisfaction should additionally pay attention to treatment expectations formed by the previous experience of treatment, service-related knowledge, stigma and patients' disempowerment, and power imbalance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28285452.001).
  • [ISSN] 1433-9285
  • [Journal-full-title] Social psychiatry and psychiatric epidemiology
  • [ISO-abbreviation] Soc Psychiatry Psychiatr Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Inpatient care / Patients satisfaction / Psychiatry / Service evaluation
  •  go-up   go-down


69. Mataix-Cols D, Fernández de la Cruz L, Monzani B, Rosenfield D, Andersson E, Pérez-Vigil A, Frumento P, de Kleine RA, Difede J, Dunlop BW, Farrell LJ, Geller D, Gerardi M, Guastella AJ, Hofmann SG, Hendriks GJ, Kushner MG, Lee FS, Lenze EJ, Levinson CA, McConnell H, Otto MW, Plag J, Pollack MH, Ressler KJ, Rodebaugh TL, Rothbaum BO, Scheeringa MS, Siewert-Siegmund A, Smits JAJ, Storch EA, Ströhle A, Tart CD, Tolin DF, van Minnen A, Waters AM, Weems CF, Wilhelm S, Wyka K, Davis M, Rück C, and the DCS Anxiety Consortium, Altemus M, Anderson P, Cukor J, Finck C, Geffken GR, Golfels F, Goodman WK, Gutner C, Heyman I, Jovanovic T, Lewin AB, McNamara JP, Murphy TK, Norrholm S, Thuras P: D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data. JAMA Psychiatry; 2017 May 01;74(5):501-510
Hazardous Substances Data Bank. CYCLOSERINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • None of the prespecified patient-level or study-level moderators was associated with outcomes.
  • Further research is needed to identify patient and/or therapy characteristics associated with DCS response.
  • [MeSH-major] Antidepressive Agents / therapeutic use. Anxiety Disorders / therapy. Cycloserine / pharmacology. Excitatory Amino Acid Agonists / pharmacology. Implosive Therapy / methods. N-Methylaspartate / agonists. Obsessive-Compulsive Disorder / therapy. Outcome Assessment (Health Care) / statistics & numerical data. Stress Disorders, Post-Traumatic / therapy


70. Yoshida EM, Kwo P, Agarwal K, Duvoux C, Durand F, Peck-Radosavljevic M, Lilly L, Willems B, Vargas H, Kumar P, Brown RS Jr, Horsmans Y, De-Oertel S, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, Terrault N, Rizzetto M, Müllhaupt B: Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. Ann Hepatol; 2017 May - Jun;16(3):375-381

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.
  • INTRODUCTION: Recurrence of HCV infection in patients with chronic hepatitis C virus (HCV) at the time of liver transplantation is nearly universal and reduces the likelihood of graft and patient survival.
  • MATERIALS AND METHODS: We evaluated outcomes of 17 patients (16 with HCV genotype 1 and 1 with genotype 4) who received up to 12 or 24 weeks of ledipasvir/sofosbuvir plus ribavirin prior to or up to the time of liver transplant in the SOLAR-1 and SOLAR-2 trials.
  • In all patients, HCV RNA was < 15 IU/mL prior to transplant.
  • At screening, 6 patients were Child-Pugh-Turcotte (CPT) class B and 11 were CPT class C.
  • Seven patients underwent transplant prior to completing assigned treatment, with 4 treated for < 12 weeks.
  • The primary endpoint was posttransplant virologic response 12 weeks after transplant (pTVR12) in patients with HCV RNA < 15 IU/mL at their last measurement prior to transplant.
  • The single patient who did not achieve pTVR12 discontinued study drug on day 21 and underwent liver transplant the following day.
  • The patient had HCV RNA < 15 IU/mL at post-transplant week 2 but died 15 days post-transplant because of multi-organ failure and septic shock.
  • CONCLUSION: Among a small population of HCV patients with decompensated cirrhosis, virologic response to ledipasvir / sofosbuvir plus ribavirin prior to liver transplantation was maintained after transplantation, even if treatment was stopped early.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28425407.001).
  • [ISSN] 1665-2681
  • [Journal-full-title] Annals of hepatology
  • [ISO-abbreviation] Ann Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


71. Dreber H, Reynisdottir S, Angelin B, Tynelius P, Rasmussen F, Hemmingsson E: Mental distress in treatment seeking young adults (18-25 years) with severe obesity compared with population controls of different body mass index levels: cohort study. Clin Obes; 2017 Feb;7(1):1-10
MedlinePlus Health Information. consumer health - Obesity.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Young adults (18-25) with severe obesity constitute a challenging patient group, and there is limited evidence about their mental health status compared to population controls.

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 World Obesity Federation.
  • (PMID = 28058812.001).
  • [ISSN] 1758-8111
  • [Journal-full-title] Clinical obesity
  • [ISO-abbreviation] Clin Obes
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Clinical care (major topic) / mental distress (major topic) / severe obesity (major topic) / young adult (major topic)
  •  go-up   go-down


72. Guise A, Seguin M, Mburu G, McLean S, Grenfell P, Islam Z, Filippovych S, Assan H, Low A, Vickerman P, Rhodes T: Integrated opioid substitution therapy and HIV care: a qualitative systematic review and synthesis of client and provider experiences. AIDS Care; 2017 Sep;29(9):1119-1128

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated opioid substitution therapy and HIV care: a qualitative systematic review and synthesis of client and provider experiences.
  • People who use drugs in many contexts have limited access to opioid substitution therapy and HIV care.
  • We reviewed and synthesized literature exploring client and provider experiences of integrated opioid substitution therapy and HIV care to identify acceptable approaches to care delivery.
  • We identify five descriptive themes: the convenience and comprehensive nature of co-located care, contrasting care philosophies and their role in shaping integration, the limits to disclosure and communication between clients and providers, opioid substitution therapy enabling HIV care access and engagement, and health system challenges to delivering integrated services.
  • The discussion explores how integrated opioid substitution therapy and HIV care needs to adapt to specific social conditions, rather than following universal approaches.
  • Acceptable integrated opioid substitution therapy and HIV care for people who use drugs and providers is most likely through co-located care and relies upon attention to stigma, supportive relationships and client centred cultures of delivery.
  • Further research is needed to understand experiences of integrated care, particularly delivery in low and middle income settings and models of care focused on community and non-clinic based delivery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Public Health Rep. 1998 Jun;113 Suppl 1:42-57 [9722809.001]
  • [Cites] J Int AIDS Soc. 2015 Jul 21;18:19936 [26202669.001]
  • [Cites] Int J Drug Policy. 2013 Nov;24(6):e14-7 [24007689.001]
  • [Cites] Int J Drug Policy. 2007 Aug;18(4):306-12 [17689379.001]
  • [Cites] Addiction. 2010 May;105(5):907-13 [20331553.001]
  • [Cites] AIDS Care. 2014 Feb;26(2):214-25 [23879637.001]
  • [Cites] AIDS. 2016 Jun 19;30(10 ):1639-53 [27058350.001]
  • [Cites] Int J Drug Policy. 2015 Oct;26(10):999-1006 [26275578.001]
  • [Cites] Int J Drug Policy. 2014 Jan;25(1):53-60 [24113623.001]
  • [Cites] Int J Drug Policy. 2014 Mar;25(2):204-11 [24332457.001]
  • [Cites] J Int AIDS Soc. 2010 Jul 19;13:26 [20642843.001]
  • [Cites] BMJ. 2012 Oct 03;345:e5945 [23038795.001]
  • [Cites] Clin Infect Dis. 2016 Oct 15;63(8):1094-1104 [27343545.001]
  • [Cites] Lancet. 2010 Jul 24;376(9737):268-84 [20650523.001]
  • [Cites] Int J Drug Policy. 2015 Jan;26(1):30-6 [24951024.001]
  • [Cites] J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 2:S96-9 [21857306.001]
  • [Cites] Int J Drug Policy. 2014 Sep;25(5):865-70 [24559604.001]
  • [Cites] Subst Use Misuse. 2011;46(2-3):171-80 [21303237.001]
  • [Cites] Implement Sci. 2016 Jan 04;11:1 [26727969.001]
  • [Cites] Clin Infect Dis. 2004 Jun 1;38 Suppl 5:S402-8 [15156430.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003318 [16625576.001]
  • [Cites] Addiction. 2012 Oct;107(10):1827-36 [22404277.001]
  • [Cites] AIDS Care. 2004 May;16(4):426-33 [15203411.001]
  • [Cites] J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S46-53 [21317594.001]
  • [Cites] PLoS Med. 2015 Oct 27;12(10):e1001895 [26506244.001]
  • [Cites] AIDS Behav. 2014 Apr;18(4):740-6 [23918244.001]
  • [Cites] Lancet. 2010 Jul 31;376(9738):355-66 [20650513.001]
  • [Cites] Int J Drug Policy. 2014 Nov;25(6):1066-70 [24939555.001]
  • [Cites] Lancet Infect Dis. 2011 Nov;11(11):855-67 [22035614.001]
  • [Cites] Clin Infect Dis. 2004 Jun 1;38 Suppl 5:S409-13 [15156431.001]
  • [Cites] Int J Drug Policy. 2010 Jan;21(1):4-9 [19747811.001]
  • [Cites] Int J Drug Policy. 2014 Jan;25(1):22-5 [24210295.001]
  • [Cites] Drugs (Abingdon Engl). 2015;22(3):255-262 [27087758.001]
  • [Cites] BMC Med Res Methodol. 2008 Jul 10;8:45 [18616818.001]
  • [Cites] J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S68-75 [21317597.001]
  • [Cites] Int J Drug Policy. 2012 Mar;23(2):94-102 [21996165.001]
  • [Cites] AIDS Care. 2013;25(1):1-10 [22568569.001]
  • [Cites] Drug Alcohol Depend. 2013 May 1;129(3):180-209 [23306095.001]
  • [Cites] AIDS Patient Care STDS. 2014 Feb;28(2):71-81 [24428768.001]
  • [Cites] AIDS Care. 2013;25(11):1370-4 [23406479.001]
  • [Cites] AIDS. 2015 Jan 2;29(1):1-4 [25387315.001]
  • [Cites] Lancet. 2010 Mar 20;375(9719):1014-28 [20189638.001]
  • [Cites] Qual Health Res. 2009 Sep;19(9):1321-34 [19690211.001]
  • [Cites] Int J Drug Policy. 2013 Nov;24(6):e43-50 [23199896.001]
  • [Cites] Health Policy Plan. 2013 Oct;28(7):681-91 [23197431.001]
  • [Cites] AIDS Care. 2015;27(12):1455-67 [26272473.001]
  • [Cites] Int J Drug Policy. 2011 May;22(3):194-5 [21550791.001]
  • [Cites] Int J Drug Policy. 2015 Oct;26(10):992-8 [25697089.001]
  • [Cites] Int J Drug Policy. 2015 Feb;26 Suppl 1:S16-21 [25277726.001]
  • [Cites] J Acquir Immune Defic Syndr. 2015 Jun 1;69 Suppl 2:S98-9 [25978490.001]
  • [Cites] Implement Sci. 2016 Jul 18;11:98 [27430879.001]
  • [Cites] AIDS Care. 2010 Nov;22(11):1305-13 [20640954.001]
  • [Cites] Int J Prison Health. 2013;9(2):82-91 [25758440.001]
  • [Cites] Clin Infect Dis. 2006 Jun 1;42(11):1628-35 [16652321.001]
  • [Cites] Cult Med Psychiatry. 2000 Jun;24(2):165-95 [10885786.001]
  • [Cites] Int J Drug Policy. 2013 Nov;24(6):e51-6 [23743178.001]
  • [Cites] J Addict Med. 2010 Dec;4(4):204-10 [21170143.001]
  • (PMID = 28281354.001).
  • [ISSN] 1360-0451
  • [Journal-full-title] AIDS care
  • [ISO-abbreviation] AIDS Care
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / Z99 DA999999
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; ART / HIV / OST / People who inject drugs / integration
  •  go-up   go-down


73. Dugas M, Trottier MÈ, Chipenda Dansokho S, Vaisson G, Provencher T, Colquhoun H, Dogba MJ, Dupéré S, Fagerlin A, Giguere AM, Haslett L, Hoffman AS, Ivers NM, Légaré F, Légaré J, Levin CA, Menear M, Renaud JS, Stacey D, Volk RJ, Witteman HO: Involving members of vulnerable populations in the development of patient decision aids: a mixed methods sequential explanatory study. BMC Med Inform Decis Mak; 2017 Jan 19;17(1):12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involving members of vulnerable populations in the development of patient decision aids: a mixed methods sequential explanatory study.
  • BACKGROUND: Patient decision aids aim to present evidence relevant to a health decision in understandable ways to support patients through the process of making evidence-informed, values-congruent health decisions.
  • METHODS: To describe and compare the development practices of research teams that did and did not specifically involve members of vulnerable populations in the development of patient decision aids, we conducted a secondary analysis of data from a systematic review about the development processes of patient decision aids.
  • CONCLUSIONS: There are a small number of key differences in the development processes for patient decision aids in which members of vulnerable populations were or were not specifically involved.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28103862.001).
  • [ISSN] 1472-6947
  • [Journal-full-title] BMC medical informatics and decision making
  • [ISO-abbreviation] BMC Med Inform Decis Mak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Decision aids / Marginalized populations / Patient engagement / Shared decision making / Vulnerable populations
  •  go-up   go-down


74. Nandan AR, Bohnen JD, Sangji NF, Peponis T, Han K, Yeh DD, Lee J, Saillant N, De Moya M, Velmahos GC, Chang DC, Kaafarani HMA: The Emergency Surgery Score (ESS) accurately predicts the occurrence of postoperative complications in emergency surgery patients. J Trauma Acute Care Surg; 2017 Jul;83(1):84-89

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Emergency Surgery Score (ESS) accurately predicts the occurrence of postoperative complications in emergency surgery patients.
  • BACKGROUND: The Emergency Surgery Score (ESS) was recently validated as a scoring system to predict mortality in emergency surgery (ES) patients.
  • Each patient-related ESS was calculated, and the correlation between ESS and the probability of occurrence of 30-day postoperative complications was assessed by calculating the c-statistic.
  • CONCLUSIONS: ESS reliably predicts postoperative complications in ES patients.
  • Such a score could prove useful for (1) perioperative patient and family counseling and (2) benchmarking the quality of ES care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28422908.001).
  • [ISSN] 2163-0763
  • [Journal-full-title] The journal of trauma and acute care surgery
  • [ISO-abbreviation] J Trauma Acute Care Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Wang F, Hong D, Wang Y, Feng Y, Wang L, Yang L, ISN AKF 0 by 25 China Consortium: Renal replacement therapy in acute kidney injury from a Chinese cross-sectional study: patient, clinical, socioeconomic and health service predictors of treatment. BMC Nephrol; 2017 May 04;18(1):152

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal replacement therapy in acute kidney injury from a Chinese cross-sectional study: patient, clinical, socioeconomic and health service predictors of treatment.
  • BACKGROUND: Renal replacement therapy (RRT) is important to support critically ill patients with acute kidney injury (AKI).
  • RESULTS: of the 896 patients that had indications for RRT, only 59.3% received RRT.
  • Patients who were older, male, from lower income areas, in local hospitals, or with severe comorbidities, were less likely to receive RRT.
  • Of the subgroup of patients receiving RRT who did not have an indication for modality of CRRT, 36.8% in fact received CRRT, and their medical cost and mortality rate was higher (7944[4248, 16,055] vs. 5100[2948, 9396] US dollars, p < 0.001 and 10.6% vs. 4.4%, p = 0.047, respectively) compared with those treated with other RRT modalities).
  • CONCLUSIONS: Extrapolated to the whole of China our results indicate that an estimated 139,000 patients with an indication of RRT are under treated without RRT over a year.
  • Non-clinical factors influence RRT prescription for severe AKI patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2015 Oct 10;386(10002):1465-71 [26466051.001]
  • [Cites] J Nephrol. 1999 May-Jun;12 (3):173-8 [10440514.001]
  • [Cites] Am J Med Sci. 2015 Mar;349(3):199-205 [25494217.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Jan;1(1):43-51 [17699189.001]
  • [Cites] Biomed Res Int. 2013;2013:108951 [23971020.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2011 Jun 28;91(24):1663-7 [21914312.001]
  • [Cites] J Am Soc Nephrol. 2010 Feb;21(2):345-52 [20019168.001]
  • [Cites] J Am Soc Nephrol. 2005 Nov;16(11):3365-70 [16177006.001]
  • [Cites] J Am Soc Nephrol. 2007 Apr;18(4):1292-8 [17314324.001]
  • [Cites] Semin Dial. 2009 Mar-Apr;22(2):160-4 [19426421.001]
  • [Cites] Kidney Int. 2013 Mar;83(3):372-6 [23302721.001]
  • [Cites] Curr Opin Crit Care. 2011 Dec;17(6):556-61 [22027405.001]
  • [Cites] Clin J Am Soc Nephrol. 2013 Sep;8(9):1482-93 [23744003.001]
  • [Cites] N Engl J Med. 2006 Mar 9;354(10):997-9 [16525136.001]
  • [Cites] Kidney Int. 2006 Sep;70(6):1107-14 [16883316.001]
  • [Cites] Kidney Int. 2002 Sep;62(3):986-96 [12164882.001]
  • [Cites] Kidney Int. 2007 Jul;72(2):208-12 [17507907.001]
  • [Cites] Cochrane Database Syst Rev. 2014 Jun 15;(6):CD008566 [24929959.001]
  • [Cites] Blood Purif. 2010;30(2):120-6 [20714143.001]
  • [Cites] Kidney Int. 2006 Sep;70(6):982-4 [16957745.001]
  • [Cites] Kidney Int. 2013 Sep;84(3):457-67 [23636171.001]
  • [Cites] Curr Opin Crit Care. 2006 Dec;12(6):538-43 [17077683.001]
  • [Cites] Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003773 [17636735.001]
  • [Cites] Semin Dial. 2009 Mar-Apr;22(2):165-8 [19426422.001]
  • [Cites] BMC Nephrol. 2010 Nov 25;11:32 [21106112.001]
  • [Cites] Adv Chronic Kidney Dis. 2013 Jan;20(1):76-84 [23265599.001]
  • [Cites] Nat Clin Pract Nephrol. 2008 Mar;4(3):138-53 [18212780.001]
  • (PMID = 28472927.001).
  • [ISSN] 1471-2369
  • [Journal-full-title] BMC nephrology
  • [ISO-abbreviation] BMC Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Acute kidney injury / China / Developing countries / Hemodialysis / Peritoneal dialysis / Renal replacement therapy
  • [Investigator] Yang L; Xing G; Wang L; Wu Y; Li S; Xu G; He Q; Chen J; Chen M; Liu X; Zhu Z; Yang L; Lian X; Ding F; Li Y; Wang H; Wang J; Wang R; Mei C; Xu J; Li R; Cao J; Zhang L; Wang Y; Xu J; Bao B; Liu B; Chen H; Li S; Zha Y; Luo Q; Chen D; Shen Y; Liao Y; Zhang Z; Wang X; Zhang K; Liu L; Mao P; Guo C; Li J; Wang Z; Bai S; Shi S
  •  go-up   go-down


76. Califf RM, Robb MA, Bindman AB, Briggs JP, Collins FS, Conway PH, Coster TS, Cunningham FE, De Lew N, DeSalvo KB, Dymek C, Dzau VJ, Fleurence RL, Frank RG, Gaziano JM, Kaufmann P, Lauer M, Marks PW, McGinnis JM, Richards C, Selby JV, Shulkin DJ, Shuren J, Slavitt AM, Smith SR, Washington BV, White PJ, Woodcock J, Woodson J, Sherman RE: Transforming Evidence Generation to Support Health and Health Care Decisions. N Engl J Med; 2016 Dec 15;375(24):2395-2400
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming Evidence Generation to Support Health and Health Care Decisions.
  • [MeSH-major] Delivery of Health Care / organization & administration. Evidence-Based Medicine. Health Policy. Translational Medical Research

  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27974039.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Jolles S, Sánchez-Ramón S, Quinti I, Soler-Palacín P, Agostini C, Florkin B, Couderc LJ, Brodszki N, Jones A, Longhurst H, Warnatz K, Haerynck F, Matucci A, de Vries E: SCREENING PROTOCOLS TO MONITOR RESPIRATORY STATUS IN PRIMARY IMMUNODEFICIENCY DISEASE: FINDINGS FROM A EUROPEAN SURVEY AND SUBCLINICAL INFECTION WORKING GROUP. Clin Exp Immunol; 2017 Jul 14;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many patients with primary immunodeficiency (PID) who have antibody deficiency develop progressive lung disease due to underlying subclinical infection and inflammation.
  • To understand how these patients are monitored we conducted a retrospective survey based on patient records of 13 PID centres across Europe, regarding the care of 1,061 adult and 178 paediatric patients with PID on IgG replacement.
  • The frequency of clinic visits varied both within and between centres: every 1 to 12 months for adult patients and every 3 to 6 months for paediatric patients.
  • Patients diagnosed with lung diseases were more likely to receive pharmaceutical therapies and received a wider range of therapies than patients without lung disease.
  • The percentage of patients seen regularly by a chest physician, or who had microbiology tests performed following chest and sinus exacerbations, also varied widely between centres.
  • Our survey revealed a great deal of variation across Europe in how frequently patients with PID visit the clinic and how frequently some monitoring tests are carried out.
  • These results highlight the urgent need for consensus guidelines on how to monitor lung complications in PID patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 British Society for Immunology.
  • (PMID = 28708268.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Primary immunodeficiency disease / antibody deficiency / lung disease / monitoring / subclinical infection
  •  go-up   go-down


78. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L: Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. J Clin Oncol; 2017 Jun 20;35(18):2082-2094
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Methods The International Pediatric Fever and Neutropenia Guideline Panel is a multidisciplinary and multinational group of experts in pediatric oncology and infectious diseases that includes a patient advocate.
  • Key differences from our 2012 FN CPG included the listing of a fourth-generation cephalosporin for empirical therapy in high-risk FN, refinement of risk stratification to define patients with high-risk invasive fungal disease (IFD), changes in recommended biomarkers and radiologic investigations for the evaluation of IFD in prolonged FN, and a weak recommendation to withhold empirical antifungal therapy in IFD low-risk patients with prolonged FN.
  • Conclusion Changes to the updated FN CPG recommendations will likely influence the care of pediatric patients with cancer and those undergoing hematopoietic stem-cell transplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28459614.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Powell JT, Sweeting MJ, Ulug P, Blankensteijn JD, Lederle FA, Becquemin JP, Greenhalgh RM, EVAR-1, DREAM, OVER and ACE Trialists: Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years. Br J Surg; 2017 Feb;104(3):166-178
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years.
  • METHODS: An individual-patient data meta-analysis of four multicentre randomized trials of EVAR versus open repair was conducted to a prespecified analysis plan, reporting on mortality, aneurysm-related mortality and reintervention.
  • RESULTS: The analysis included 2783 patients, with 14 245 person-years of follow-up (median 5·5 years).
  • Patients with moderate renal dysfunction or previous coronary artery disease had no early survival advantage under EVAR.
  • Over 5 years, patients of marginal fitness had no early survival advantage from EVAR compared with open repair.
  • Aneurysm-related mortality and patients with low ankle : brachial pressure index contributed to the erosion of the early survival advantage for the EVAR group.
  • Trial registration numbers: EVAR-1, ISRCTN55703451; DREAM (Dutch Randomized Endovascular Aneurysm Management), NCT00421330; ACE (Anévrysme de l'aorte abdominale, Chirurgie versus Endoprothèse), NCT00224718; OVER (Open Versus Endovascular Repair Trial for Abdominal Aortic Aneurysms), NCT00094575.

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.
  • [Cites] Br J Surg. 2013 Apr;100(5):638-44 [23334950.001]
  • [Cites] N Engl J Med. 2005 Jun 9;352(23):2398-405 [15944424.001]
  • [Cites] Ann Intern Med. 1999 Mar 16;130(6):461-70 [10075613.001]
  • [Cites] J Endovasc Ther. 2015 Dec;22(6):897-904 [26403831.001]
  • [Cites] N Engl J Med. 2012 Nov 22;367 (21):1988-97 [23171095.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] J Vasc Surg. 2013 Oct;58(4):879-85 [23683383.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2004 Apr;27(4):372-81 [15015186.001]
  • [Cites] Cochrane Database Syst Rev. 2014 Jan 23;(1):CD004178 [24453068.001]
  • [Cites] Lancet. 2004 Sep 4-10;364(9437):843-8 [15351191.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2010 Jan;39(1):55-61 [19775919.001]
  • [Cites] JAMA. 2012 Nov 7;308(17):1795-801 [23117780.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] Ann Surg. 2010 Nov;252(5):805-12 [21037436.001]
  • [Cites] J Vasc Surg. 2009 Oct;50(4):880-96 [19786241.001]
  • [Cites] J Cardiovasc Surg (Torino). 2002 Jun;43(3):379-84 [12055570.001]
  • [Cites] Atherosclerosis. 2006 Nov;189(1):61-9 [16620828.001]
  • [Cites] N Engl J Med. 2015 Jul 23;373(4):328-38 [26200979.001]
  • [Cites] Surgery. 1969 May;65(5):763-71 [5777227.001]
  • [Cites] N Engl J Med. 2010 May 20;362(20):1863-71 [20382983.001]
  • [Cites] J Vasc Surg. 2011 May;53(5):1167-1173.e1 [21276681.001]
  • [Cites] Lancet. 2005 Jun 25-Jul 1;365(9478):2156-8 [15978908.001]
  • (PMID = 28160528.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Investigator] Greenhalgh RM; Beard JD; Buxton MJ; Brown LC; Harris PL; Powell JT; Rose JD; Russell IT; Sculpher MJ; Thompson SG; Lilford RJ; Bell PR; Greenhalgh RM; Whitaker SC; Poole-Wilson TL; Ruckley CV; Campbell WB; Dean MR; Ruttley MS; Coles EC; Powell JT; Halliday A; Gibbs SJ; Brown LC; Epstein D; Sculpher MJ; Thompson SG; Hannon RJ; Johnston L; Bradbury AW; Henderson MJ; Parvin SD; Shepherd DF; Greenhalgh RM; Mitchell AW; Edwards PR; Abbott GT; Higman DJ; Vohra A; Ashley S; Robottom C; Wyatt MG; Rose JD; Byrne D; Edwards R; Leiberman DP; McCarter DH; Taylor PR; Reidy JF; Wilkinson AR; Ettles DF; Clason AE; Leen GL; Wilson NV; Downes M; Walker SR; Lavelle JM; Gough MJ; McPherson S; Scott DJ; Kessell DO; Naylor R; Sayers R; Fishwick NG; Harris PL; Gould DA; Walker MG; Chalmers NC; Garnham A; Collins MA; Beard JD; Gaines PA; Ashour MY; Uberoi R; Braithwaite B; Whitaker SC; Davies JN; Travis S; Hamilton G; Platts A; Shandall A; Sullivan BA; Sobeh M; Matson M; Fox AD; Orme R; Yusef W; Doyle T; Horrocks M; Hardman J; Blair PH; Ellis PK; Morris G; Odurny A; Vohra R; Duddy M; Thompson M; Loosemore TM; Belli AM; Morgan R; Adiseshiah M; Brookes JA; McCollum CN; Ashleigh R; Aukett M; Baker S; Barbe E; Batson N; Bell J; Blundell J; Boardley D; Boyes S; Brown O; Bryce J; Carmichael M; Chance T; Coleman J; Cosgrove C; Curran G; Dennison T; Devine C; Dewhirst N; Errington B; Farrell H; Fisher C; Fulford P; Gough M; Graham C; Hooper R; Horne G; Horrocks L; Hughes B; Hutchings T; Ireland M; Judge C; Kelly L; Kemp J; Kite A; Kivela M; Lapworth M; Lee C; Linekar L; Mahmood A; March L; Martin J; Matharu N; McGuigen K; Morris-Vincent P; Murray S; Murtagh A; Owen G; Ramoutar V; Rippin C; Rowley J; Sinclair J; Spencer S; Taylor V; Tomlinson C; Ward S; Wealleans V; West J; White K; Williams J; Wilson L; Grobbee DE; Blankensteijn JD; Bak AA; Buth J; Pattynama PM; Verhoeven EL; van Voorthuisen AE; Blankensteijn JD; Balm R; Buth J; Cuypers PW; Grobbee DE; Prinssen M; van Sambeek MR; Verhoeven EL; Baas AF; Hunink MG; van Engelshoven JM; Jacobs MJ; de Mol BA; van Bockel JH; Balm R; Reekers J; Tielbeek X; Verhoeven EL; Wisselink W; Boekema N; Heuveling LM; Sikking I; Prinssen M; Balm R; Blankensteijn JD; Buth J; Cuypers PW; van Sambeek MR; Verhoeven EL; de Bruin JL; Baas AF; Blankensteijn JD; Prinssen M; Buth J; Tielbeek AV; Blankensteijn JD; Balm R; Reekers JA; van Sambeek MR; Pattynama P; Verhoeven EL; Prins T; van der Ham AC; van der Velden JJ; van Sterkenburg SM; Ten Haken GB; Bruijninckx CM; van Overhagen H; Tutein Nolthenius RP; Hendriksz TR; Teijink JA; Odink HF; de Smet AA; Vroegindeweij D; van Loenhout RM; Rutten MJ; Hamming JF; Lampmann LE; Bender MH; Pasmans H; Vahl AC; de Vries C; Mackaay AJ; van Dortmont LM; van der Vliet AJ; Schultze Kool LJ; Boomsma JH; van Dop HR; de Mol van Otterloo JC; de Rooij TP; Smits TM; Yilmaz EN; Wisselink W; van den Berg FG; Visser MJ; van der Linden E; Schurink GW; de Haan M; Smeets HJ; Stabel P; van Elst F; Poniewierski J; Vermassen FE; Lederle FA; Freischlag JA; Kohler TR; Latts E; Matsumura J; Padberg FT Jr; Kyriakides TC; Swanson KM; Guarino P; Peduzzi P; Antonelli M; Cushing C; Davis E; Durant L; Joyner S; Kossack TL; Kyriakides TC; LeGwin M; McBride V; O'Connor T; Poulton J; Stratton TL; Zellner S; Snodgrass AJ; Thornton J; Swanson KM; Haakenson CM; Stroupe KT; Jonk Y; Hallett JW; Hertzer N; Towne J; Katz DA; Karrison T; Matts JP; Marottoli R; Kasl S; Mehta R; Feldman R; Farrell W; Allore H; Perry E; Niederman J; Randall F; Zeman M; Beckwith TL; O'Leary TJ; Huang GD; Latts E; Bader M; Ketteler ER; Kingsley DD; Marek JM; Massen RJ; Matteson BD; Pitcher JD; Langsfeld M; Corson JD; Goff JM Jr; Kasirajan K; Paap C; Robertson DC; Salam A; Veeraswamy R; Milner R; Kasirajan K; Guidot J; Lal BK; Busuttil SJ; Lilly MP; Braganza M; Ellis K; Patterson MA; Jordan WD; Whitley D; Taylor S; Passman M; Kerns D; Inman C; Poirier J; Ebaugh J; Raffetto J; Chew D; Lathi S; Owens C; Hickson K; Dosluoglu HH; Eschberger K; Kibbe MR; Baraniewski HM; Matsumura J; Endo M; Busman A; Meadows W; Evans M; Giglia JS; El Sayed H; Reed AB; Ruf M; Ross S; Jean-Claude JM; Pinault G; Kang P; White N; Eiseman M; Jones TL; Timaran CH; Modrall JG; Welborn MB 3rd; Lopez J; Nguyen T; Chacko JK; Granke K; Vouyouka AG; Olgren E; Chand P; Allende B; Ranella M; Yales C; Whitehill TA; Krupski TL; Nehler MR; Johnson SP; Jones DN; Strecker P; Bhola MA; Shortell CK; Gray JL; Lawson JH; McCann R; Sebastian MW; Kistler Tetterton J; Blackwell C; Prinzo PA; Lee N; Padberg FT Jr; Cerveira JJ; Lal BK; Zickler RW; Hauck KA; Berceli SA; Lee WA; Ozaki CK; Nelson PR; Irwin AS; Baum R; Aulivola B; Rodriguez H; Littooy FN; Greisler H; O'Sullivan MT; Kougias P; Lin PH; Bush RL; Guinn G; Bechara C; Cagiannos C; Pisimisis G; Barshes N; Pillack S; Guillory B; Cikrit D; Lalka SG; Lemmon G; Nachreiner R; Rusomaroff M; O'Brien E; Cullen JJ; Hoballah J; Sharp WJ; McCandless JL; Beach V; Minion D; Schwarcz TH; Kimbrough J; Ashe L; Rockich A; Warner-Carpenter J; Moursi M; Eidt JF; Brock S; Bianchi C; Bishop V; Gordon IL; Fujitani R; Kubaska SM 3rd; Behdad M; Azadegan R; Ma Agas C; Zalecki K; Hoch JR; Carr SC; Acher C; Schwarze M; Tefera G; Mell M; Dunlap B; Rieder J; Stuart JM; Weiman DS; Abul-Khoudoud O; Garrett HE; Walsh SM; Wilson KL; Seabrook GR; Cambria RA; Brown KR; Lewis BD; Framberg S; Kallio C; Barke RA; Santilli SM; d'Audiffret AC; Oberle N; Proebstle C; Johnson LL; Jacobowitz GR; Cayne N; Rockman C; Adelman M; Gagne P; Nalbandian M; Caropolo LJ; Pipinos II; Johanning J; Lynch T; DeSpiegelaere H; Purviance G; Zhou W; Dalman R; Lee JT; Safadi B; Coogan SM; Wren SM; Bahmani DD; Maples D; Thunen S; Golden MA; Mitchell ME; Fairman R; Reinhardt S; Wilson MA; Tzeng E; Muluk S; Peterson NM; Foster M; Edwards J; Moneta GL; Landry G; Taylor L; Yeager R; Cannady E; Treiman G; Hatton-Ward S; Salabsky TL; Kansal N; Owens E; Estes M; Forbes BA; Sobotta C; Rapp JH; Reilly LM; Perez SL; Yan K; Sarkar R; Dwyer SS; Perez S; Chong K; Kohler TR; Hatsukami TS; Glickerman DG; Sobel M; Burdick TS; Pedersen K; Cleary P; Back M; Bandyk D; Johnson B; Shames M; Reinhard RL; Thomas SC; Hunter GC; Leon LR Jr; Westerband A; Guerra RJ; Riveros M; Mills JL Sr; Hughes JD; Escalante AM; Psalms SB; Day NN; Macsata R; Sidawy A; Weiswasser J; Arora S; Jasper BJ; Dardik A; Gahtan V; Muhs BE; Sumpio BE; Gusberg RJ; Spector M; Pollak J; Aruny J; Kelly EL; Wong J; Vasilas P; Joncas C; Gelabert HA; DeVirgillio C; Rigberg DA; Cole L; Becquemin JP; Marzelle J; Becquemin JP; Sapoval M; Becquemin JP; Favre JP; Watelet J; Lermusiaux P; Sapoval M; Lepage E; Hemery F; Dolbeau G; Hawajry N; Cunin P; Harris P; Stockx L; Chatellier G; Mialhe C; Fiessinger JN; Pagny L; Kobeiter H; Boissier C; Lacroix P; Ledru F; Pinot JJ; Deux JF; Tzvetkov B; Duvaldestin P; Watelet J; Jourdain C; David V; Enouf D; Ady N; Krimi A; Boudjema N; Jousset Y; Enon B; Blin V; Picquet J; L'Hoste P; Thouveny F; Borie H; Kowarski S; Pernes JM; Auguste M; Becquemin JP; Desgranges P; Allaire E; Marzelle J; Kobeiter H; Meaulle PY; Chaix D; Juliae P; Fabiani JN; Chevalier P; Combes M; Seguin A; Belhomme D; Sapoval M; Baque J; Pellerin O; Favre JP; Barral X; Veyret C; Watelet J; Peillon C; Plissonier D; Thomas P; Clavier E; Lermusiaux P; Martinez R; Bleuet F; C D; Verhoye JP; Langanay T; Heautot JF; Koussa M; Haulon S; Halna P; Destrieux L; Lions C; Wiloteaux S; Beregi JP; Bergeron P; Pinot JJ; Patra P; Costargent A; Chaillou P; D'Alicourt A; Goueffic Y; Cheysson E; Parrot A; Garance P; Demon A; Tyazi A; Pillet JC; Lescalie F; Tilly G; Steinmetz E; Favier C; Brenot R; Krause D; Cercueil JP; Vahdat O; Sauer M; Soula P; Querian A; Garcia O; Levade M; Colombier D; Cardon JM; Joyeux A; Borrelly P; Dogas G; Magnan PÉ; Branchereau A; Bartoli JM; Hassen-Khodja R; Batt M; Planchard PF; Bouillanne PJ; Haudebourg P; Bayne J; Gouny P; Badra A; Braesco J; Nonent M; Lucas A; Cardon A; Kerdiles Y; Rolland Y; Kassab M; Brillu C; Goubault F; Tailboux L; Darrieux H; Briand O; Maillard JC; Varty K; Cousins C
  •  go-up   go-down


80. Petkovic J, Barton JL, Flurey C, Goel N, Bartels CM, Barnabe C, de Wit MP, Lyddiatt A, Lacaille D, Welch V, Boonen A, Shea B, Christensen R, Maxwell LJ, Campbell W, Jull J, Toupin-April K, Singh JA, Goldsmith CH, Sreih AG, Pohl C, Hofstetter C, Beaton DE, Buchbinder R, Guillemin F, Tugwell PS: Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group. J Rheumatol; 2017 Feb 15;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group.
  • OBJECTIVE: Despite advances integrating patient-centered outcomes into rheumatologic studies, concerns remain regarding their representativeness across diverse patient groups and how this affects equity.
  • METHODS: We surveyed current and previous OMERACT meeting attendees and members of the Campbell and Cochrane Equity Group regarding whether to address equity issues within the OMERACT Filter 2.0 Core Outcome Sets and how to assess the appropriateness of domains, instruments, and measurement properties among diverse patients.
  • RESULTS: We proposed 6 moments for which an equity lens could be added to the development, selection, or testing of patient-reported outcome measures (PROM):.
  • CONCLUSION: There is a need to (1) conduct a systematic review to assess how equity and population characteristics have been considered in PROM development and whether these differences influence the ranking of importance of outcome domains or a patient's response to questionnaire items, and (2) conduct the same survey described above with patients representing groups experiencing health inequities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28202740.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K23 AR064372
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


81. Williams MC, Hunter A, Shah A, Assi V, Lewis S, Mangion K, Berry C, Boon NA, Clark E, Flather M, Forbes J, McLean S, Roditi G, van Beek EJ, Timmis AD, Newby DE, Scottish COmputed Tomography of the HEART (SCOT-HEART) Trial Investigators: Symptoms and quality of life in patients with suspected angina undergoing CT coronary angiography: a randomised controlled trial. Heart; 2017 Jul;103(13):995-1001
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptoms and quality of life in patients with suspected angina undergoing CT coronary angiography: a randomised controlled trial.
  • BACKGROUND: In patients with suspected angina pectoris, CT coronary angiography (CTCA) clarifies the diagnosis, directs appropriate investigations and therapies, and reduces clinical events.
  • The effect on patient symptoms is currently unknown.
  • METHODS: In a prospective open-label parallel group multicentre randomised controlled trial, 4146 patients with suspected angina due to coronary heart disease were randomised 1:1 to receive standard care or standard care plus CTCA.
  • Compared with standard care alone, CTCA was associated with less marked improvements in physical limitation (difference -1.74 (95% CIs, -3.34 to -0.14), p=0.0329), angina frequency (difference -1.55 (-2.85 to -0.25), p=0.0198) and quality of life (difference -3.48 (-4.95 to -2.01), p<0.0001) at 6 months.
  • For patients undergoing CTCA, improvements in symptoms were greatest in those diagnosed with normal coronary arteries or who had their preventative therapy discontinued, and least in those with moderate non-obstructive disease or had a new prescription of preventative therapy (p<0.001 for all).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
  • (PMID = 28246175.001).
  • [ISSN] 1468-201X
  • [Journal-full-title] Heart (British Cardiac Society)
  • [ISO-abbreviation] Heart
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Williams M; Pawade T; Flapan A; Hargreaves A; Leslie S; McKillop G; Reid J; Spratt J; Uren N; Craig P; Barlow T; McCormack C; Shepherd S; Bucukoglu M; Parker R; Krishan A; Wee F; Wackett A; Walker A; Milne L; Oatey K; Neary P; Donaldson G; Fairbairn T; Fotheringham M; Hall F; Glen S; Perkins S; Taylor F; Cram L; Beveridge C; Cairns A; Dougherty F; Eteiba H; Rae A; Robb K; Crawford W; Clarkin P; Lennon E; Houston G; Pringle S; Prasad GR; Sudarshan T; Fogarty Y; Barrie D; Bissett K; Dawson A; Dundas S; Letham D; O'Neill L; Ritchie V; Weir-McCall J; Dougall H; Ahmed F; Cormack A; Findlay I; Hood S; Murphy C; Peat E; McCabe L; McCubbin M; Allen B; Behan M; Bertram D; Brian D; Cowan A; Cruden N; Denvir M; Dweck M; Flint L; Fyfe S; Grubb N; Keanie C; Lang C; MacGillivray T; MacLachlan D; MacLeod M; Mirsadraee S; Morrison A; Mills N; Northridge D; Phillips A; Queripel L; Weir N; Jacob A; Bett F; Divers F; Fairley K; Keegan E; White T; Fowler J; Gemmill J; McGowan J; Henry M; Francis M; Sandeman D; Dinnel L; Bloomfield P; Denvir M; Henriksen P; MacLeod D; Morrison A; Mordi I; Tzemos N; Connolly E; Boylan H; Brown A; Farrell L; Frood A; Glover C; Johnstone J; Lanaghan K; McGlynn D; McGregor L; McLennan E; Murdoch L; Paterson V; Teyhan F; Teenan M; Woodward R; Steedman T
  •  go-up   go-down


82. Buntrock C, Berking M, Smit F, Lehr D, Nobis S, Riper H, Cuijpers P, Ebert D: Preventing Depression in Adults With Subthreshold Depression: Health-Economic Evaluation Alongside a Pragmatic Randomized Controlled Trial of a Web-Based Intervention. J Med Internet Res; 2017 Jan 04;19(1):e5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Participants were randomized to a Web-based guided self-help intervention (ie, cognitive-behavioral therapy and problem-solving therapy assisted by supervised graduate students or health care professionals) in addition to usual care or to usual care supplemented with Web-based psycho-education (enhanced usual care).
  • Costs measured from a societal and health care perspective were related to DFYs and quality-adjusted life years (QALYs).
  • Taking the health care perspective and assuming a willingness-to-pay of €20,000 (£17,000), the intervention's likelihood of being cost-effective was 99% for gaining a DFY and 64% or 99% for gaining an EQ-5D or a SF-6D QALY.
  • Offering the intervention has an acceptable likelihood of being more cost-effective than enhanced usual care and could therefore reach community members on a wider scale.
  • TRIAL REGISTRATION: German Clinical Trials Register: DRKS00004709; http://www.drks.de/DRKS00004709 (Archived by WebCite at http://www.webcitation.org/6kAZVUxy9).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2012 Dec 15;380(9859):2163-96 [23245607.001]
  • [Cites] J Affect Disord. 2015 May 1;176:9-17 [25682378.001]
  • [Cites] Health Policy. 1996 Jul;37(1):53-72 [10158943.001]
  • [Cites] Value Health. 2013 Mar-Apr;16(2):231-50 [23538175.001]
  • [Cites] Int J Epidemiol. 2014 Apr;43(2):318-29 [24760873.001]
  • [Cites] Am J Geriatr Psychiatry. 2014 Mar;22(3):253-62 [23759290.001]
  • [Cites] Epidemiol Psychiatr Sci. 2015 Jun;24(3):210-26 [25720357.001]
  • [Cites] Med J Aust. 2002 Oct 7;177 Suppl:S122-5 [12358571.001]
  • [Cites] J Affect Disord. 2007 Feb;98(1-2):29-43 [16952399.001]
  • [Cites] J Psychosom Res. 2003 Oct;55(4):385-7 [14507551.001]
  • [Cites] Br J Psychiatry. 2010 Apr;196(4):319-25 [20357310.001]
  • [Cites] J Clin Epidemiol. 1998 Nov;51(11):1171-8 [9817135.001]
  • [Cites] Health Econ. 2004 Sep;13(9):873-84 [15362179.001]
  • [Cites] J Affect Disord. 2015 Mar 15;174:400-10 [25553400.001]
  • [Cites] Gesundheitswesen. 2005 Oct;67(10):736-46 [16235143.001]
  • [Cites] Patient Prefer Adherence. 2008 Feb 02;2:97-105 [19920949.001]
  • [Cites] Br J Psychiatry. 2004 May;184:393-403 [15123502.001]
  • [Cites] J Med Internet Res. 2004 Dec 22;6(4):e46 [15631970.001]
  • [Cites] Int J Technol Assess Health Care. 2005 Summer;21(3):298-304 [16110708.001]
  • [Cites] Med Care. 2004 Sep;42(9):851-9 [15319610.001]
  • [Cites] BMC Health Serv Res. 2013 Jun 15;13:217 [23768141.001]
  • [Cites] Med Care. 1997 Nov;35(11):1095-108 [9366889.001]
  • [Cites] Br J Psychiatry. 2010 Apr;196(4):310-8 [20357309.001]
  • [Cites] Expert Rev Pharmacoecon Outcomes Res. 2013 Apr;13(2):237-42 [23570434.001]
  • [Cites] Value Health. 2015 Mar;18(2):161-72 [25773551.001]
  • [Cites] Psychol Med. 2013 Mar;43(3):471-81 [22831756.001]
  • [Cites] PLoS One. 2011;6(8):e22884 [21853053.001]
  • [Cites] Health Econ. 1994 Sep-Oct;3(5):309-19 [7827647.001]
  • [Cites] Br J Psychiatry. 2006 Apr;188:330-6 [16582059.001]
  • [Cites] Gesundheitswesen. 2015 Jan;77(1):53-61 [25025287.001]
  • [Cites] JAMA. 2016 May 3;315(17):1854-63 [27139058.001]
  • [Cites] J Med Internet Res. 2011 Dec 31;13(4):e126 [22209829.001]
  • [Cites] J Clin Psychiatry. 1991 May;52 Suppl:28-34 [1903134.001]
  • [Cites] Psychol Med. 2007 Dec;37(12):1797-806 [17466110.001]
  • [Cites] Int Rev Psychiatry. 2007 Dec;19(6):655-70 [18092243.001]
  • [Cites] Aust N Z J Psychiatry. 2011 Jan;45(1):36-44 [21073354.001]
  • [Cites] BMC Psychiatry. 2014 Jan 31;14:25 [24485283.001]
  • [Cites] Br J Psychiatry. 2004 Jun;184:526-33 [15172947.001]
  • [Cites] J Med Internet Res. 2010 Dec 19;12(5):e53 [21169166.001]
  • [Cites] Psychol Med. 2016 Oct;46(13):2679-93 [27649340.001]
  • [Cites] Health Econ. 2006 Nov;15(11):1229-36 [16625671.001]
  • (PMID = 28052841.001).
  • [ISSN] 1438-8871
  • [Journal-full-title] Journal of medical Internet research
  • [ISO-abbreviation] J. Med. Internet Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Internet / cost effectiveness / early intervention / major depressive disorders / prevention
  •  go-up   go-down


83. Witt SH, Streit F, Jungkunz M, Frank J, Awasthi S, Reinbold CS, Treutlein J, Degenhardt F, Forstner AJ, Heilmann-Heimbach S, Dietl L, Schwarze CE, Schendel D, Strohmaier J, Abdellaoui A, Adolfsson R, Air TM, Akil H, Alda M, Alliey-Rodriguez N, Andreassen OA, Babadjanova G, Bass NJ, Bauer M, Baune BT, Bellivier F, Bergen S, Bethell A, Biernacka JM, Blackwood DHR, Boks MP, Boomsma DI, Børglum AD, Borrmann-Hassenbach M, Brennan P, Budde M, Buttenschøn HN, Byrne EM, Cervantes P, Clarke TK, Craddock N, Cruceanu C, Curtis D, Czerski PM, Dannlowski U, Davis T, de Geus EJC, Di Florio A, Djurovic S, Domenici E, Edenberg HJ, Etain B, Fischer SB, Forty L, Fraser C, Frye MA, Fullerton JM, Gade K, Gershon ES, Giegling I, Gordon SD, Gordon-Smith K, Grabe HJ, Green EK, Greenwood TA, Grigoroiu-Serbanescu M, Guzman-Parra J, Hall LS, Hamshere M, Hauser J, Hautzinger M, Heilbronner U, Herms S, Hitturlingappa S, Hoffmann P, Holmans P, Hottenga JJ, Jamain S, Jones I, Jones LA, Juréus A, Kahn RS, Kammerer-Ciernioch J, Kirov G, Kittel-Schneider S, Kloiber S, Knott SV, Kogevinas M, Landén M, Leber M, Leboyer M, Li QS, Lissowska J, Lucae S, Martin NG, Mayoral-Cleries F, McElroy SL, McIntosh AM, McKay JD, McQuillin A, Medland SE, Middeldorp CM, Milaneschi Y, Mitchell PB, Montgomery GW, Morken G, Mors O, Mühleisen TW, Müller-Myhsok B, Myers RM, Nievergelt CM, Nurnberger JI, O'Donovan MC, Loohuis LMO, Ophoff R, Oruc L, Owen MJ, Paciga SA, Penninx BWJH, Perry A, Pfennig A, Potash JB, Preisig M, Reif A, Rivas F, Rouleau GA, Schofield PR, Schulze TG, Schwarz M, Scott L, Sinnamon GCB, Stahl EA, Strauss J, Turecki G, Van der Auwera S, Vedder H, Vincent JB, Willemsen G, Witt CC, Wray NR, Xi HS, Bipolar Disorders Working Group of the Psychiatric Genomics Consortium, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Schizophrenia Working Group of the Psychiatric Genomics Consortium, Tadic A, Dahmen N, Schott BH, Cichon S, Nöthen MM, Ripke S, Mobascher A, Rujescu D, Lieb K, Roepke S, Schmahl C, Bohus M, Rietschel M: Genome-wide association study of borderline personality disorder reveals genetic overlap with bipolar disorder, major depression and schizophrenia. Transl Psychiatry; 2017 Jun 20;7(6):e1155

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Up to 20% of BIP patients show comorbidity with BOR.
  • This report describes the first case-control genome-wide association study (GWAS) of BOR, performed in one of the largest BOR patient samples worldwide.
  • GWAS, gene-based tests and gene-set analyses were performed in 998 BOR patients and 1545 controls.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurochem. 1997 Oct;69(4):1343-55 [9326262.001]
  • [Cites] Schizophr Bull. 2009 Mar;35(2):383-402 [19011234.001]
  • [Cites] Nat Genet. 2011 Sep 18;43(10):969-76 [21926974.001]
  • [Cites] Nat Genet. 2013 Sep;45(9):984-94 [23933821.001]
  • [Cites] Nat Genet. 2013 Oct;45(10):1150-9 [23974872.001]
  • [Cites] G3 (Bethesda). 2011 Nov;1(6):457-70 [22384356.001]
  • [Cites] Transl Psychiatry. 2016 Apr 26;6:e791 [27115122.001]
  • [Cites] Mol Psychiatry. 2014 Aug;19(8):923-9 [23979607.001]
  • [Cites] Nervenarzt. 2007 Sep;78(9):1069-80; quiz 1081 [17846736.001]
  • [Cites] Nat Methods. 2011 Dec 04;9(2):179-81 [22138821.001]
  • [Cites] Nature. 2014 Jul 24;511(7510):421-7 [25056061.001]
  • [Cites] Nat Genet. 2015 Mar;47(3):291-5 [25642630.001]
  • [Cites] Arch Gen Psychiatry. 1983 Jan;40(1):23-30 [6849616.001]
  • [Cites] Int J Neuropsychopharmacol. 2016 Dec 3;19(12 ):null [27450446.001]
  • [Cites] Mol Psychiatry. 2015 May;20(5):563-72 [25113377.001]
  • [Cites] Nucleic Acids Res. 2010 Jul;38(Web Server issue):W749-54 [20501604.001]
  • [Cites] Mol Psychiatry. 2009 Apr;14(4):359-75 [19065144.001]
  • [Cites] Acta Psychiatr Scand. 2015 Oct;132(4):281-2 [25923951.001]
  • [Cites] PLoS Comput Biol. 2015 Apr 17;11(4):e1004219 [25885710.001]
  • [Cites] J Pers Disord. 2014 Oct;28(5):734-50 [25248122.001]
  • [Cites] Nat Genet. 2012 Dec;44(12):1365-9 [23042115.001]
  • [Cites] Nat Neurosci. 2015 Feb;18(2):199-209 [25599223.001]
  • [Cites] J Neural Transm (Vienna). 2016 Aug;123(8):867-83 [26856328.001]
  • [Cites] Med J Aust. 2013 Sep 16;199(6 Suppl):S36-9 [25370284.001]
  • [Cites] Biol Psychiatry. 2009 Dec 15;66(12):1131-8 [19748081.001]
  • [Cites] J Drug Educ. 2007;37(3):277-94 [18047183.001]
  • [Cites] J Affect Disord. 2016 Nov 15;205:225-233 [27449555.001]
  • [Cites] Acta Psychiatr Scand. 2014 Aug;130(2):99-108 [24571137.001]
  • [Cites] JAMA Psychiatry. 2013 Nov;70(11):1206-14 [24048243.001]
  • [Cites] Nat Genet. 2015 Nov;47(11):1236-41 [26414676.001]
  • [Cites] JAMA Psychiatry. 2016 Apr;73(4):354-61 [26913486.001]
  • [Cites] Acta Psychiatr Scand. 2008 Mar;117(3):177-84 [18241308.001]
  • [Cites] Acta Psychiatr Scand. 2011 May;123(5):349-59 [21198457.001]
  • [Cites] Nucleic Acids Res. 2010 Jul;38(Web Server issue):W90-5 [20435672.001]
  • [Cites] Arch Gen Psychiatry. 2011 Jul;68(7):753-62 [21727257.001]
  • [Cites] Arch Gen Psychiatry. 1982 Jul;39(7):795-9 [7165479.001]
  • [Cites] Am J Hum Genet. 2014 Dec 4;95(6):744-53 [25434007.001]
  • [Cites] J Psychiatr Res. 2013 Oct;47(10):1275-87 [23810197.001]
  • [Cites] Lancet. 2004 Jul 31-Aug 6;364(9432):453-61 [15288745.001]
  • [Cites] Mol Cancer Res. 2016 Feb;14 (2):196-206 [26609109.001]
  • [Cites] J Affect Disord. 2016 May;195:105-18 [26881339.001]
  • [Cites] Compr Psychiatry. 2000 Nov-Dec;41(6):416-25 [11086146.001]
  • [Cites] Biol Chem. 2013 Aug;394(8):1005-17 [23640939.001]
  • [Cites] Nat Neurosci. 2012 Dec;15(12):1621-3 [23143512.001]
  • [Cites] Am J Hum Genet. 2007 Sep;81(3):559-75 [17701901.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2013 Apr;52(4):414-430.e14 [23582872.001]
  • [Cites] Nature. 2010 Oct 28;467(7319):1061-73 [20981092.001]
  • [Cites] Nature. 2009 Aug 6;460(7256):748-52 [19571811.001]
  • [Cites] PLoS One. 2015 Dec 16;10(12):e0144719 [26674772.001]
  • [Cites] J Pers Disord. 2010 Aug;24(4):427-44 [20695804.001]
  • (PMID = 28632202.001).
  • [ISSN] 2158-3188
  • [Journal-full-title] Translational psychiatry
  • [ISO-abbreviation] Transl Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Kaiser SV, Rodean J, Bekmezian A, Hall M, Shah SS, Mahant S, Parikh K, Morse R, Puls H, Cabana MD, Pediatric Research in Inpatient Settings (PRIS) Network: Rising utilization of inpatient pediatric asthma pathways. J Asthma; 2017 May 19;:1-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Clinical pathways are detailed care plans that operationalize evidence-based guidelines into an accessible format for health providers.
  • Their goal is to link evidence to practice to optimize patient outcomes and delivery efficiency.
  • Future studies should determine optimal implementation strategies to better support hospital-level efforts in improving pediatric asthma care and outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28521558.001).
  • [ISSN] 1532-4303
  • [Journal-full-title] The Journal of asthma : official journal of the Association for the Care of Asthma
  • [ISO-abbreviation] J Asthma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Children / clinical pathways / hospital / implementation / quality improvement
  •  go-up   go-down


85. Dent E, Lien C, Lim WS, Wong WC, Wong CH, Ng TP, Woo J, Dong B, de la Vega S, Hua Poi PJ, Kamaruzzaman SBB, Won C, Chen LK, Rockwood K, Arai H, Rodriguez-Mañas L, Cao L, Cesari M, Chan P, Leung E, Landi F, Fried LP, Morley JE, Vellas B, Flicker L: The Asia-Pacific Clinical Practice Guidelines for the Management of Frailty. J Am Med Dir Assoc; 2017 Jul 01;18(7):564-575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No recommendation was given regarding the provision of a patient support and education plan.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28648901.001).
  • [ISSN] 1538-9375
  • [Journal-full-title] Journal of the American Medical Directors Association
  • [ISO-abbreviation] J Am Med Dir Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Frail elderly / Practice Guidelines as Topic* / aged / disease management / evidence-based medicine/standards* / patient care management
  •  go-up   go-down


86. Duval X, Millot S, Chirouze C, Selton-Suty C, Moby V, Tattevin P, Strady C, Euvrard E, Agrinier N, Thomas D, Hoen B, Alla F, EI-dents Association pour l'Etude et la Prévention de l'Endocardite Infectieuse (AEPEI) Study Group: Oral Streptococcal Endocarditis, Oral Hygiene Habits, and Recent Dental Procedures: A Case-Control Study. Clin Infect Dis; 2017 Jun 15;64(12):1678-1685

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Background.: We aimed to compare oral hygiene habits, orodental status, and dental procedures in patients with infective endocarditis (IE) according to whether the IE-causing microorganism originated in the oral cavity.
  • Methods.: We conducted an assessor-blinded case-control study in 6 French tertiary-care hospitals.
  • History of dental procedures was obtained through patient and dentist interviews.
  • Conclusions.: Patients with IE caused by oral streptococci differ from patients with IE caused by nonoral pathogens regarding background characteristics, oral hygiene habits, and recent dental procedures, but not current orodental status.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28369398.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; case-control study / dental status. / endocarditis / hygiene / prophylaxis
  • [Investigator] Duval X; Hoen B; Alla F; Bouvet A; Chirouze C; Doco-Lecompte T; Iung B; Selton-Suty C; Strady C; Tattevin P; Chirouze C; Curlier E; Descottes-Genon C; Euvrad E; Hoen B; Meyer C; Patry I; Vettoretti L; Aissa N; Bannay A; Doco-Lecompte T; Goehringer F; Keil N; Letranchant L; Malela H; Moby V; Selton-Suty C; Bretheaux NBM; Broda S; Duval X; Fargou C; Habensus EI; Iung B; Imbert S; Millot S; Cambau E; Andremont A; Messeka C; Leport C; Thomas D; Bricaire F; Chastre J; Trouillet JL; Yeni P; Wolff M; Bourgeois G; Nazeyrollas P; Véronique V; Strady C; De Mello G; Piau C; Brener A; Martin-Thomé H; Michelet C; Revest M; Tattevin P; Thébault E; Alla F; Erpelding ML; Agrinier N
  •  go-up   go-down


87. Moradi S, Sahebi Z, Ebrahim Valojerdi A, Rohani F, Ebrahimi H: The association between the number of office visits and the control of cardiovascular risk factors in Iranian patients with type2 diabetes. PLoS One; 2017;12(6):e0179190

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association between the number of office visits and the control of cardiovascular risk factors in Iranian patients with type2 diabetes.
  • INTRODUCTION: Patients with diabetes type2 should receive regular medical care.
  • METHODS: Four hundred and ninety patients with type 2 diabetes mellitus who were followed in a tertiary center were enrolled in this longitudinal study.
  • Patient data were extracted from manual or electronic records.
  • The association between changes in these parameters and the number of patients' office visits per year were not statistically significant.
  • In patients with disease duration less than 5 years, each additional office visits by one visit per year was associated with a decrease in serum total cholesterol by 6.94 mg/dl.
  • The mean number of office visits per year in patients older than 60 years old was more than younger patient (p = 0.001).
  • Yet, these changes were not related to the mean number of patients' office visits per year, which may reflect the poor compliance of patients to treatment regardless of the number of their office visits.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28666031.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Ghiasvand F, Riazi H, Hajian S, Kazemi E, Firoozi A: The effect of a self-care program based on the teach back method on the postpartum quality of life. Electron Physician; 2017 Apr;9(4):4180-4189

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of a self-care program based on the teach back method on the postpartum quality of life.
  • OBJECTIVE: To determine the effect of a self-care program based on the Teach Back method on the postpartum quality of life.
  • The control group received only routine postpartum care according to the national guidelines.
  • The trial group received the routine care in addition to two sessions of physical and psychological postpartum self-care based on the Teach Back method.
  • CONCLUSIONS: Using the Teach Back model for a self-care program appears to dramatically improve the postpartum quality of life and is therefore recommended as a useful method for postpartum care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiovasc Nurs. 2013 Mar-Apr;28(2):137-46 [22580624.001]
  • [Cites] Arch Intern Med. 2003 Jan 13;163(1):83-90 [12523921.001]
  • [Cites] Issues Compr Pediatr Nurs. 2008 Jan-Mar;31(1):7-22 [18300059.001]
  • [Cites] Lancet. 2014 Sep 20;384(9948):1129-45 [24965816.001]
  • [Cites] Int J Fertil Steril. 2013 Oct;7(3):169-74 [24520482.001]
  • [Cites] Womens Health Issues. 2008 Jul-Aug;18(4):267-80 [18468922.001]
  • [Cites] Women Health. 2015;55(3):353-65 [25719436.001]
  • [Cites] Midwifery. 2015 Jan;31(1):155-63 [25174540.001]
  • [Cites] Iran J Nurs Midwifery Res. 2014 Nov;19(6):653-8 [25558265.001]
  • [Cites] Iran Red Crescent Med J. 2014 Feb;16(2):e14995 [24719747.001]
  • [Cites] Br J Obstet Gynaecol. 1998 Sep;105(9):991-7 [9763051.001]
  • [Cites] Rehabil Nurs. 1985 May-Jun;10(3):33-6 [3846326.001]
  • [Cites] J Sex Marital Ther. 2017 Feb 17;43(2):132-141 [26800362.001]
  • [Cites] J Health Commun. 2011;16 Suppl 3:89-102 [21951245.001]
  • [Cites] J Sex Med. 2012 Sep;9(9):2330-41 [22672428.001]
  • [Cites] J Res Med Sci. 2013 Nov;18(11):943-50 [24523780.001]
  • [Cites] Expert Rev Pharmacoecon Outcomes Res. 2009 Apr;9(2):123-32 [19402799.001]
  • [Cites] Midwifery. 2014 Mar;30(3):378-84 [23619027.001]
  • [Cites] J Clin Nurs. 2012 Jun;21(11-12):1534-43 [22023714.001]
  • [Cites] Prim Care Diabetes. 2013 Jul;7(2):111-8 [23195913.001]
  • [Cites] J Pediatr Nurs. 2012 Oct;27(5):451-9 [22920656.001]
  • [Cites] Birth. 1995 Sep;22(3):138-43 [7575861.001]
  • [Cites] J Obstet Gynaecol Res. 2014 May;40(5):1257-66 [24689693.001]
  • [Cites] Midwifery. 2013 Sep;29(9):1050-5 [23415369.001]
  • [Cites] Appl Nurs Res. 2003 Feb;16(1):38-45 [12624861.001]
  • [Cites] BMJ. 2000 Sep 9;321(7261):593-8 [10977833.001]
  • [Cites] BJOG. 2000 Feb;107(2):186-95 [10688502.001]
  • [Cites] Birth. 2008 Sep;35(3):179-87 [18844643.001]
  • [Cites] Matern Child Health J. 2017 Jan;21(1):77-84 [27435729.001]
  • [Cites] J Clin Outcomes Manag. 2009 Jan 1;16(1):20-29 [20046798.001]
  • [Cites] BMC Public Health. 2009 Feb 01;9:45 [19183504.001]
  • [Cites] PLoS One. 2016 Jun 16;11(6):e0156809 [27309528.001]
  • [Cites] Patient Educ Couns. 2015 May;98 (5):669-73 [25746128.001]
  • [Cites] Attach Hum Dev. 2014;16(5):515-33 [25028251.001]
  • [Cites] Nurs Clin North Am. 2007 Dec;42(4):507-14; v [17996752.001]
  • [Cites] Nurs Sci Q. 2013 Oct;26(4):360-4 [24085674.001]
  • [Cites] Midwifery. 2007 Dec;23(4):392-403 [17196714.001]
  • [Cites] Interact J Med Res. 2015 Oct 08;4(4):e20 [26449647.001]
  • [Cites] Patient Educ Couns. 2009 Jun;75(3):315-20 [19297116.001]
  • [Cites] Ann Med Health Sci Res. 2014 Sep;4(Suppl 3):S264-71 [25364600.001]
  • (PMID = 28607653.001).
  • [Journal-full-title] Electronic physician
  • [ISO-abbreviation] Electron Physician
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Keywords] NOTNLM ; Postpartum quality of life / Self-care / Teach Back method
  •  go-up   go-down


89. Robinson D, Humbert M, Buhl R, Cruz AA, Inoue H, Korom S, Hanania NA, Nair P: Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy; 2017 Feb;47(2):161-175

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Asthma is a complex respiratory disorder characterized by marked heterogeneity in individual patient disease triggers and response to therapy.
  • Endotypes further describe the functional or pathophysiologic mechanisms underlying the patient's disease. type 2-driven asthma is an emerging nomenclature for a common subtype of asthma and is characterized by the release of signature cytokines IL-4, IL-5 and IL-13 from cells of both the innate and adaptive immune systems.
  • These type 2 cytokines are targets for pharmaceutical intervention, and a number of therapeutic options are under clinical investigation for the management of patients with uncontrolled severe asthma.
  • Anticipating and understanding the heterogeneity of asthma and subsequent improved characterization of different phenotypes and endotypes must guide the selection of treatment to meet individual patients' needs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons Ltd.
  • (PMID = 28036144.001).
  • [ISSN] 1365-2222
  • [Journal-full-title] Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • [ISO-abbreviation] Clin. Exp. Allergy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


90. Etard JF, Sow MS, Leroy S, Touré A, Taverne B, Keita AK, Msellati P, Magassouba N, Baize S, Raoul H, Izard S, Kpamou C, March L, Savane I, Barry M, Delaporte E, Postebogui Study Group: Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study. Lancet Infect Dis; 2017 May;17(5):545-552
MedlinePlus Health Information. consumer health - Ebola.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this multidisciplinary observational cohort study, we recruited patients aged 1 year or more in four sites in Guinea (Donka National Hospital, Conakry; Macenta Prefectoral Hospital, Macenta; N'zérékoré Regional Hospital, N'zérékoré; and Forécariah Prefectoral Hospital, Forécariah) following discharge from any Ebola treatment centre in Guinea.
  • Eligible patients had had laboratory-confirmed EVD and had then been declared clear of the virus in the blood.
  • All consenting patients were included, with no exclusion criteria.
  • Trained clinicians assessed patients at enrolment to the cohort, recording clinical symptoms and signs of depression.
  • FINDINGS: Between March 23, 2015, and July 11, 2016, we recruited 802 patients, of whom 360 (45%) were male, 442 (55%) were female; 158 (20%) were younger than 18 years.
  • The most frequent symptoms were general symptoms (324 [40%] patients), musculoskeletal pain (303 [38%]), headache (278 [35%]), depression (124 [17%] of 713 responses), abdominal pain (178 [22%]), and ocular disorders (142 [18%]).
  • 204 (26%) of 793 patients reported stigmatisation.
  • Ocular complications were more frequent at enrolment than at discharge (142 [18%] vs 61 [8%] patients).
  • FUNDING: INSERM/Reacting, the French Ebola Task Force, and Institut de Recherche pour le Développement.
  • [MeSH-major] Disease Outbreaks / prevention & control. Hemorrhagic Fever, Ebola / complications. Patient Care Team / organization & administration. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28094208.001).
  • [ISSN] 1474-4457
  • [Journal-full-title] The Lancet. Infectious diseases
  • [ISO-abbreviation] Lancet Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Observational Study
  • [Publication-country] United States
  • [Investigator] Ayouba A; Baize S; Bangoura K; Barry A; Barry M; Cissé M; Cissé M; Delaporte E; Delfraissy JF; Delmas C; Desclaux A; Diallo SB; Diallo MS; Diallo MS; Étard JF; Etienne C; Faye O; Fofana I; Granouillac B; Hébert EH; Izard S; Kassé D; Keita AK; Keita S; Koivogui L; Kpamou C; Lacarabaratz C; Leroy S; Marchal CL; Levy Y; Magassouba N; March L; Mendiboure V; Msellati P; Niane H; Peeters M; Pers YM; Raoul H; Sacko SL; Savané I; Sow MS; Taverne B; Touré A; Traoré FA; Traoré F; Youla Y; Yazdanpanah Y
  •  go-up   go-down


91. Dámaso Fernández-Ginés F, Cortiñas-Sáenz M, Mateo-Carrasco H, de Aranda AN, Navarro-Muñoz E, Rodríguez-Carmona R, Fernández-Sánchez C, Sierra-García F, Morales-Molina JA: Efficacy and safety of topical sevoflurane in the treatment of chronic skin ulcers. Am J Health Syst Pharm; 2017 May 01;74(9):e176-e182

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Results of efficacy and safety assessments of topical sevoflurane use in patients with long-term treatment-refractory vascular ulcers are reported.
  • METHODS: Patients were randomly assigned to receive sevoflurane instillations (1 mL per cm<sup>2</sup> of ulcer area 1-4 times daily) plus standard wound care (ulcer cleaning, debridement, and dressing changes) or standard care only.
  • The primary efficacy measures were debridement-related and overall pain (assessed using a 10-point visual analog scale), daily opioid use, and ulcer size; secondary measures were patient and clinician impressions of improvement and ulcer-related admissions during treatment.
  • RESULTS: Compared with the group receiving standard care alone (<i>n</i> = 5), the sevoflurane group (<i>n</i> = 10) had significant (<i>p</i> = 0.001) reductions in mean ± S.D. scores for debridement-related pain on day 1 of treatment and at subsequent time points; the sevoflurane group also had significant reductions in overall pain, daily opioid use, and ulcer size.
  • Outcomes in terms of patient- and clinician-rated improvement and emergency admissions also favored the sevoflurane group.
  • Mild localized reddening in the area surrounding ulcers occurred in 4 sevoflurane-treated patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 by the American Society of Health-System Pharmacists, Inc. All rights reserved.
  • (PMID = 28438822.001).
  • [ISSN] 1535-2900
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; opioid skin ulcer / pain / sevoflurane / topical drug administration
  •  go-up   go-down


92. Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ, CheckMate 025 investigators: CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. Eur Urol; 2017 Mar 03;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The benefit with nivolumab versus everolimus was noteworthy for patients with poor MSKCC risk (hazard ratio 0.48, 95% confidence interval 0.32-0.70).
  • CONCLUSION: The trend for OS and ORR benefit with nivolumab for multiple subgroups, without notable safety concerns, may help to guide treatment decisions, and further supports nivolumab as the standard of care in previously treated patients with aRCC.
  • PATIENT SUMMARY: We investigated the impact of demographic and pretreatment features on survival benefit and tumor response with nivolumab versus everolimus in advanced renal cell carcinoma (aRCC).
  • Survival benefit and response were observed for multiple subgroups, supporting the use of nivolumab as a new standard of care across a broad range of patients with previously treated aRCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 28262413.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Everolimus / Immune checkpoint inhibitor / Nivolumab / Phase 3 / Renal cell carcinoma
  •  go-up   go-down


93. Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, García-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation: 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol; 2017 May;69(5):898-910

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial.
  • RESULTS: Consensus was reached for a conjoint analysis-based continuous model using absolute percent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels).
  • Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017, American College of Rheumatology.
  • [Cites] Arthritis Rheum. 1997 Jul;40(7):1202-9 [9214419.001]
  • [Cites] Arthritis Rheum. 2009 May 15;61(5):658-66 [19405003.001]
  • [Cites] Lancet. 2016 Feb 13;387(10019):671-8 [26645190.001]
  • [Cites] Rheumatology (Oxford). 2001 Nov;40(11):1262-73 [11709610.001]
  • [Cites] Arch Dis Child. 2011 Jun;96(6):596-601 [21317432.001]
  • [Cites] Arthritis Care Res (Hoboken). 2016 May;68(5):667-72 [26414176.001]
  • [Cites] Ann Rheum Dis. 2014 Dec;73(12):2168-73 [24026675.001]
  • [Cites] Eur J Clin Pharmacol. 2011 May;67 Suppl 1:125-31 [21103985.001]
  • [Cites] Health Econ. 2012 Feb;21(2):145-72 [22223558.001]
  • [Cites] Curr Rheumatol Rep. 2008 Apr;10(2):142-6 [18460270.001]
  • [Cites] Can J Psychiatry. 2002 Apr;47(3):262-6 [11987478.001]
  • [Cites] Arthritis Rheum. 2013 Feb;65(2):314-24 [23124935.001]
  • [Cites] Open Rheumatol J. 2012;6:54-63 [22723809.001]
  • [Cites] Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S118-57 [22588740.001]
  • [Cites] Arthritis Rheum. 2008 Jan 15;59(1):4-13 [18163404.001]
  • [Cites] Ann Rheum Dis. 2010 May;69(5):790-7 [20388738.001]
  • [Cites] Arthritis Rheum. 2004 Jul;50(7):2281-90 [15248228.001]
  • [Cites] J Rheumatol. 2003 Mar;30(3):603-17 [12610824.001]
  • [Cites] Arthritis Care Res (Hoboken). 2010 Nov;62(11):1533-41 [20583105.001]
  • [Cites] Arthritis Rheum. 2011 Oct;63(10):3142-52 [21647864.001]
  • [Cites] Rheumatology (Oxford). 2003 Dec;42(12):1452-9 [12832713.001]
  • [Cites] Semin Nucl Med. 1978 Oct;8(4):283-98 [112681.001]
  • [Cites] J Rheumatol. 2007 May;34(5):1184-7 [17477484.001]
  • [Cites] Arthritis Rheum. 1995 Jun;38(6):727-35 [7779114.001]
  • [Cites] Ther Adv Neurol Disord. 2014 Nov;7(6):263-75 [25371708.001]
  • [Cites] Arthritis Rheumatol. 2015 Oct;67(10):2557-68 [26352873.001]
  • [Cites] Arthritis Rheumatol. 2017 May;69(5):898-910 [28382787.001]
  • [Cites] Arthritis Rheum. 2007 Mar 15;57(2):193-202 [17330293.001]
  • [Cites] Arthritis Rheumatol. 2017 May;69(5):911-923 [28382778.001]
  • (PMID = 28382787.001).
  • [ISSN] 2326-5205
  • [Journal-full-title] Arthritis & rheumatology (Hoboken, N.J.)
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA ES101081-15; United States / Intramural NIH HHS / / ZIA ES101081-14; United States / Intramural NIH HHS / / ZIA ES101081-13; United States / Intramural NIH HHS / / ZID ES102465-05; United States / Intramural NIH HHS / / ZIA ES101081-12; United States / Intramural NIH HHS / / Z99 ES999999
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Investigator] Rider LG; Ruperto N; Aggarwal R; Miller FW; Vencovsky J; Aggarwal R; Erman B; Bayat N; Pistorio A; Huber AM; Feldman BM; Hansen P; Rockette H; Lachenbruch PA; Ruperto N; Rider LG; Amato AA; Chinoy H; Christopher-Stine L; Chung L; Cooper RG; Criscione-Schreiber L; Crofford L; Cronin ME; Dankó K; Fiorentino D; García-De la Torre I; Gordon P; Hengstman G; Katz JD; Mammen A; Marder G; McHugh N; Oddis CV; Schiopu E; Selva-O'Callaghan A; Wook Song Y; Vencovsky J; Wolfe G; Wortmann R; Amato AA; Chinoy H; Chung L; Cooper RG; Dankó K; Fiorentino D; García-De la Torre I; Gourley M; Lundberg I; Miller FW; Oddis CV; Plotz P; Rider LG; Wook Song Y; Vencovsky J; Aggarwal R; Amato AA; Ascherman D; Barohn R; Benveniste O; De Bleecker J; Callen J; Charles-Schoeman C; Chinoy H; Christopher-Stine L; Chung L; Cooper RG; Crofford L; Cronin ME; Dankó K; Danoff S; Dastmalchi M; de Visser M; Dimachkie M; DiMartino S; Dourmishev L; Ernste F; Fiorentino D; García-De la Torre I; Gono T; Gordon P; Gourley M; Isenberg D; Katsumata Y; Katz JD; Kissel J; Leff RL; Levine T; Lundberg I; Mammen A; Mann H; Marder G; Marie I; McHugh N; Merola J; Miller FW; Oddis CV; Olesinska M; Olsen N; Pipitone N; Ramchandren S; Rutkove S; Saketkoo LA; Schiffenbauer A; Selva-O'Callaghan A; Katsuyuki Shinjo S; Shupak R; Wook Song Y; Swierkocka K; Vencovsky J; Wanschitz J; Werth V; Whitt I; Wortmann R; Ytterberg SR; Aggarwal R; Amato AA; Chinoy H; Christopher-Stine L; Chung L; Cooper RG; Cronin ME; Dankó K; Dimachkie M; DiMartino S; Fiorentino D; García-De la Torre I; Gordon P; Lundberg I; Mann H; Miller FW; Oddis CV; Selva-O'Callaghan A; Vencovsky J; Werth V; Wortmann R; Ytterberg SR; Amato AA; Chinoy H; Cooper RG; Dastmalchi M; de Visser M; Fiorentino D; Isenberg D; Katz JD; Mammen A; Oddis CV; Vencovsky J; Ytterberg SR; Cimaz R; Cuttica R; Feitosa de Oliveira SK; Feldman BM; Huber AM; Lindsley CB; Pilkington C; Punaro M; Ravelli A; Reed A; Rouster-Stevens K; van Royen-Kerkhof A
  •  go-up   go-down


94. Hellings PW, Fokkens WJ, Bachert C, Akdis CA, Bieber T, Agache I, Bernal-Sprekelsen M, Canonica GW, Gevaert P, Joos G, Lund V, Muraro A, Onerci M, Zuberbier T, Pugin B, Seys SF, Bousquet J, ARIA and EPOS working groups: Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy; 2017 Mar 17;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement.
  • Precision medicine (PM) is increasingly recognized as the way forward for optimizing patient care.
  • Introduced in the field of oncology, it is now considered of major interest in other medical domains like allergy and chronic airway diseases, which face an urgent need to improve the level of disease control, enhance patient satisfaction and increase effectiveness of preventive interventions.
  • The combination of personalized care, prediction of treatment success, prevention of disease and patient participation in the elaboration of the treatment plan is expected to substantially improve the therapeutic approach for individuals suffering from chronic disabling conditions.
  • Given the emerging data on the impact of patient stratification on treatment outcomes, European and American regulatory bodies support the principles of PM and its potential advantage over current treatment strategies.
  • At the time of diagnosis, prediction of success of the initiated treatment and patient participation in the decision of the treatment plan can be implemented.
  • The second-level approach ideally involves strategies to prevent progression of disease, in addition to prediction of success of therapy, and patient participation in the long-term therapeutic strategy.
  • Endotype-driven treatment is part of a personalized approach and should be positioned at the tertiary level of care, given the efforts needed for its implementation and the high cost of molecular diagnosis and biological treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
  • (PMID = 28306159.001).
  • [ISSN] 1398-9995
  • [Journal-full-title] Allergy
  • [ISO-abbreviation] Allergy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Keywords] NOTNLM ; allergic rhinitis / integrated care pathway / precision medicine / rhinosinusitis
  • [Investigator] Aberer W; Agache I; Akdis CA; Akdis M; Alobid I; Ankri J; Annesi-Maesano I; Ansotegui IJ; Anto JM; Arnavielhe S; Arshad H; Asarnoj A; Avolio F; Bachert C; Bachert C; Baiardini I; Barbagallo M; Barbara C; Baroody F; Bateman ED; Bedbrook A; Beghé B; Bel EH; Bennoor KS; Benson M; Bergmann KC; Bewick M; Bialoszewski AZ; Bieber T; Bindslev-Jensen C; Bjermer L; Blain H; Blasi F; Boner AL; Bonini M; Bonini S; Bosnic-Anticevich S; Bosse I; Bouchard J; Boulet LP; Bourret R; Bousquet J; Bousquet PJ; Braido F; Briggs AH; Brightling CE; Brozek J; Bucca C; Buhl R; Bunu C; Burte E; Bush A; Caballero-Fonseca F; Caimmi DP; Calderon MA; Camargos PA; Camuzat T; Canonica GW; Cardona V; Carlsen KH; Carr W; Carreiro-Martins P; Carriazo AM; Casale T; Cepeda Sarabia AM; Cervin A; Cesari M; Chatzi L; Chavannes NH; Chiron R; Chivato T; Chkhartishvili E; Chuchalin AG; Chung KF; Ciprandi G; Cohen N; Conzález Diaz S; Cox L; Crooks G; Cruz AA; Custovic A; Dahl R; Dahlen SE; Darsow U; De Carlo G; De Manuel Keenoy E; de Sousa JC; De Vries G; Dedeu T; Deleanu D; Demoly P; Denburg JA; Devillier P; Didier A; Dinh-Xuan AT; Dokic D; Douagui H; Douglas R; Dray G; Du Toit G; Dubakiene R; Durham SR; Dykewicz MS; Eklund P; El-Gamal Y; Ellers E; Emuzyte R; Farrell J; Fink Wagner A; Fiocchi A; Fletcher M; Fokkens WJ; Fonseca J; Forastiere F; Gaga M; Gamkrelidze A; Gemicioğlu B; Georgalas C; Gereda JE; Gevaert P; Goossens H; Grisle I; Guldemond NA; Gutter Z; Guzmán MA; Haahtela T; Harvey R; Heinrich J; Hellings PW; Hellings PW; Hellquist-Dahl B; Hopkins C; Horak F; Hourihane JO; Humbert M; Hyland M; Iaccarino G; Illario M; Jares EJ; Jeandel C; Johnston SL; Jonquet O; Joos G; Joos G; Jung KS; Just J; Jutel M; Kaidashev I; Kalayci O; Kalogjera L; Kalyoncu AF; Kardas P; Keil T; Keith PK; Kerkhof M; Kern B; Kerstjens HA; Khaitov M; Khaltaev N; Klimek L; Kogevinas M; Kolek V; Koppelman GH; Kowalski M; Kowalski ML; Kuitunen M; Kull I; Kuna P; Kvedariene V; Lambrecht B; Larenas-Linnemann D; Lau S; Laune D; Le LT; Li J; Lieberman P; Lipworth B; Lodrup Carlsen KC; Louis R; Lund VJ; Lupinek C; MacNee W; Magar Y; Magnan A; Mahboub B; Maier D; Majer I; Malva J; Manning P; Marshall GD; Masjedi MR; Mathieu-Dupas E; Maurer M; Mavale-Manuel S; Melén E; Melo-Gomes E; Meltzer EO; Mercier J; Merk H; Miculinic N; Mihaltan F; Milenkovic B; Millot-Keurinck J; Mohammad Y; Momas I; Morais-Almeida M; Mösges R; Mullol J; Mullol J; Muraro A; Murray R; Naclerio R; Nadif R; Namazova-Baranova L; Neffen H; Nekam K; Nieto A; Niggemann B; Nogueira-Silva L; Nogues M; Nyembue TD; O'Hehir RE; Ohta K; Okamoto Y; Okubo K; Olive-Elias M; Ouedraogo S; Paggiaro P; Pali-Schöll I; Palkonen S; Panzner P; Papadopoulos NG; Papi A; Park HS; Passalacqua G; Pawankar R; Pedersen S; Pereira AM; Pfaar O; Picard R; Pigearias B; Pin I; Plavec D; Pohl W; Popov TA; Portejoie F; Postma D; Potter P; Poulsen LK; Price D; Price D; Rabe KF; Raciborski F; Riechelmann H; Robalo-Cordeiro C; Roberts G; Rodenas F; Rodriguez-Mañas L; Rolland C; Roman Rodriguez M; Romano A; Rosado-Pinto J; Rosario N; Rottem M; Ryan D; Samolinski B; Sanchez-Borges M; Sastre-Dominguez J; Scadding GK; Schlosser R; Schmid-Grendelmeier P; Schunemann HJ; Scichilone N; Senior B; Serrano E; Sheikh A; Shields M; Simons F; Siroux V; Sisul JC; Skrindo I; Smit HA; Solé D; Sooronbaev T; Spranger O; Stellato C; Stelmach R; Sterk PJ; Strandberg T; Sunyer J; Thijs C; Thomas M; Todo-Bom A; Tomazic PV; Toskala E; Triggiani M; Valenta R; Valero A; Valiulis A; Valovirta E; van Eerd M; van Ganse E; van Hague M; van Wick RG; Vandenplas O; Varona LL; Vazankari T; Vellas B; Ventura MT; Vezzani G; Viegi G; Voegels R; Vontetsianos T; Wagenmann M; Wahn U; Walker S; Wang DY; Wang Y; Werfel T; Whalley B; Wickman M; Williams DM; Williams S; Wilson N; Wormald PJ; Wright J; Yawn BP; Yiallouros PK; Yorgancioglu A; Young I; Yusuf OM; Zaidi A; Zar HJ; Zernotti ME; Zhang L; Zhong N; Zidarn M; Zuberbier T
  •  go-up   go-down


95. Erb S, Letang E, Glass TR, Natamatungiro A, Mnzava D, Mapesi H, Haschke M, Duthaler U, Berger B, Muri L, Bader J, Marzolini C, Elzi L, Klimkait T, Langewitz W, Battegay M, Kilombero Ulanga Antiretroviral Cohort (KIULARCO) study group: Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems. HIV Med; 2017 Mar 13;
HIV InSite. treatment guidelines - Adherence to HIV Antiretroviral Therapy .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems.
  • OBJECTIVES: Self-reported adherence assessment in HIV-infected patients on antiretroviral therapy (ART) is challenging and may overestimate adherence.
  • The aim of this study was to improve the ability of health care providers to elicit patients' reports of nonadherence using a "patient-centred" approach in a rural sub-Saharan African setting.
  • METHODS: A prospective interventional cohort study of HIV-infected patients on ART for ≥ 6 months attending an HIV clinic in rural Tanzania was carried out.
  • The intervention consisted of a 2-day workshop for health care providers on patient-centred communication and the provision of an adherence assessment checklist for use in the consultations.
  • Patients' self-reports of nonadherence (≥ 1 missed ART dose/4 weeks), subtherapeutic plasma ART concentrations (< 2.5th percentile of published population-based pharmacokinetic models), and virological and immunological failure according to the World Health Organization definition were assessed before and after (1-3 and 6-9 months after) the intervention.
  • RESULTS: Before the intervention, only 3.3% of 299 patients included in the study reported nonadherence.
  • Subtherapeutic plasma ART drug concentrations and virological and immunological failure were recorded in 6.5%, 7.7% and 14.5% of the patients, respectively.
  • Two months after the intervention, health care providers detected significantly more patients reporting nonadherence compared with baseline (10.7 vs. 3.3%, respectively; P < 0.001), decreasing to 5.7% after 6-9 months.
  • CONCLUSIONS: Patient-centred communication can successfully be implemented with a simple intervention in rural Africa.
  • It increases the likelihood of HIV-infected patients reporting problems with adherence to ART; however, sustainability remains a challenge.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
  • (PMID = 28296019.001).
  • [ISSN] 1468-1293
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; HIV / antiretroviral therapy / patient-centred communication / self-reported adherence / sub-Saharan Africa / therapeutic drug monitoring
  • [Investigator] Asantiel A; Chale A; Faini D; Felger I; Francis G; Furrer H; Gamell A; Glass T; Hatz C; Hatz S; Kasuga B; Kalinjuma AV; Kimera N; Kisunga Y; Luhombero A; Luwanda LB; Mbwile L; Mkulila M; Mkumbo J; Mkusa M; Mossad G; Mpundunga D; Msami D; Mtandanguo A; Mwamelo KD; Myeya S; Nahota S; Ndaki R; Ngulukila A; Ntamatungiro AJ; Samson L; Sikalengo G; Tanner M; Vanobberghen F
  •  go-up   go-down


96. van der Zee J, Gijselinck I, Van Mossevelde S, Perrone F, Dillen L, Heeman B, Bäumer V, Engelborghs S, De Bleecker J, Baets J, Gelpi E, Rojas-García R, Clarimón J, Lleó A, Diehl-Schmid J, Alexopoulos P, Perneczky R, Synofzik M, Just J, Schöls L, Graff C, Thonberg H, Borroni B, Padovani A, Jordanova A, Sarafov S, Tournev I, de Mendonça A, Miltenberger-Miltényi G, Simões do Couto F, Ramirez A, Jessen F, Heneka MT, Gómez-Tortosa E, Danek A, Cras P, Vandenberghe R, De Jonghe P, De Deyn PP, Sleegers K, Cruts M, Van Broeckhoven C, Goeman J, Nuytten D, Smets K, Robberecht W, Damme PV, Bleecker J, Santens P, Dermaut B, Versijpt J, Michotte A, Ivanoiu A, Deryck O, Bergmans B, Delbeck J, Bruyland M, Willems C, Salmon E, Pastor P, Ortega-Cubero S, Benussi L, Ghidoni R, Binetti G, Hernández I, Boada M, Ruiz A, Sorbi S, Nacmias B, Bagnoli S, Sorbi S, Sanchez-Valle R, Llado A, Santana I, Rosário Almeida M, Frisoni GB, Maetzler W, Matej R, Fraidakis MJ, Kovacs GG, Fabrizi GM, Testi S: TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Hum Mutat; 2017 Mar;38(3):297-309
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis.
  • : We investigated the mutation spectrum of the TANK-Binding Kinase 1 (TBK1) gene and its associated phenotypic spectrum by exonic resequencing of TBK1 in a cohort of 2,538 patients with frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), or FTD plus ALS, ascertained within the European Early-Onset Dementia Consortium.
  • Although missense mutations were also present in controls, over three times more mutations affecting TBK1 functioning were found in the mutation fraction observed in patients only, suggesting high-risk alleles (P = 0.03).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2016 The Authors. **Human Mutation published by Wiley Periodicals, Inc.
  • (PMID = 28008748.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; ALS / FTD / NFκB luciferase reporter assay / TANK-Binding Kinase 1 / TBK1 / amyotrophic lateral sclerosis / frontotemporal dementia / mutations
  •  go-up   go-down


97. Sanossian N, Rosenberg L, Liebeskind DS, Starkman S, Eckstein M, Stratton S, Pratt FD, Hamilton S, Kim-Tenser M, Sharma LK, Restrepo L, Valdes-Suieras M, Conwit R, Saver JL, FAST-MAG Investigators and Coordinators: A Dedicated Spanish Language Line Increases Enrollment of Hispanics Into Prehospital Clinical Research. Stroke; 2017 May;48(5):1389-1391
Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Cerebral Hemorrhage / therapy. Clinical Trials as Topic / standards. Culturally Competent Care / standards. Hispanic Americans. Patient Selection. Stroke / therapy

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28389617.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / U01 NS044364
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuroprotective Agents; I38ZP9992A / Magnesium
  • [Keywords] NOTNLM ; ambulances / cell phones / clinical trial / magnesium / stroke
  •  go-up   go-down


98. Demeyer H, Louvaris Z, Frei A, Rabinovich RA, de Jong C, Gimeno-Santos E, Loeckx M, Buttery SC, Rubio N, Van der Molen T, Hopkinson NS, Vogiatzis I, Puhan MA, Garcia-Aymerich J, Polkey MI, Troosters T, Mr Papp PROactive study group and the PROactive consortium: Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial. Thorax; 2017 May;72(5):415-423
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial.
  • RATIONALE: Reduced physical activity (PA) in patients with COPD is associated with a poor prognosis.
  • Increasing PA is a key therapeutic target, but thus far few strategies have been found effective in this patient group.
  • OBJECTIVES: To investigate the effectiveness of a 12-week semiautomated telecoaching intervention on PA in patients with COPD in a multicentre European randomised controlled trial.
  • METHODS: 343 patients from six centres, encompassing a wide spectrum of disease severity, were randomly allocated to either a usual care group (UCG) or a telecoaching intervention group (IG) between June and December 2014.
  • In IG patients, an improvement could be observed in the functional state domain of the clinical COPD questionnaire (p=0.03) compared with UCG.
  • CONCLUSIONS: The amount and intensity of PA can be significantly increased in patients with COPD using a 12-week semiautomated telecoaching intervention including a step counter and an application installed on a smartphone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
  • (PMID = 28137918.001).
  • [ISSN] 1468-3296
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Exercise / Pulmonary Rehabilitation
  • [Investigator] Janssens W; Van den Brande P; Spruyt M; Hornikx M; Tanner R; Raste Y; Yerramasu C; Oosterom H; Buesching G; Strassman A; Frey M; Turk A; Keusch S; Zürcher A; Serra I; Ivanoff N; Karlsson N; Corriol-Rohou S; Jarrod I; Erzen D; Scuri M; McBride P; Kamel N; Tabberer M; Dobbels F; de Boer P; Nikai E; MacNee B
  •  go-up   go-down


99. Weiss CR, Akinwande O, Paudel K, Cheskin LJ, Holly B, Hong K, Fischman AM, Patel RS, Shin EJ, Steele KE, Moran TH, Kaiser K, Park A, Shade DM, Kraitchman DL, Arepally A: Clinical Safety of Bariatric Arterial Embolization: Preliminary Results of the BEAT Obesity Trial. Radiology; 2017 May;283(2):598-608
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Purpose To conduct a pilot prospective clinical trial to evaluate the feasibility, safety, and short-term efficacy of bariatric embolization, a recently developed endovascular procedure for the treatment of obesity, in patients with severe obesity.
  • Five severely obese patients (four women, one man) who were 31-49 years of age and who had a mean body mass index of 43.8 kg/m<sup>2</sup> ± 2.9 with no clinically important comorbidities were enrolled in this study.
  • Results The left gastric artery, with or without the gastroepiploic artery, was embolized in five patients, with a technical success rate of 100%.
  • A hospital stay of less than 48 hours for routine supportive care was provided for three patients.
  • Conclusion Bariatric embolization is feasible and appears to be well tolerated in severely obese patients.
  • In this small patient cohort, it appears to induce appetite suppression and may induce weight loss.

  • Genetic Alliance. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetes. 2001 Aug;50(8):1714-9 [11473029.001]
  • [Cites] Cardiovasc Intervent Radiol. 2012 Dec;35(6):1460-6 [22367009.001]
  • [Cites] Obes Surg. 2015 Mar;25(3):550-8 [25511751.001]
  • [Cites] Adv Ther. 2012 Nov;29(11):970-8 [23149862.001]
  • [Cites] JACC Cardiovasc Interv. 2015 Oct;8(12):1641-4 [26493259.001]
  • [Cites] Am J Prev Med. 2008 Aug;35(2):118-26 [18617080.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):108-14 [16371744.001]
  • [Cites] Gastroenterology. 2007 May;132(6):2253-71 [17498516.001]
  • [Cites] Obesity (Silver Spring). 2008 Jun;16(6):1413-20 [18421273.001]
  • [Cites] Radiology. 2008 Oct;249(1):127-33 [18796671.001]
  • [Cites] N Engl J Med. 2002 May 23;346(21):1623-30 [12023994.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):780-5 [17968169.001]
  • [Cites] Ann Pharmacother. 2000 Sep;34(9):1066-9 [10981254.001]
  • [Cites] J Obes. 2014;2014:185349 [25349724.001]
  • [Cites] Int J Obes (Lond). 2009 Apr;33 Suppl 1:S33-40 [19363506.001]
  • [Cites] N Engl J Med. 2011 Oct 27;365(17):1597-604 [22029981.001]
  • [Cites] J Radiol Case Rep. 2015 Sep 30;9(9):36-43 [26629307.001]
  • [Cites] Arch Surg. 2006 Mar;141(3):262-8 [16549691.001]
  • [Cites] Int J Obes (Lond). 2014 Sep;38(9):1147-52 [24352292.001]
  • [Cites] Radiology. 2013 Feb;266(2):471-9 [23204538.001]
  • [Cites] Trends Endocrinol Metab. 2010 Jun;21(6):337-44 [20133150.001]
  • [Cites] Nat Med. 2012 May 04;18(5):666-7 [22561823.001]
  • [Cites] J Am Diet Assoc. 2010 Apr;110(4):571-84 [20338283.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):389-96 [12686525.001]
  • [Cites] Nat Med. 2012 May 04;18(5):668-9 [22561824.001]
  • [Cites] J Vasc Interv Radiol. 2014 Mar;25(3):455-61 [24462005.001]
  • [Cites] Radiology. 2007 Jul;244(1):138-43 [17581899.001]
  • (PMID = 28195823.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB017615; United States / NIBIB NIH HHS / EB / T32 EB006351
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemostatics
  •  go-up   go-down


100. Zingg W, Hopkins S, Gayet-Ageron A, Holmes A, Sharland M, Suetens C, ECDC PPS study group: Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey. Lancet Infect Dis; 2017 Apr;17(4):381-389

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey.
  • BACKGROUND: In 2011-12, the European Centre for Disease Prevention and Control (ECDC) held the first Europe-wide point-prevalence survey of health-care-associated infections in acute care hospitals.
  • We analysed paediatric data from this survey, aiming to calculate the prevalence and type of health-care-associated infections in children and adolescents in Europe and to determine risk factors for infection in this population.
  • Patients present on the ward at 0800 h on the day of the survey and who were not discharged at the time of the survey were included.
  • Data were collected by locally trained health-care workers according to patient-based or unit-based protocols.
  • We extracted data from the ECDC database for all paediatric patients (age 0-18 years).
  • We report adjusted prevalence for health-care-associated infections by clustering at the hospital and country level.
  • We also calculated risk factors for development of health-care-associated infections with use of a generalised linear mixed-effects model.
  • 770 health-care-associated infections were reported in 726 children and adolescents, corresponding to a prevalence of 4·2% (95% CI 3·7-4·8).
  • The prevalence of infections was highest in paediatric intensive care units (15·5%, 95% CI 11·6-20·3) and neonatal intensive care units (10·7%, 9·0-12·7).
  • 392 microorganisms were reported for 342 health-care-associated infections, with Enterobacteriaceae being the most frequently found (113 [15%]).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28089444.001).
  • [ISSN] 1474-4457
  • [Journal-full-title] The Lancet. Infectious diseases
  • [ISO-abbreviation] Lancet Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Investigator] Almeida M; Asembergiene J; Borg MA; Budimir A; Cairns S; Cunney R; Deptula A; Berciano PG; Gudlaugsson O; Hadjiloucas A; Hammami N; Harrison W; Heisbourg E; Kolman J; Kontopidou F; Kristensen B; Lyytikäinen O; Märtin P; McIlvenny G; Moro ML; Piening B; Presterl E; Serban R; Smid E; Sorknes NK; Stefkovicova M; Sviestina I; Szabo R; Tkadlecova H; Vatcheva-Dobrevska R; VerjatTrannoy D
  •  go-up   go-down






Advertisement